

# THE 36TH ANNUAL SCIENTIFIC MEETING HONG KONG OPHTHALMOLOGICAL SYMPOSIUM

HELD IN CONJUNCTION WITH

THE 12TH ASIAN NEURO-OPHTHALMOLOGY SOCIETY MEETING

AND

THE ANNUAL SCIENTIFIC MEETING OF ASIA-PACIFIC SOCIETY OF OCULAR ONCOLOGY AND PATHOLOGY

> Dec 6-8, 2024 Hong Kong Convention and Exhibition Center

# PROGRAMME BOOK

www.asmhk-asnos2024.com

# Content 🔴

Welcome Messages	P. 3 - 7
Introduction	P. 8 - 11
Organising Committee	P. 12 - 14
General Information	P. 15 - 18
Social Programs	P. 19
Floor Plan	P. 20
Program Overview	P. 21 - 22
Keynote Speakers	P. 23 - 24
Scientific Program	P. 25 - 105
Exhibition	P. 106
Sponsors	P. 107



### Dr Emily Yeung

President, The College of Ophthalmologists of Hong Kong

On behalf of the College of Ophthalmologists of Hong Kong (COHK), it is my immense pleasure to extend a warm welcome to all of you to the 36th Annual Scientific Meeting/ Hong Kong Ophthalmological Symposium held in conjunction with the Asian Neuro-Ophthalmology Society (ASNOS) and the Asia Pacific Society of Ocular Oncology and Pathology (APSOOP) on 6-8 December 2024 at the Hong Kong Convention and Exhibition Center. This conjoint meeting is unique. We have the privilege to bring many world-renowned experts from different parts of the world in the field of Neuro-Ophthalmology, Ocular Oncology and Pathology to come and share their expertise and novel treatment modalities. Although these subspecialties and topics are not as widely discussed, it is all the more important for us to recognize their significance and vital roles in our daily practice. We can also acknowledge the professionals who dedicate their time and efforts in the advancement of these fields for improved diagnosis, more effective treatment and hence better patient care. ASNOS is held every 2 years in different Asian cities and we are honored that Hong Kong was chosen to be the host in 2024. APSOOP is a member society of Asia Pacific Academy of Ophthalmology and holds its conference in the region.

This year also marks the 30th anniversary of the COHK and the 70th anniversary of the Hong Kong Ophthalmological Society. A series of celebratory activities are organized throughout the year. To end on a high note, nothing better than having an anniversary symposium in our Annual Scientific Meeting with two regional congresses namely ASNOS and APSOOP as the grand finale of the anniversary celebration. We are thrilled to be able to celebrate our anniversary with friends from other parts of the world.

This meeting serves as an invaluable platform for members to share new ideas and knowledge with experts from other regions. Beyond the scientific sessions, it is an excellent opportunity for networking and forging lasting friendships. It is a time where we can reconnect with our old friends and make new acquaintances.

To all speakers, I would like to take this opportunity to thank all of you for your contributions and your commitment in advancing our knowledge.

Lastly, I would like to express my gratitude to the organizing committee for working tirelessly to ensure the success of this meeting and our sponsors for their support to make this meeting possible.

Once again, welcome to the 36th Annual Scientific Meeting/ Hong Kong Ophthalmological Symposium held in conjunction with the Asian Neuro-Ophthalmology Society and the Asia Pacific Society of Ocular Oncology and Pathology. I sincerely hope that each and every one of you will have an enjoyable and fruitful conference here in Hong Kong,

Thank you.



# Dr Emmy Li

President, The Hong Kong Ophthalmological Society

On behalf of the Hong Kong Ophthalmological Society (HKOS), I extend a warm welcome to all speakers and delegates attending the 36th Annual Scientific Meeting (ASM) jointly held by the College of Ophthalmologists of Hong Kong (COHK), the Hong Kong Ophthalmological Society (HKOS), the Asian Neuro-ophthalmology Society (ASNOS) and Asia Pacific Ocular Oncology and Pathology (APSOOP). This year marks the 70th anniversary of the HKOS. a significant milestone that reflects the remarkable progress in the field of ophthalmology over the past seven decades. By collaborating with these esteemed regional organizations, the ASM has transformed into a highly enriched and outstanding platform for delegates to share their academic and clinical experiences in ophthalmology.

This year is the first time for us to join hands with the ASNOS and APSOOP, we are confident that this will be another fruitful meeting especially with the contribution of various top-notch neuro-ophthalmologists, ocular oncologists, and pathologists. On behalf of HKOS, I wish to welcome every delegate from local and overseas to enjoy the meeting and have a memorable event in Hong Kong.



### Dr Thomas Chiu

Chairman, Annual Scientific Meeting/ Hong Kong Ophthalmological Symposium 2024

Dear Friends and colleagues,

It is my great pleasure to welcome you to Annual Scientific Meeting (ASM)/ the Hong Kong Ophthalmological Symposium 2024 held in conjunction with the Asia Neuro-Ophthalmology Society Congress (ASNOS) and Asia Pacific Society of Ocular Oncology and Pathology (APSOOP) at Hong Kong Convention and Exhibition Centre, Hong Kong, China, on December 6-8, 2024.

Every year the ASM/ Hong Kong Ophthalmological Symposium is one of the most exciting events co-organised by the College of Ophthalmologist of Hong Kong (COHK) and Hong Kong Ophthalmological Society (HKOS). This is not only an excellent platform for trainees, experts, and scientists from local and overseas institutes to share their expertise, research, and innovations in different disciplines of Ophthalmology, but also a good chance to reunite old friends and making new collaborations.

This year's ASM is a special occasion as it marks the first time it will be held in conjunction with the ASNOS and APSOOP. While it is often said that "the eye is the window to the soul," it should also be recognized as "the window to the brain and our body." Guided by the leadership of Professor Carmen Chan, the ASNOS 2024 Congress President, and Professor Hunter Yuen, President of APSOOP, this congress presents a unique opportunity for ophthalmologists, neurologists, neurosurgeons, oncologists, pathologists, and scientists to collaborate and explore the intricate neuro-ophthalmic and systemic connections. We look forward to seeing you in the congress to learn, share and enjoy the nice weather, good food and beautiful views of our Victoria Harbour.



# Dr. Satoshi Kashii

President, Asian Neuro-ophthalmology Society

Dear All Participants,

I would like to extend a few words of congratulations on the opening of the 12th ASNOS Meeting in Hong Kong. Since its start in 2002 when the 1st ASNOS was held in Tokyo, the society has been growing steadily and regional neuro-ophthalmology societies in six Asian countries have hosted ASNOS meetings in the past, which included the 4th in Taipei, Taiwan, the 7th in Bali, Indonesia, the 8th in Beijing, China, the 9th in Seoul, Korea, the 10th in Manila, Phillipines, and the 11th in Bangkok, Thailand. I strongly believe the 12th ASNOS meeting in Hong Kong will provide a spark for the ASNOS to develop into a global player in Neuro-ophthalmology.

On behalf of the Asian Neuro-Ophthalmology Society, I extend my sincere gratitude to all who are working on this congress to make it a truly memorable event. And I would like to express my special thanks to Professor Carmen Chan, the President of 12th ASNOS meeting and her staffs for their enormous effort in making this happen, and hope all of the participants will enjoy them. I am sure, the Hong Kong meeting will provide a forum for the exchange of friendship as well as academic exchange.



# Prof Carmen Chan

Congress President, 12th Asian Neuro-Ophthalmology Society Congress 2024

Dear friends and colleagues,

Neuro-ophthalmology is an increasingly recognized and vital subspecialty of both ophthalmology and neurology, given the expanding range of therapeutic options available for neuro-ophthalmic disorders. Established in 2002, ASNOS aims to promote education, research, and the practice of neuro-ophthalmology in the Asia region, paralleling the efforts of other regional societies like the North American Neuro-Ophthalmology Society (NANOS) and the European Neuro-Ophthalmology Society (EUNOS). The ASNOS Congress takes place every 2 years, and the 12th ASNOS Congress in 2024 promises to be a remarkable event.

Dr. Thomas Chiu, ASMHK Chairman, and I eagerly look forward to welcoming neuro-ophthalmologists, ophthalmologists, neurologists, and neurosurgeons not only from Hong Kong and our neighbouring Asian countries but also from around the world. This Congress presents a fantastic opportunity to share the latest advancements in clinical practice and research within the field of neuro-ophthalmology.



# **Prof Hunter Yuen**

President, The Asia-Pacific Society of Ocular Oncology and Pathology

Dear Esteemed Members, Distinguished Guests and Fellow Colleagues,

It is with great pleasure and excitement that we extend a warm welcome to all of you to the Asia Pacific Society of Ocular Oncology and Pathology (APSOOP) Meeting, conjoined with the Asia Pacific Society of Neuroophthalmology Meeting (ASNOS) and COHK and HKOS Annual Scientific Meeting (ASM). This event brings together leading experts, researchers, and practitioners from across the region in the field of ocular oncology/ pathology, neuroophthalmology and other aspects of Ophthalmology.

With numerous advancements and breakthroughs occurring in these specialized areas, this joint meeting serves as an important platform to facilitate collaborative exchange, foster innovative ideas, and promote cutting-edge research. We aim to create an atmosphere of intellectual stimulation, networking, and professional growth that will undoubtedly contribute to the betterment of patient care and outcomes in these crucial disciplines. Our esteemed panel of speakers comprises renowned experts who will share their expertise, knowledge, and experiences, providing valuable insights and shedding light on current and future trends in ocular oncology, pathology, and neuroophthalmology. We encourage all attendees to take full advantage of this opportunity to foster synergistic partnerships that drive innovation and enhance patients care.

We would like express our sincere appreciation to The College of Ophthalmologists of Hong Kong and The Hong Kong Ophthalmological Society as the local host of the meeting. Moreover, we would like to thanks the participants, speakers, sponsors, and the organizing committee who have played an indispensable role in making this event a reality.

Your dedication and commitment to advancing the fields of ocular oncology, pathology, and neuroophthalmology are commendable, and we are grateful for your invaluable contributions.

We look forward to your presence and active participation in this exceptional scientific gathering.



# Introduction of THE COLLEGE OF OPHTHALMOLOGISTS OF HONG KONG

The College of Ophthalmologists of Hong Kong was incorporated in October 1994 with the following objectives:

1. To promote for public benefit the advancement of knowledge in the field of ophthalmology

2. To promote for public benefit the standard of ophthalmic care in Hong Kong

3. To develop and maintain good practice and high professional standards of competence in the field of ophthalmology

4. To act as a consultative body for matters of educational or public interest concerning ophthalmology

5. To encourage and support training, continuing education and research in ophthalmology

Website: https://www.cohk.org.hk/

The COHK Council 2024-2025 President: Vice President (Professional Affairs): Vice-President (General Affairs): Honorary Secretary: Honorary Treasurer: Editor-in-Chief: Immediate Past President: Council Members:

Dr YEUNG Fung Yee, Emily Dr LAM Fung, Robert Dr YUNG Hon Wah Dr CHIU Yee Hang, Thomas Dr YEUNG Chun Chun, Jane Dr YAM Cheuk Sing, Jason Prof THAM Chee Yung, Clement Dr AU Ka Hong, Alvin Dr BAIG, Nafees Begum Dr CHAN, Kar Mun Carmen Dr CHING, Hok Ying Ruby Dr CHONG, Kam Lung Kelvin Dr LAI, Hiu Ping Frank Dr LAI, Hong Yee Connie Dr SHIH. Kendrick Co Dr SIN, Pui Yee, Helena Dr WONG, Suhan Emily Dr WONG, Lai Man, Raymond Dr YUEN Shi Yin, Nancy

#### **Co-opted Council Member:**

# Introduction of THE HONG KONG OPHTHALMOLOGICAL SOCIETY (HKOS)

The Hong Kong Ophthalmological Society (HKOS) was formed and registered on 16 August 1954 with Dr Dansey Browning as the first Chairman. The Society was established with the objectives to maintain and upgrade the quality of eye care in Hong Kong, and to foster brotherhood among eye care professionals serving the public in Hong Kong. Every year since 1989, the HKOS has organized the annual scientific meeting in ophthalmology, as well as other ad-hoc open lectures by internationally renowned speakers. This tradition has been carried on jointly with other health-related associations and has supported any public health talks and vision screening programs. There are at present over 300 members registered with the Society.

Website: http://www.hkos.org.hk/

#### The HKOS Council 2024-2025

President: Vice President (Internal Affairs): Vice President (External Affairs): Honorary Secretary: Honorary Treasurer: Ex-officio: Council Members: Dr Ll Yuen Mei, Emmy Dr YAM Cheuk Sing, Jason Dr CHAN Chung Yan, Tommy Dr NG Lap Ki, Alex Dr WONG Lai Man, Raymond Dr WONG Yat Hin, Ian Dr AU Chi Lik, Sunny Dr CHOW She Wan, Sharon Dr FAN Ching Yim, Michelle Dr FONG Hon Chi, Angie Dr HO Wing Lau Dr IU Pui Leung, Lawrence Dr LAI Hiu Ping, Frank Dr LEUNG Wing Yun, Joy Dr SZETO Ka Ho, Simon Dr WONG Wai Nam. Eva Dr YEUNG Chun Chun, Jane Dr YIU On Ying, Angela



# Introduction of ASIAN NEURO-OPHTHALMOLOGY SOCIETY (ASNOS)

The Asian Neuro-ophthalmology Society (ASNOS) has been established with the aim to promote and contribute to the development of neuro-ophthalmology in Asian countries. ASNOS Congresses have been held every 2 years since 2002.

•				
ASNOS Co	ouncil		Walsh-in-A	sia Committee
President: Satoshi KASHII (Ja Secretary general: An-Guor WANG (Chinese Taipei)		Satoshi KASHII (Japan) An-Guor WANG (Chinese Taipei)	Chair: Members:	Dr Andrew Mak (Hong Kong) Dr Noel Chan (Hong Kong) Dr Matthew Lam (Hong Kong)
				Dr Jing-Liang Loo (Singapore)
				Dr Shweta Singhal (Singapore)
				Dr Clement Tan (Singapore)
Members:	Hyoso	ok AHN (South Korea) en CHAN (Hong Kong, China)		
	Noel	CHAN (Hong Kong, China)	ASNOS Awa	ard Judges
	Hui-Cl	hen CHENG (Chinese Taipei)	Walsh in Asia:	Prof Anthony Arnold (US)
	Nipho	n CHIRAPAPAISAN (Thailand)		Prof Neil Miller (US)
	Wanic	ha CHUENKONGKAEW (Thailand)	Oral:	Prof Andrew Lee (US)
	Rashm	nin GANDHI (India)		Dr An-Guor Wang (Chinese Taipei)
	Kong `	Yong GOH (Singapore)	Poster:	Dr Laura Bonelli (US)
	Jeong	-Min HWANG (South Korea)		Prof Celia Chen (Australia)
	Hitosh	ii ISHIKAWA (Japan)		Prof Umapathi Thirugnanam (Singapore)
	Syntia	NUSANTI (Indonesia)		
	Karen	REYES (Philippines)		
	Rohit \$	SAXENA (India)		
	Mohar	mad SIDIK (Indonesia)		
	Jesus	TAMESIS Jr. (Philippines)		
	Cleme	ent TAN (Singapore)		
	Rong- Masat	Kung TSAI (Chinese Taipei) o WAKAKURA (Japan)		
	Wan F	lazabbah WAN HITAM (Malaysia)		
	ShiHui	i WEI (China)		
	Lina-C	Chung WOUNG (Chinese Taipei)		
	Mav-Y	ung YEN (Chinese Taipei)		
	Joona	ha YOO (South Korea)		
	Xiaoiu	n ZHANG (China)		



# Introduction of ASIA-PACIFIC SOCIETY OF OCULAR ONCOLOGY & PATHOLOGY (APSOOP)

The Asia-Pacific Society of Ocular Oncology & Pathology (APSOO) was established with the collaborative effort of all the council members. APSOOP has been the international scientific society concentrated on the subspecialty of Ocular Oncology & Pathology, and also an important branch of the Asia-Pacific Academy of Ophthalmology (APAO). We performed periodic conferences to promote communications across the countries and update the latest knowledge. At a regional level, APSOOP participates in numerous national ocular meetings in our member countries. Through academic activities, we promote the development of the specialty, strengthen the collaboration between our member countries and provide the best possible health care of our patients.

# Organizing Committee



Christopher Leung

Advisors

Emmy Li



**Clement Tham** 

Emily Yeung

Chairman, Annual Scientific Meeting/ Hong Kong Ophthalmological Symposium 2024



Thomas Chiu

Congress President, 12th Asian Neuro-ophthalmology Society Congress 2024



Carmen Chan

#### President, The Asia-Pacific Society of Ocular Oncology and Pathology



Hunter Yuen

### **Immediate Past Presidents**



Guy Chen



Dennis Lam

# Organizing Committee 🔴

#### Secretary





Andy Cheng



Noel Chan (Chair)

#### Scientific Program Committee

Kendrick Shih

(Cornea and Refractive)



Alex Ng (Cornea and Refractive)



Nancy Yuen (Glaucoma)



Dorothy Fan (Paediatrics)



Mary Ho (Vitreo-retina)



Kenneth Li (Vitreo-retina)



Kelvin Chong

(Orbits and Oculoplastics)

Connie Lai (Paediatrics)



Kendrick Shih (Residents' Challenge)



Poemen Chan (Glaucoma)



Hunter Yuen (Orbits and Oculoplastics)



Calvin Pang (Translational and Basic Science)



Andrew Mak (Walsh-in-Asia)

# Organizing Committee

### **Publication Committee**



Matthew LAM (Chair)



Benjamin Lui

#### Social Committee



Joy See Leung (Chair)



Jerry Lok



Jonathan Tam



Emily Wong





### Judges for the Best Oral Presentation



Frank LAI



Simon SZETO

### Judges for the Best Poster Presentation



Raymond WONG



Jason YAM



# General Information 🔴

### **REGISTRATION AND INFORMATION COUNTER**

The ASMHK-ASNOS-APSOOP Conference 2024 registration is located at the entrance of the N200 series with the following opening hours:

**Opening Hours:** 

Dec 6, 2024 (Fri) 13:30 - 17:00 Dec 7, 2024 (Sat) 08:00 - 17:30 Dec 8, 2024 (Sun) 07:30 - 15:30

Invited Speakers: Please proceed to the Invited Faculty Counter

Other Delegates: Use the self-service kiosks to scan your QR code for badge printing Please prepare your QR code for Badge Pickup!

If you cannot find your QR code, please proceed to the registration counter, our helpers will assist you in printing your badge using your registered name or email address.



We highly recommend registering online before your visit to minimize waiting times. Please visit our official website to register and make your payment. Once the online registration process has been completed, you can pick up your name badge using the QR code from your confirmation email.

Please note that we only accept online registration; there will be no cash or credit card facilities available on-site.

If you have been invited to the social program and you have indicated you would attend through the Congress system, you will also receive the following:

-A Welcome Dinner ticket

and/or

-A Gala Dinner ticket

(If you have changed your mind and no longer wishes to attend either dinner, please return your ticket(s) to the registration counter, so we can distribute the tickets to guests on the waiting list)

# General Information

#### CONFERENCE PROGRAM BOOK AND ABSTRACT BOOK

A PDF copy of the abstract book will be available online from December 6, 2024 at https://program.asmhk-asnos2024.com/publication/ . No hard copies will be distributed

#### E-POSTERs

There are over 100 accepted posters. Whilst all poster authors have been asked to upload their posters online, some have been selected to be presented as physical posters. The physical posters may be viewed at the Poster area located at the foyer and inside N211-212; while E-Posters are available at https://program.asmhk-asnos2024.com/e-poster/.

#### **CERTIFICATE OF ATTENDANCE**

Certificates of Attendance can be downloaded through the Conference system starting from Dec 11, 2024. Please log in to your account to download. Event Website: https://congress.asmhk-asnos2024.com/ .

### <u>CME</u>

CME points have been granted by:

College	Max for whole func- tion	Dec 6	Dec 7	Dec 8	Group Category
The College of Ophthalmologists of Hong Kong	16*	3	7*	6	Passive
The Hong Kong College of Pathologists	13.5	3	6	4.5	CME-PP
Hong Kong College of Physicians	7.5	1.5	3	3	PP-PP
Hong Kong College of Radiologists	13	3	5.5	4.5	B-PP

For fellows of the College of Ophthalmologists of Hong Kong (COHK), please proceed to the COHK CME kiosk located inside N204-205 to register your attendance daily.

\*COHK Fellows can gain 2 extra active CME points by answering MCQs based on the keynote lectures by Prof Neil Miller and Prof Anthony Arnold on Dec 7, 2024. There is one active CME point for each set of MCQs with a pass mark of 50%. The MCQs can be accessed by logging into the eHKAM LMS system (https://e.hkam.hk/).

For fellows of the Hong Kong Colleges of Pathologists/ Physicians/ Radiologists, please proceed to the Secretariat Office (N209) to sign the attendance sheet.

### **General Information**

### SPEAKER READY ROOM

All speakers are recommended to upload their PowerPoint 48 hours before their scheduled presentation.

Virtual Speaker Ready Room

Login to the conference portal, under "Speaker", "Speaker Ready Room" choose the relevant topic and upload the PowerPoint.

Physical Speaker Ready Room - Room N210

If you would like to upload an updated version of your presentation PowerPoint, you can visit the Speaker Ready Room onsite, where our technicians will help you resolve any compatibility and/or formatting issues.

The PowerPoint and video files you have uploaded onto the computer in the Speaker Ready Room will be automatically transmitted to the laptop computer at the podium before your session begins.

Opening Hours: Dec 7, 2024 (Sat) 08:00 - 17:30 Dec 8, 2024 (Sun) 07:30 - 16:00

### ASMHK-ASNOS-APSOOP 2024 app installation



**Android** https://play.google.com/store/apps/details?id=com.guestwork.asmhk

### VIDEO ON DEMAND

Presentations, with the consent of the speakers, will be accessible via the event website from December 16, 2024, to February 28, 2025. Delegates can log in to their accounts to view the available presentations.

Social Programs

### **ASNOS Flag Transfer Ceremony**

Date: December 6, 2024 (Friday) Time: 1345 - 1400 Venue: N201A All are welcome

### Welcome Dinner (By invitation only)

Date: December 6, 2024 (Friday)

Time: 1830- 2130 Venue: Madam Fù, Grand Café Chinois, 3/F, Barrack Block, Tai Kwun, No. 10 Hollywood Road, Central, Hong Kong

# **Opening Ceremony and Anniversary Symposium**

Date: December 7, 2024 (Saturday) Time: 1330 – 1430

Venue: Room N201A, Hong Kong Convention and Exhibition Center

**Gala Dinner** Date: December 7, 2024 (Saturday) Time: 1830 – 2200 Venue: Chancellor Room, Hong Kong Convention and Exhibition Center Floor Plan



# Program Overview

(1	Time	N201A
24 (Fri	1345-1400	ASNOS Flag Transfer
Dec 6, 202	1400-1530	ASNOS #1 Walsh 1
	1530-1600	Break
	1600-1730	ASNOS #2 Walsh 2
	1900	Welcome Dinner at Tai Kwun (By Invitation)

	Time	N201B	N204-205	N201A	N202-N203	N206-208
	0830-1000			ASNOS #3 Paediatric Ophthalmology & Genetic Disorders	Rapid fire Free paper 1 (ASNOS)	ASM Session 1 Translational Ophthalmology & Basic Sciences
	1000-1030			Break		
	1030-1200		ASNOS#4 Recent Advances in Neuro-ophthalmology	Rapid fire Free paper 2 (ASNOS)	ASM Session 2 Orbit & Oculoplastics	
f)	1200-1215				Break	
24 (Sa	1215-1315			Bayer Lunch Symposium		
, 20	1315-1330	Exh	Exhibition		Break	
Dec	1330-1430		Opening Ceremony and Anniversary Symposium			
	1430-1545			Keynote lectures		
	1545-1600				Break	
	1600-1730		ASNOS #5 Debate & Controversies in Neuro-Ophthalmology	Rapid fire Free paper 3 (ASM)	ASM Session 3 Retina 1	
	1730-1830			Alcon Evening Symposium	ASNOS Council meeting	
	1845-2100			Gala Dinner at Chancellor Room (By Invitation)		

# Program Overview

	Time	N201B	N204-205	N201A	N202-N203	N206-208
	0800-0845		Johnson and Johnson Breakfast Symposium			
	0900-1030		ASNOS #6 When to Order What?	APSOOP #1 What's new in Ocular Oncology and Pathology?	ASM Session 4 Paediatric Ophthalmology	
	1030-1100				Break	
	1100-1230			ASNOS #7 Optic Neuropathies & Sys- temic Diseases	APSOOP #2 Achieving Optimal Outcomes in Ocular Oncology	ASM Session 5 HKGS Inaugural Symposium
nc) 42	1230-1245				Break	
Dec o, zu	1245-1345			Roche Lunch Symposium		
	1345-1400	Exh	nibition		Break	
	1400-1530		ASNOS #8 Efferent Disorder + Closing Ceremony	ASM Session 6 Retina 2	ASM Session 7 Cataract, Cornea & Refractive	
	1530-1545				Break	
	1545-1715				ASM Session 8 Train-the-Trainer	ASM Session 9 YO + Residents' Challenge
	1730-1800		COHK Conferment Reception (By Invitation)			
	1800-1900			COHK Conferment (By Invitation)		
	1900-			COHK Conferment Dinner at Room 209-210 (By Invitation)		

### Keynote Speakers



### Anthony C Arnold

#### MD

Anthony C. Arnold, MD is Vice Chair for Education, Professor and Chief, Neuro-Ophthalmology Division, Dept. of Ophthalmology, University of California, Los Angeles. He has a research interest in ischemic and inflammatory optic neuropathies, with more than 100 publications. He has served as the President of the AUPO Ophthalmology Program Directors Council 2000-2007, Chair of the ACGME Residency Review Committee for Ophthalmology 2010-2016, Chair of the ACGME Ophthalmology Milestones Development Group 2010-2013, and member of the ACGME Board of Directors 2015-2017, Director of the American Board of Ophthalmology 2008-2016, and President and Chairman of the Board of the North American Neuro-Ophthalmology Society 2008-2012.



# Neil R Miller

#### MD, FACS

Dr. Neil Miller is Professor Emeritus of Ophthalmology, Neurology, and Neurosurgery at the Johns Hopkins University School of Medicine. He has authored over 590 articles, 97 chapters, and 15 books, including the 4th edition of "Walsh and Hoyt's Clinical Neuro-Ophthalmology" and has co-edited the 5th and 6th editions of this textbook as well as four editions of an abbreviated version of the textbook: "Walsh and Hoyt's Clinical Neuro-Ophthalmology: The Essentials", the most recent of which was published in 2020. Dr. Miller also has co-authored two editions of "The Neuro-Ophthalmology Survival Guide", a textbook designed for both physicians and students. The third edition is due out this year. Dr. Miller has spoken at numerous local, national, and international meetings and has given 65 named lectures around the world. In addition, he has been involved in many clinical trials in the field of neuro-ophthalmology. Many of Dr. Miller's previous fellows and residents hold faculty positions at major institutions throughout the United States and around the world.

### Keynote Speakers



### Fan Xianqun

#### MD, PhD

Prof. Fan Xianqun is currently Deputy Secretary of the CPC of Shanghai Jiao Tong University, Secretary of the CPC of Shanghai Jiao Tong University School of Medicine, and professor of Dept. of Ophthalmology, Shanghai Ninth People's Hospital.

Prof. Fan was graduated from BengBu Medical College with a bachelor degree in Clinical Medicine in 1987. He successively got his master degree and Ph.D from Shanghai Second Medical University in 1993 and 1998. Prof. Fan worked as the visiting scholar in Massachusetts Eye and Ear Infirmary affiliated to Harvard University in 2001 and Mayo Clinic in 2005. He was awarded the Fellowship of Royal College of Ophthalmologists (UK) in 2015. Prof. Fan was awarded as both Chang Jiang Scholarship by Ministry of Education of China and Expert with Outstanding Contributions by the Ministry of Human Resources and Social Security of China.

As Discipline Leader of Dept. of Ophthalmology, Shanghai Ninth People's Hospital, Dr. Fan has been devoting his efforts to investigating orbital diseases and ocular tumors. With his leadership, his team established the digital orbital surgery platform and endo-navigation system for orbital surgery, and the surgical results of orbital disease have improved. Prof. Fan also made an important contribution to the investigation of functional orbital implant material. Dr. Fan was in charge of 12 national research grants, which includes National 863 project, projects of National Natural Science Foundation and the Ministry of Science and Technology of China. He has published over 100 peer-reviewed SCI papers as the first author or corresponding author, among which was published on Cell Stem Cell, Genome Biology, Advanced Functional Materials and Ophthalmology. He has received successively 12 awards, including Second Prize of National Science and Technology Progress Awards, First Prize of Shanghai Science and Technology Progress Awards. Prof. Fan also serves as the Chairman of Shanghai Ophthalmological Society, Vice President of Shanghai Hospital Association, Standing Committee Member of Chinese Ophthalmological Society, Secretary-general of Chinese Ophthalmologist Association, Chairman of Chinese Society of Ophthalmic Plastic and Orbital Disease Director of Institute of Ophthalmology and Visual Science, Shanghai Jiao Tong University School of Medicine, past President of Asia-Pacific Society of Ophthalmic Plastic & Reconstructive Surgery.

Dr. Fan has rich managerial experience of the Party building, medical education and hospital management. Prof. Fan has successively served as the Party Secretary and President of Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, the Dean of Jiuyuan College of Clinical Medicine of Shanghai Jiao Tong University and the President of third People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Prof. Fan was named as the Excellent Talent by the Ministry of Health of China, National Excellent Scientific and Technical Talent by the Ministry of Science and Technology of China, and the Shanghai Leading Talent by Shanghai Municipal Government.

# Scientific Program

#### 6 December 2024 (FRIDAY)



The Walsh-in-Asia Session is named and patterned after the Frank B. Walsh Session at the annual meeting of the North American Neuro-Ophthalmology Society (NANOS). Eight unusual, interesting, and challenging cases with supportive radiologic and histopathologic images are presented and discussed with input from a panel of experts comprising of neuro-ophthalmologists, a neuro-radiologist, and a pathologist.

ſ
L

Time: 14:00 - 15:30

Room: N201A

Time	Speakers	Торіс
14:00-14:20	Hui-Chen CHENG	Are the steroids working?
14:20-14:40	Chee Fang CHIN	Atypical by Design
14:40-15:00	Muhammad Rizqy ABDULLAH	Silent Threat
15:00-15:20	Hazel LIN	Triple Threat



# CHEUK Wah

Hong Kong, China

Dr. Cheuk Wah is a general pathologist with special interest in hematolymphoid tumors, head and neck tumors, gynecology pathology, molecular pathology, eye pathology and particularly IgG4-related disease. Graduating with first class honors in Biomedical Sciences from the University of Hong Kong in 1993. He completed his MBBS in 1996 in the same University.

Dr. Cheuk had initially worked as a resident in Ophthalmology for 6 months at Prince of Wales Hospital before switching to Anatomical Pathology at Queen Elizabeth Hospital. He obtained fellowships from The Royal College of Pathologists of Australasia and The Hong Kong College of Pathologists. He undertook fellowship training under Dr. John KC Chan at Queen Elizabeth Hospital and elective training with Dr. Esther Oliva at Massachusetts General Hospital, Harvard Medical School.

Dr. Cheuk has authored over 120 peer-reviewed papers and contributed to key medical texts, including WHO tumor classification blue books and Fletcher's Diagnostic Histopathology of Tumors. Currently, Dr. Cheuk serves as Chief of Service of the Pathology Department at Queen Elizabeth Hospital.



# POON Wai Lun

#### Hong Kong, China

Dr. Poon Wai Lun obtained his MBBS degree with honour from the University of Hong Kong in 1995. He obtained his fellowship from the Hong Kong College of Radiologists (HKCR) in 2004. He spent his Neuroradiology and Interventional Neuroradiology training period in France, under late Professor Pierre Lasjaunias, and in Canada under Professor Karl terBrugge. He learnt his interventional technique in the treatment of vascular malformations from Dr Wayne Yakes and Dr Young-soo Do, two renowned interventional radiologists in the field.

Dr Poon is now Chief-of-Service of Department of Diagnostic and Interventional Radiology at Queen Elizabeth Hospital. His fields of interest are Neuroradiology, Interventional Neuroradiology and Interventional management of vascular anomalies. He has various peer-reviewed publications and presentations in these fields.

He is Warden of Hong Kong College of Radiologists, President of the Hong Kong Society of Interventional and Therapeutic Neuroradiology (HKSITN) and a member of the Hong Kong Society of Interventional Radiology (HKSIR).



### Hui-Chen CHENG

#### Chinese Taipei

HUI-CHEN CHENG, MD,PhD completed her ophthalmic residency training and fellowship training of neuro-ophthalmology, pediatric ophthalmology and strabismus at the Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. She is currently the attending physician of Neuro-ophthalmology & Strabismus Section of the Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. She is also the assistant professor of department of ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Dr. Cheng had been the executive secretary of local organizing committee of the 31th Asia-Pacific Academy of Ophthalmology Congress. She is currently the council member of Women in Ophthalmology Standing Committee of the Asia Pacific Academy of Ophthalmology (APAO).



### **Chee Fang CHIN**

#### Singapore

Dr Chin Chee Fang is a Senior Consultant Ophthalmologist at the National Healthcare Group (NHG) Eye Institute at Tan Tock Seng Hospital, Singapore. Dr Chin obtained her Bachelor of Medicine & Surgery from the University of Edinburgh, United Kingdom. She completed her specialist training in Singapore, attaining the Masters of Medicine in Ophthalmology, and is a Fellow of the Royal College of Surgeons of Edinburgh, as well as the Academy of Medicine Singapore.

Dr Chin underwent a clinical fellowship in Neuro-Ophthalmology at the National Hospital for Neurology & Neurosurgery in London, United Kingdom. Her clinical interests are neuro-ophthalmology, visual rehabilitation and general ophthalmology.

Dr Chin is currently the Head of Neuro-Ophthalmology of the NHG Eye Institute and the Head of Clinical Services of the Ophthalmology Department, Tan Tock Seng Hospital. She is active in teaching residents and medical students alike, and is a member of the Exam Working Committee and a former National Examiner with the American Board of Medical Specialties (Singapore). She is also a member of the Neuro-Ophthalmology Subspecialty Committee in the College of Ophthalmologists, Singapore.



# Muhammad Rizqy ABDULLAH

#### Indonesia

Ophthalmologist trained in neuro-ophthalmology, part of the lecturer staff Department of Ophthalmology, Universitas Airlangga, Surabaya, Indonesia. Completed medical school and ophthalmology residency at Universitas Airlangga, Surabaya, Indonesia, and continuing a Neuro-Ophthalmology Fellowship at Cicendo National Eye Center Hospital, Bandung, Indonesia. Currently practicing at Dr Soetomo General Academic Hospital and Universitas Airlangga Hospital, Surabaya, Indonesia. Focus interest in Neuro-Ophthalmology diseases related to vascular, autoimmune, and infection.



# Hazel LIN

#### Singapore

Senior Consultant Neuro-ophthalmologist and Cataract Specialist at National University Hospital, Singapore. Deputy Head of Ophthalmology, National University Hospital Assistant Professor, National University of Singapore

# Scientific Program

### 6 December 2024 (FRIDAY)

### Session Theme: Walsh-in-Asia #2









Anthony Arnold

Noel P Ching-yan Chan

Prem Subramanian

Clement Tan

The Walsh-in-Asia Session is named and patterned after the Frank B. Walsh Session at the annual meeting of the North American Neuro-Ophthalmology Society (NANOS). Eight unusual, interesting, and challenging cases with supportive radiologic and histopathologic images are presented and discussed with input from a panel of experts comprising of neuro-ophthalmologists, a neuro-radiologist, and a pathologist.



Cheuk Wah



Neuro-radiology

Poon Wai Lun

Time: 16:00 - 17:30

Room: N201A

Time	Speakers	Торіс
16:00-16:20	Akarawit EIAMSAMARNG	A Dominant Ophthalmoplegia
16:20-16:40	Sophia LI	Whispers from 1973
16:40-17:00	Madhumita GOPAL	Oh bLYRMey
17:00-17:20	Zizhong HU	Twists and Turns



# CHEUK Wah

Hong Kong, China

Dr. Cheuk Wah is a general pathologist with special interest in hematolymphoid tumors, head and neck tumors, gynecology pathology, molecular pathology, eye pathology and particularly IgG4-related disease. Graduating with first class honors in Biomedical Sciences from the University of Hong Kong in 1993. He completed his MBBS in 1996 in the same University.

Dr. Cheuk had initially worked as a resident in Ophthalmology for 6 months at Prince of Wales Hospital before switching to Anatomical Pathology at Queen Elizabeth Hospital. He obtained fellowships from The Royal College of Pathologists of Australasia and The Hong Kong College of Pathologists. He undertook fellowship training under Dr. John KC Chan at Queen Elizabeth Hospital and elective training with Dr. Esther Oliva at Massachusetts General Hospital, Harvard Medical School.

Dr. Cheuk has authored over 120 peer-reviewed papers and contributed to key medical texts, including WHO tumor classification blue books and Fletcher's Diagnostic Histopathology of Tumors. Currently, Dr. Cheuk serves as Chief of Service of the Pathology Department at Queen Elizabeth Hospital.



# POON Wai Lun

#### Hong Kong, China

Dr. Poon Wai Lun obtained his MBBS degree with honour from the University of Hong Kong in 1995. He obtained his fellowship from the Hong Kong College of Radiologists (HKCR) in 2004. He spent his Neuroradiology and Interventional Neuroradiology training period in France, under late Professor Pierre Lasjaunias, and in Canada under Professor Karl terBrugge. He learnt his interventional technique in the treatment of vascular malformations from Dr Wayne Yakes and Dr Young-soo Do, two renowned interventional radiologists in the field.

Dr Poon is now Chief-of-Service of Department of Diagnostic and Interventional Radiology at Queen Elizabeth Hospital. His fields of interest are Neuroradiology, Interventional Neuroradiology and Interventional management of vascular anomalies. He has various peer-reviewed publications and presentations in these fields.

He is Warden of Hong Kong College of Radiologists, President of the Hong Kong Society of Interventional and Therapeutic Neuroradiology (HKSITN) and a member of the Hong Kong Society of Interventional Radiology (HKSIR).



### Akarawit EIAMSAMARNG

#### Thailand

Dr. Akarawit Eiamsamarng is a neuro-ophthalmologist in the Ophthalmology Department at Siriraj Hospital, affiliated with Mahidol University in Bangkok, Thailand. He graduated from the Faculty of Medicine Siriraj Hospital and has a keen interest in facial movement disorders, botulinum toxin applications, and optic neuropathies. Additionally, Dr. Eiamsamarng is focused on facial aesthetics and eyelid surgery. In 2020, he completed a fellowship at the Korean College of Cosmetic Surgery and Medicine. His research encompasses ptosis surgery, optic neuropathy, and botulinum toxin.



# Sophia Ll

#### Hong Kong, China

Dr Sophia Li Ling is originally from Beijing, China. She received her medical degree at the Chinese University of Hong Kong. Prior to her medical training, she had exposure to various clinical research and obtained PhD at the University of Hong Kong. Her residency in ophthalmology was started in 2019 at the Prince of Wales hospital. She has particular interest in vitreo-retina and neuro-ophthalmology, and has started the sub-specialty training under the CUHK fellowship program since 2023.



### Madhumita GOPAL

India

A practicing neuro ophthalmologist with a love for teaching, research and neuro ophthalmology. Completed residency from LV Prasad Eye Hospital, Hyderabad. Underwent fellowship in neuro-ophthalmology at Sankara Nethralaya, Chennai, receiving training under some of the top neuro ophthalmologists of the country is now practicing at Aravind Eye Hospital, Chennai. Has several publications in peer reviewed journals and is a frequent presenter at various national and international conferences.



# Zizhong HU

#### China

Dr Zizhong Hu finished his PhD study of retinal diseases at the Nanjing Medical University. He is now a vitreoretinal surgeon and a neuro-ophthalmologist, and focuses his research on pathological mechanism of retinal and neuro-ophthalmological diseases in the Department of Ophthalmology of the First Affiliated Hospital with Nanjing Medical University. His work has been supported by 5 funds and has published over 30 peer-reviewered articles (Diabetes, Retina, ect.).

# Scientific Program

	7 December 2024 (SATURDAY)			
Session Theme: Chair(s):   Paediatric Image: Chair(s):   Neuro-Ophthalmology Image: Chair(s):   Genetic disorders Image: Chair(s):   Jeong-min Hwang Image: Chair(s):   Neil Miller Patrick   Patrick Patrick				
Time	: 08:30 - 10:00	Room: N201A		
Time	Speakers	Торіс		
08:30-08:42	Virender SACHDEVA	Approach to Pediatric Cranial Nerve Palsies		
08:42-08:54	Patrick YU-WAI-MAN	Therapeutic Benefit of Idebenone in LHON: from RHODOS to LEROS		
08:54-09:06	Neil MILLER	Congenital Optic Disc Elevation: Types and Associations		
09:06-09:18	Jeong-Min HWANG	The Many Faces of Congenital Cranial Dysin- nervation Disorders: Deciphering the Unpre- dictable Clinical Presentations		
09:18-09:30	Umapathi N. THIRUGNANAM	Don't Fear Nystagmus		
09:30-09:42	Shweta SINGHAL	OPA1 Optic Atrophy- A Multiethnic Asian Perspective		
09:42-10:00	-	Panel Discussion		



### Virender SACHDEVA

#### India

Virender Sachdeva received his basic medical training from Maulana Azad Medical College, University of Delhi, New Delhi, and specialized in ophthalmology from Safdarjung Hospital, University of Delhi. He completed a fellowship in comprehensive ophthalmology at LVPEI with specialization in pediatric ophthalmology before joining the Nimmagadda Prasad Children's Eye Care Centre, GMR Varalakshmi campus, Visakhapatnam. He also did a Clinical research Fellowship in Neuro-Ophthalmology at Emory University. His clinical and research interests include strabismus (squint), pediatric ophthalmology, and neuro-ophthalmological disorders. His keen interests include optic neuritis, IIH, myasthenia, cranial nerve palsies. His research works have been presented at various national and international forums.



### Patrick YU-WAI-MAN

#### United Kingdom

Professor Yu-Wai-Man is an academic neuro-ophthalmologist with a major research interest in mitochondrial genetics and inherited eye diseases. He holds a tenured Faculty position as Chair of Ophthalmology at the University of Cambridge, affiliated with the Cambridge Centre for Brain Repair and the MRC Mitochondrial Biology Unit. In addition to his academic roles, he has joint clinical appointments at Addenbrooke's Hospital in Cambridge and Moorfields Eye Hospital in London as an Honorary Consultant Neuro-Ophthalmologist.

Professor Yu-Wai-Man's research group is exploring the disease mechanisms leading to progressive retinal ganglion cell loss in inherited optic neuropathies by using a combination of patient tissues, induced pluripotent stem cells and animal models. He was awarded a prestigious NIHR Advanced Fellowship (2021-2026) to evaluate patient outcomes and therapies for this group of disorders.

Professor Yu-Wai-Man is the Director of the Cambridge Clinical Vision Laboratory (CCVL) that was set up as a cross-cutting facility to support advanced therapeutics on the Cambridge Biomedical Campus. In parallel, he has established a strong collaborative link with the NIHR Moorfields Biomedical Research Centre to fast track the development of effective therapies for inherited optic neuropathies, including novel gene therapy approaches. With funding from the NIHR and the MRC, he has built a national referral network for the investigation and management of patients with mitochondrial eye diseases. His research group is capitalising on this unique resource to explore disease biomarkers and the clinical applicability of high-resolution structural and functional imaging (eye and brain).



# Neil MILLER

#### **United States**

Dr. Neil Miller is Professor Emeritus of Ophthalmology, Neurology, and Neurosurgery at the Johns Hopkins University School of Medicine. He has authored over 595 articles, 97 chapters, and 16 books, including the 4th edition of "Walsh and Hoyt's Clinical Neuro-Ophthalmology" and has co-edited the 5th and 6th editions of this textbook as well as four editions of an abbreviated version of the textbook: "Walsh and Hoyt's Clinical Neuro-Ophthalmology: The Essentials", the most recent of which was published in 2020. Dr. Miller also has co-authored three editions of "The Neuro-Ophthalmology Survival Guide", a textbook designed for both physicians and students. The third edition was published this year. Dr. Miller has spoken at numerous local, national, and international meetings and has given 67 named lectures around the world. In addition, he has been involved in many clinical trials in the field of neuroophthalmology. Many of Dr. Miller's previous Fellows and residents hold faculty positions at major institutions throughout the United States and around the world.



### Jeong-Min HWANG

#### Korea, Republic of

Jeong-Min Hwang, M.D. attended Seoul National University for medical school and ophthalmology residency. She underwent an observership in University of Wisconsin and Childrens Hospital Los Angeles learning from Dr. Kushner, Dr. Wright, Dr. Murphree and Dr. Borchert from 1992 to 1994. She also had an observership in Wilmer Eye Institute learning from Dr. Guyton and Dr. Miller in 1998, and in Cleveland Clinic and The Hospital for Sick Children of the University of Toronto learning from Dr. Kraft, Dr. Sharpe, and Dr. Traboulsi in 2002.

She is currently a professor of Ophthalmology at Seoul National Universityand and is appointed as a physician at Seoul National University Bundang Hospital. She has been a member of the National Academy of Medicine of Korea since 2011, and has been a councilor of Asia-Pacific Strabismus and Pediatric Ophthalmology Society and Asian Neuro-Ophthalmology Society since 2016. She served as the president of Korean Neuro-Ophthalmology Society (2015-2017), vice chairperson of Korean Ophthalmological Society (2015-2016), editorial director of Korean Neuro-Ophthalmology Society Context (2015-2016), editorial director of Korean Neuro-Ophthalmology Society (2013-2015), Audit Director of Korean Strabismus and Pediatric Ophthalmological Society (2012-2014).

She has continued research interest in optic neuropathies, pupillary disorders, and congenital cranial dysinnervation disorders, with 363 SCI(E) articles, 137 non-SCI(E) articles, and chapters in 19 books.



# Umapathi N. THIRUGNANAM

Singapore

Professor and senior consultant Neurologist Singapore National Eye Centre and National Neuroscience Institute Specialist interests: Eye movements and nystagmus Neuromuscular diseases Electrophysiologist The practise of medicine in under- resourced regions



### Shweta SINGHAL

Singapore

Dr Shweta Singhal is a Senior Consultant at Singapore National Eye Centre. She also holds additional research and teaching appointments including Assistant Professor of Ophthalmology with Duke-NUS Medical School and Clinical Lecturer with Yong Loo Lin School of Medicine, National University of Singapore.

Dr Singhal completed her basic medical training at Christian Medical College, Vellore in India before moving to the UK to undergo research training. She obtained a PhD at the UCL Institute of Ophthalmology, London in 2009 and subsequently moved to Singapore where she completed ophthalmic training in 2016 with honours, including two gold medals at the FAMS exit exam and the Richard Fan Gold Medal for outstanding ophthalmic resident in 2016. She completed a two year clinical neuro-ophthalmology fellowship (2017-2019) at SNEC and 6mths advanced training in Inherited Neuro-ophthalmic diseases at Moorfields Eye Hospital, London, UK in 2023. In her clinical practice at SNEC, apart from treating patients with general ophthalmic conditions and performing cataract surgery, she specializes in treatment of neuro-ophthalmic diseases with particular focus on neuro-immunology and inherited optic neuropathies.

Dr Singhal is a clinician scientist and concurrent to her clinical work, she is actively involved in clinical and laboratory based ophthalmic research. During her PhD she demonstrated that the adult human retina harbours stem cells with the potential to restore retinal function, a finding with key implications for retinal regeneration. In 2009, she won the Oxford Ophthalmology Congress Founders Cup for this work. She has authored over 25 high quality scientific publications and has won multiple competitive research grants from National Medical Research Council Singapore, SingHealth and Duke NUS University to continue her research. She runs a basic science laboratory at Singapore Eye Research Institute where her team is developing stem cell based models of optic nerve disease and studying the cellular mechanisms of toxic and inherited optic neuropathies.

# Scientific Program

7 December 2024 (SATURDAY)

# Session Theme: Rapid Fire Free Paper 1 (ASNOS) Susan Mollan Chair(s): $\int_{Susan Mollan}$

Time: 08:30 - 10:00

Room: N202-N203

Time	Speakers	Торіс
08:30- 08:38	Gang LIU	A new surgical procedure using "trigeminal-facial nerve neural circuit blocking" - Report of 47 patients with failed deep brain stimulation therapy for Meige patients with blepharospasm
08:38- 08:46	Phakinee RUEANGCHARIN	Treatment outcomes of isolated peri-ocular botulinum toxin A injection in hemifacial spasm compared with conventional injection : RCT non- inferiority crossover trial.
08:46- 08:54	Lihua HOU	A new MRI biomarker for idiopathic intracranial hypertension
08:54- 09:02	Keysha ABIGAIL	Methanol Toxic Optic Neuropathy During Coronavirus Disease Of 2019 Pandemic In Indonesia
09:02-09:10	Ling-Ping CEN	Clinical Features of COVID-19-Related Optic Neuritis: A Retrospective Study
09:10-09:18	Ming Ming ZHU	Clinical Features and Visual outcomes of Optic Neuritis in Chinese population: a 5-year retrospective study in Hong Kong
09:18-09:26	Yuyu Ll	Ofatumumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open- label pilot study
Time	Speakers	Торіс
-------------	--------------------------	---
09:26-09:34	Suwichaya MUKMONTHIEN	Ocular manifestations and outcomes of carotid cavernous fistulas: A 10-year retrospective study
09:34-09:42	Jia MA	Treatment outcomes of isolated peri-ocular botulinum toxin A injection in hemifacial spasm compared with conventional injection : RCT non-inferiority crossover trial.
09:42-09:50	Yuezhu LU	A new MRI biomarker for idiopathic intracranial hypertension
09:50-10:00	_	Panel Discussion

7 December 2024 (SATURDAY)



Time	Speakers	Торіс
08:30-08:38	Yu HUA	A Radiotherapy Sensitizer for Uveal Melanoma that interrupts Cu-Fe Balance
08:38-08:46	Tianyu ZHU	Elesclomol-elicited Cuproptosis Abrogates Cisplatin Resistance in Uveal Melanoma
08:46-08:54	Shan HE	Combination of Single-cell and Bulk RNA seq reveals the Immune Landscape in Retinal Ischemia-reperfusion injury
08:54-09:02	Jing KONG	Research on the Relationship Between CD47 Expression and the Prognosis as well as Im- mune Microenvironment of Uveal Melanoma
09:02-09:10	Xiang GU	Histone Lactylation-boosted ALKBH3 Potentiates Tumor Progression and Diminished Promyelocytic Leukemia Protein Nuclear Condensates by N1-Methyladenosine Demethylation of SP100
09:10-09:18	Qili LIAO	Aurora A Kinase Inhibition Is Synthetic Lethal with the Activation of MYCN in Retinoblastoma

Time	Speakers	Торіс
09:18-09:26	Rong ZHANG	CYTOR-NFAT1 Feedback Loop regulates Epithelial-mesenchymal Transition of Retinal Pigment Rpithelial Cells
09:26-09:34	Qili LIAO	FTO Elicits Tumor Neovascularization in Cancer-associated Fibroblasts Through Eliminating m6A Modifications of Multiple Pro-angiogenic Factors
09:34-09:42	Zhiqiang XIAO	A Novel Model of Traumatic Optic Neuropathy under Direct Vision through Anterior Orbital Approach in Non-human Primates
09:42-09:50	Xiayin YANG	The Temporal Dynamics of Pathological Profile and Functional Impairment in Neuromyelitis Optica Spectrum Disorders associated Optic Neuritis
09:50-10:00	-	Panel Discussion

7 December 2024 (SATURDAY)			
Session Theme: <b>Recent Advances In</b> <b>Neuro-ophthalmology</b>	Chair(s): Ing Liang Loo	Frem Subramanian	Yong Zhong
Time: <b>10:30 - 12:00</b>		Room: <b>N201A</b>	

Time	Speakers	Торіс
10:30-10:42	Patrick YU-WAI-MAN	Gene Therapy for LHON – Recent Advances and Future Challenges
10:42-10:54	Prem SUBRAMANIAN	Navigating the management of TED
10:54-11:06	Dan MILEA	Al in Neuro-Ophthalmology
11:06-11:18	Neil MILLER	Current & Evolving Therapies for Optic Pathway Gliomas
11:18-11:30	Susan MOLLAN	Potential of GLP-1 Receptor Agonist in Treating IIH
11:30-11:42	Rong-Kung TSAI	Pegfilgrastim Use in Patients with Traumatic Optic Neuropathy



#### Patrick YU-WAI-MAN

#### United Kingdom

Professor Yu-Wai-Man is an academic neuro-ophthalmologist with a major research interest in mitochondrial genetics and inherited eye diseases. He holds a tenured Faculty position as Chair of Ophthalmology at the University of Cambridge, affiliated with the Cambridge Centre for Brain Repair and the MRC Mitochondrial Biology Unit. In addition to his academic roles, he has joint clinical appointments at Addenbrooke's Hospital in Cambridge and Moorfields Eye Hospital in London as an Honorary Consultant Neuro-Ophthalmologist.

Professor Yu-Wai-Man's research group is exploring the disease mechanisms leading to progressive retinal ganglion cell loss in inherited optic neuropathies by using a combination of patient tissues, induced pluripotent stem cells and animal models. He was awarded a prestigious NIHR Advanced Fellowship (2021-2026) to evaluate patient outcomes and therapies for this group of disorders.

Professor Yu-Wai-Man is the Director of the Cambridge Clinical Vision Laboratory (CCVL) that was set up as a cross-cutting facility to support advanced therapeutics on the Cambridge Biomedical Campus. In parallel, he has established a strong collaborative link with the NIHR Moorfields Biomedical Research Centre to fast track the development of effective therapies for inherited optic neuropathies, including novel gene therapy approaches. With funding from the NIHR and the MRC, he has built a national referral network for the investigation and management of patients with mitochondrial eye diseases. His research group is capitalising on this unique resource to explore disease biomarkers and the clinical applicability of high-resolution structural and functional imaging (eye and brain).



#### Prem SUBRAMANIAN

#### **United States**

Prem S. Subramanian, MD, PhD, is the Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology and is professor of ophthalmology, neurology, and neurosurgery and vice chair for academic affairs at the Sue Anschutz-Rodgers University of Colorado Eye Center/School of Medicine. He is also Adjunct Professor of Surgery at the Uniformed Services University of the Health Sciences. He received his MD with high honors and PhD in molecular and human genetics at Baylor College of Medicine in Houston, Texas. He is a founding member of the medical staff of the Marcus Institute for Brain Health, which serves to improve the functioning of patients with traumatic brain injury through intensive outpatient rehabilitation. He is also an active orbitocranial surgeon with a specific interest in tumors of the skull base and small-incisional approaches. His current research is focused on finding more effective medical treatments for patients at risk for progressive thyroid ophthalmopathy, developing better treatments of vision problems in patients with increased intracranial pressure, and using vestibular and visual therapies to overcome visual and balance dysfunction after traumatic brain injury. He is President of the North American Neuro-Ophthalmology Society, Chair of the Council of the American Academy of Ophthalmology and member of the AAO Board of Trustees and serves on the Board of Directors of the North American Society of Academic Orbital Surgeons; in addition, he has published over 250 research articles, book chapters, and web-based educational materials and is a dedicated educator in several countries around the world.



### Dan MILEA

#### France

Dan MILEA, MD, PhD is a Neuro-Ophthalmologist and Clinician Scientist, Head of the Neuro-Ophthalmology department and Director of the Rothschild BRAIN Visual and Computational Neuroscience Group at the Rothschild Foundation Hospital, Paris (France). He is also an adjunct Clinician Scientist at the Singapore Eye Research Eye Institute and Professor of Ophthalmology (Angers/France, Copenhagen/Denmark and Duke-NUS Medical School/Singapore).

In 2018 he has created an international Consortium gathering the efforts of more than 40 expert academic centers from over 20 countries (BONSAI: Brain and Optic Nerve Study with Artificial Intelligence), which has published its findings in various journals, such as The New England Journal of Medicine, JAMA Ophthalmol, Neurology, Annals of Neurology, Journal of Neuro-Ophthalmology, etc.

He has mentored numerous clinical and research fellows in Europe and Asia, including France, Denmark, Singapore, India, Malaysia, Thailand, Philippines, while also performing numerous mission trips in Vietnam, Cambodia, Myanmar, India, etc. Author of over 250 peer-reviewed publications and textbooks in Ophthalmology and Neuro-ophthalmology, he has lectured at more than 200 medical and scientific meetings. Dan Milea is currently CO-Editor-in-Chief of the Journal "Neuro-Ophthalmology".



#### Neil MILLER

#### United States

Dr. Neil Miller is Professor Emeritus of Ophthalmology, Neurology, and Neurosurgery at the Johns Hopkins University School of Medicine. He has authored over 595 articles, 97 chapters, and 16 books, including the 4th edition of "Walsh and Hoyt's Clinical Neuro-Ophthalmology" and has co-edited the 5th and 6th editions of this textbook as well as four editions of an abbreviated version of the textbook: "Walsh and Hoyt's Clinical Neuro-Ophthalmology: The Essentials", the most recent of which was published in 2020. Dr. Miller also has co-authored three editions of "The Neuro-Ophthalmology Survival Guide", a textbook designed for both physicians and students. The third edition was published this year. Dr. Miller has spoken at numerous local, national, and international meetings and has given 67 named lectures around the world. In addition, he has been involved in many clinical trials in the field of neuro-ophthalmology. Many of Dr. Miller's previous Fellows and residents hold faculty positions at major institutions throughout the United States and around the world.



### Susan MOLLAN

#### United Kingdom

Susan Mollan has an established international reputation in Neuro-ophthalmology. She is a Consultant Neuro-Ophthalmologist at University Hospitals Birmingham and a Honorary Professor at the University of Birmingham, England. She is a board member at the North American Neuro-Ophthalmology Society and an international senior examiner for the Royal College of Ophthalmologists.

She enjoys clinical research, and is situated well within the large team in Birmingham to investigate rare conditions that affect the eye and brain. Her professional research specialties include Idiopathic Intracranial Hypertension (IIH), Giant Cell Arteritis (GCA) and the development of quantification of disease through ocular imaging. She is the director of ophthalmology research and the chief data officer for INSIGHT (a Health Data Research UK hub for eye health https://www.insight. hdrhub.org). INSIGHT is an ever green Health Data Research UK bioresource for eye health (28 million images and linked clinical data).

She actively works to provide pragmatic guidance for clinicians through guidelines and publications (International Headache Society IIH trial guidelines 2023); (IIH consensus guidelines (2018); European League Against Rheumatism GCA guidelines (2019); British Society of Rheumatology GCA guidelines (2020); and the European Headache Federation GCA guidelines (2020). She has been instrumental in key randomized control trials conducted in Idiopathic Intracranial Hypertension and reported the first randomized control trial into weight loss methods in IIH (2021).



### Rong-Kung TSAI

Chinese Taipei

Research Interest:

Neuro-ophthalmology, pediatric ophthalmology, ocular Neuroprotection, Regenerative medicine, translation medicine

#### Featured publications:

1. Miller NR, Tsai RK\*. Editorial. Optic Neuropathies: Current and Future Strategies for Optic Nerve Protection and Repair. Int J Mol Sci. 2023; 24(8):6977.

2. Desai TD, Wen YT, Daddam JR, Cheng F, Chen CC, Pan CL, Lin KL, Tsai RK\*. Long term therapeutic effects of icariin-loaded PLGA microspheres in an experimental model of optic nerve ischemia via modulation of CEBP-/G-CSF/noncanonical NF-B axis. Bioeng Transl Med. 2022; 7(2):e10289.

3. Wen YT, Huang CW, Liu CP, Chen CH, Tu CM, Hwang CS, Chen YH, Chen WR, Lin KL, Ho YC, Chen TC, Tsai RK\*. Inhibition of Retinal Ganglion Cell Loss by a Novel ROCK Inhibitor (E212) in Ischemic Optic Nerve Injury Via Antioxidative and Anti-Inflammatory Actions. Invest Ophthalmol Vis Sci. 2021; 62:21.

4. Huang CT, Wen YT, Desai TD, Tsai RK\*. Intravitreal Injection of Long-Acting Pegylated Granulocyte Colony-Stimulating Factor Provides Neuroprotective Effects via Antioxidant Response in a Rat Model of Traumatic Optic Neuropathy. Antioxidants (Basel). 2021;10(12):1934.



Time	Speakers	Торіс
10:30-10:38	Caiwen XIAO	Can changes in papillary blood flow density detected by OCTA predict prognostic vision for TON?
10:38-10:46	Wenyan SHENG	Analysis of structural injury patterns in macular superficial vessel density and retinal ganglion cell layer in ethambutol induced optic neuropathy
10:46-10:54	Jimethat CHALERMPONG	Factors influencing the rate and time of generalization in ocular myasthenia gravis
10:54-11:02	Songdi WU	Clinical Features and Functional Visual Recovery of Patients with Central Retinal Artery Occlusion Treated with Intra-Arterial Thrombolysis: A Single-Center Study
11:02-11:10	Hyun Jin SHIN	Neuro-ophthalmic findings of visual snow in East Asia
11:10-11:18	Xia ZHANG	Clinical and optic coherence tomography characteristic of acute optic neuritis secondary to neurosarcoidosis

Time	Speakers	Торіс
11:18-11:26	Chatchawal ARAMRAT	A 17-year review of presumed giant cell arteritis (GCA) patients : ophthalmic manifestations and applications of the 2022 ACR/EULAR criteria.
11:26-11:34	Antonia INDRIATI	The Effect of Androgen Deprivation Therapy on Contrast Sensitivity and Colour Vision in Metastatic Prostate Cancer Patients
11:34-11:42	Mingxing WU	Distinct clinical characteristics of optic compressive neuropathy associated with anterior clinoid process pneumatization
11:42-11:50	Ming-Hui SUN	Association between Magnetic Resonance Imaging and visual outcome in patients with neuromyelitis optica-A tertiary hospital in Taiwan
11:50-12:00	_	Panel Discussion

Time	Speakers	Торіс
10:30-10:45	Ho-Seok SA	Orbital Disease in Children
10:45-10:57	Wang YI	Some "Thrilling" Orbital Surgeries
10:57-11:05	Kenneth LAI	Low Clinical Activity Score Thyroid Eye Disease: review of 1439 patients from a Tertiary Center in Hong Kong
11:05-11:13	Wai Chak CHOY	Beta-blockers Reduce the Hazard of Developing Moderate-to-severe Thyroid Eye Disease in Autoimmune Thyroid Disease Patients – a Target Trial Emulation with Territory-wide Cohort of Autoimmune Thyroid Disease Patients from Hospital Authority Data Collaboration Laboratory
11:13-11:21	Anakin Chu Kwan LAI	The Economic Burden of Thyroid Eye Diseases – A Systematic Review
11:21-11:29	Eric Ka Ho CHOY	Psychiatric Outcome in Thyroid Eye Disease

Time	Speakers	Торіс
11:29-11:37	Mark Joseph LAGAO	Small-Incision Medial Browpexy Combined with Direct Lateral Browplasty: A Feasibility Review
11:37-11:45	Jie CHEN	Deep Learning-based Non-invasive Differential Diagnosis of Eyelid Basal Cell and Sebaceous Carcinomas Using Photographic Images
11:45-11:53	Xiang GU	Establishment and characterization of a TP53- mutated eyelid sebaceous carcinoma cell line
11:53-12:00	-	Panel Discussion



Time	Speakers	Торіс
13:30-14:00	_	Opening Ceremony
14:00-14:10	Chi Kin HO	Quality Eye Care for All: The role of Hong Kong Ophthalmological Society, Past Present and Future
14:10-14:20	Emily YEUNG	Achieving Excellence in Ophthalmic Care: Insights from the Past and Future Challenges for the College of Ophthalmologists of Hong Kong
14:20-14:30	Pak Chin CHOW	Greater Bay Area - Opportunities and Challenges



## Chi Kin HO

Hong Kong, China

President, HK Ophthalmological Society 1993-1999 President, College of Ophthalmologists of HK 2005-2007 Treasurer, Asia-Pacific Academy of Ophthalmology 2002-2012



## **Emily YEUNG**

Hong Kong, China

Dr. Yeung Fung Yee, Emily President of the College of Ophthalmologists of Hong Kong

The College of Ophthalmologists of Hong Kong is a statutory body and is responsible for organizing, supervising, evaluating, and accrediting the training of ophthalmologists in Hong Kong. The College also oversees mandatory continuous medical education and continuous professional development for all fellows to ensure that all ophthalmologists practicing in Hong Kong are up to date with the latest treatment and maintain the highest professional standards in ophthalmology. In 1998, Dr. Yeung was awarded the Best Researcher Award by Hong Kong Eye Hospital. Since 2002, Dr. Yeung has been the director of St. Teresa's Hospital Eye Centre. She is the former president of the Hong Kong Association of Private Eye Surgeons. She served in the College Council as honorary secretary from 2017 to 2021. She was the Vice president of general affairs of the College from 2021 to 2023. She received the Distinguished Service Award by the Asia-Pacific Academy of Ophthalmology in 2021.

Dr. Yeung is active in service to the profession and charity work. She serves in numerous charity organisations in Hong Kong. She was the ambassador for the Sight First China Action's initiative in 2000 and is the immediate past chairman of Eye Care Charitable Foundation. Since 2018, she has been the vice president of the Lions Eye Bank of Hong Kong and is a council member of Sports for Vision.



#### Pak Chin CHOW

Hong Kong, China

Dr. CHOW Pak Chin graduated from the University of Hong Kong, received training in Ophthalmology in Hong Kong, the University of Edinburgh and the Moorfield's Hospital. He received Fellowship from Edinburgh, United Kingdom, Hong Kong, Singapore and Malaysia.

He was the President of the College of Ophthalmologists of Hong Kong, The Hong Kong Association of Private Eye Surgeons and Vice President of The Hong Kong Medical Association.

He is the President of The Asian Foundation for the Prevention of Blindness,the Founding President of The Eye Care Charitable Foundation, the Patron of the Hong Kong Medical Association Charitable Foundation, Vice Chairman of the Project Vision and the Honourable Ambassador of the Eye First China Action.

Through these voluntary works, over 5 million charity cataract operations have been done in China.

For these works he was awarded by the Asia Pacific Academy of Ophthalmology The Distinguished Service Award, the Prevention of Blindness Award and the Susruta Lecturer. He was awarded the Hong Kong Humanity Award by the Hong Kong Red Cross.

He is a member of The Hong Kong Chief Executive Policy Unit Expert Group and The Hong Kong Metropolitan University Court.

He is a Honorary Assistant Professor of the University of Hong Kong and the Chinese University of Hong Kong.

He was invited to give many lectures in universities in China.

As a recognition of his contribution to the country he received from the China State Council The National Ethnic Group Unity and Progress Commendation, and from the Hong Kong SAR Government The Justice of the Peace and Bronze Bauhinia Star awards.

7 December 2024 (SATURDAY)

Session Theme: <b>Keynote Lecture</b>		Chair(s): Carmen Chan Carmen Chan Chan S Chiu Carmen Chan Chair S Chiu Chair S Chiu
Т	ime: <b>14:30 - 15:45</b>	Room: N201A
Time	Speakers	Торіс
14:30-14:55	Xianqun FAN	Tumorigenesis and Clinical Treatment of Ocular Malignancies
14:55-15:20	Neil MILLER	Current Diagnosis and Treatment of ONS Meningioma
15:20-15:45	Anthony ARNOLD	Optic Nerve Head Microcirculation: Implications for NAION Pathogenesis

### Scientific Program (Speakers Biography)



#### Xianqun FAN

#### China

Professor Fan Xianqun is the chief ophthalmologist at the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. He is the academician of the Chinese academy of Engineering, the distinguished professor of Changjiang Scholar of the Ministry of Education, the chair professor of Shanghai Jiao Tong University, member of the Chinese Academy of Medical Science, the member of the Academia Ophthalmologica Internationalis (AOI), fellow of the Royal College of Ophthalmologists (UK), fellow Ad Hominem of the Royal College of Surgeons in Edinburgh (UK). He is currently the vice president of Shanghai Jiao Tong University, chancellor of Shanghai Jiao Tong University School of Medicine, director of Shanghai key laboratory of Orbital Diseases and Ocular Tumor, the deputy to the 14th National People's Congress. He concurrently serves as the vice chairman of the China Anti-Cancer Association, the president of the Asia-Pacific Society of Ocular Oncology and Pathology (APSOOP), the president of the fifth Asia-Pacific Society of Ophthalmic Plastic and Reconstructive Surgery (APSOPRS). He has won second prizes of the National Science and Technology Progress Award (twice), first prizes of the Shanghai Science and Technology Progress Award (Thrice), the Ho Leung Ho Lee Science and Technology Progress Award, the first innovator award of Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and De Ocampo Lecture, the highest academic achievement award to Asia-Pacific Academy of Ophthalmology (APAO).



### Neil MILLER

#### **United States**

Dr. Neil Miller is Professor Emeritus of Ophthalmology, Neurology, and Neurosurgery at the Johns Hopkins University School of Medicine. He has authored over 595 articles, 97 chapters, and 16 books, including the 4th edition of "Walsh and Hoyt's Clinical Neuro-Ophthalmology" and has co-edited the 5th and 6th editions of this textbook as well as four editions of an abbreviated version of the textbook: "Walsh and Hoyt's Clinical Neuro-Ophthalmology: The Essentials", the most recent of which was published in 2020. Dr. Miller also has co-authored three editions of "The Neuro-Ophthalmology Survival Guide", a textbook designed for both physicians and students. The third edition was published this year. Dr. Miller has spoken at numerous local, national, and international meetings and has given 67 named lectures around the world. In addition, he has been involved in many clinical trials in the field of neuro-ophthalmology. Many of Dr. Miller's previous Fellows and residents hold faculty positions at major institutions throughout the United States and around the world.



#### Anthony ARNOLD

#### United States

Anthony C. Arnold, MD is Vice Chair for Education, Professor and Chief, Neuro-Ophthalmology Division, Dept. of Ophthalmology, University of California, Los Angeles. He has a research interest in ischemic and inflammatory optic neuropathies, with more than 100 publications. He has served as the President of the AUPO Ophthalmology Program Directors Council 2000-2007, Chair of the ACGME Residency Review Committee for Ophthalmology 2010-2016, Chair of the ACGME Ophthalmology Milestones Development Group 2010-2013, and member of the ACGME Board of Directors 2015-2017, Director of the American Board of Ophthalmology 2008-2016, and President and Chairman of the Board of the North American Neuro-Ophthalmology Society 2008-2012.

7 December 2024 (SATURDAY)



Time	Speakers	Торіс
16:00-16:10	Syntia NUSANTI	IIH - Do you need an LP - YES
16:10-16:20	Anthony ARNOLD	IIH - Do you need an LP - NO
16:20-16:30	Celia CHEN	CRAO - Is there a treatment - YES
16:30-16:40	Karen REYES	CRAO - Is there a treatment - NO
16:40-16:50	Andrew LEE	Patients with severe Isolated Idiopathic Optic Neuritis - Should they be offered Plasma Exchange - YES
16:50-17:00	Clare FRASER	Patients with severe Isolated Idiopathic Optic Neuritis - Should they be offered Plasma Exchange - NO
17:00-17:10	Kong Yong GOH	Should we use Systemic Steroid in the Treatment of Ocular MG- Yes
17:10-17:20	Rashmin GANDHI	Should we use Systemic Steroid in the Treatment of Ocular MG-NO



#### Syntia NUSANTI

#### Indonesia

Dr. Syntia Nusanti is the Head of the Neuro-ophthalmology division at the Faculty of Medicine, University of Indonesia – Dr Cipto Mangunkusumo Hospital (FMUI-RSCM). She is also affiliated with the Medical Education Department at FMUI. She holds the position of Head of Ophthalmology Residency Program at FMUI. Having graduated as a medical doctor from FMUI in 2002, she pursued her residency in the Ophthalmology Department FMUI-RSCM from October 2003 to December 2007. In 2008, she successfully completed her fellowship program in Neuro-ophthalmology at the Ophthalmology Department RSCM. Continuing her academic pursuits, she earned a Magister in Medical Education from FMUI in 2011 and obtained her Doctoral degree in 2023. Actively participating in professional organizations, Dr. Syntia is a scientific meetings department member of the Indonesian Ophthalmologist Association (IOA) and president of Neuro-ophthalmology Society. She also holds positions as vice president of the the Collegium Ophthalmology Indonesia. Within international organization, she joins the Council of the Asian Neuro-Ophthalmology Society (ASNOS).



#### Anthony ARNOLD

#### United States

Anthony C. Arnold, MD is Vice Chair for Education, Professor and Chief, Neuro-Ophthalmology Division, Dept. of Ophthalmology, University of California, Los Angeles. He has a research interest in ischemic and inflammatory optic neuropathies, with more than 100 publications. He has served as the President of the AUPO Ophthalmology Program Directors Council 2000-2007, Chair of the ACGME Residency Review Committee for Ophthalmology 2010-2016, Chair of the ACGME Ophthalmology Milestones Development Group 2010-2013, and member of the ACGME Board of Directors 2015-2017, Director of the American Board of Ophthalmology 2008-2016, and President and Chairman of the Board of the North American Neuro-Ophthalmology Society 2008-2012.



### Celia CHEN

#### Australia

Professor Celia Chen is a Clinical Professor with University of South Australia and full academic professor in the College of Medicine and Public Health, Flinders University. She is a consultant neuro-ophthalmologist/clinician-scientist at Flinders University. She completed a prestigious neuro-ophthalmology fellowship at the Wilmer Eye Institute, Johns Hopkins Hospital.

Professor Chen is the current President of the Neuro-Ophthalmic Society of Australia.

She has an excellent research record and is the recipient of both national and international scholarships and awards including the American Australian Education Fellowship, South Australian Science Excellence Award, and the Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award.

Professor Chen is dedicated to providing mentorship and learning opportunities for young ophthalmologists in the Asia-Pacific region. She has been doing field work in Cambodia for over 10 years and providing fellowship opportunity, through APAO Women in Ophthalmology International Fellowship Program, Kim Frumar Scholarship and Eye Surgeon's Foundation Fellowship Program. This has helped young ophthalmologists from a developing country to receive fellowship training in a subspecialty area of ophthalmology, at an international training center of excellence.



#### Karen REYES

Philippines

Karen B. Reyes, MD, MBA-Regis ipreviously served as the president of the Neuro-Ophthalmology Society of the Philippines and currently holds key positions as the Resident Training Officer of the Department of Ophthalmology at Cardinal Santos Medical Center and as the Division Chief of Neuro-Ophthalmology at both the University of the Philippines Philippine General Hospital and Ospital ng Makati. Dr. Reyes is an active member of the Philippine Cornea Society, Inc. and part of the Technical Working Group of the Philippine Board of Ophthalmology. She is also pursuing a Master of Arts in Health Professions Education.



### Andrew LEE

#### United States

Andrew G. Lee, M.D. is the Herb and Jean Lyman Centennial Chair in Ophthalmology and is the Founding Chairman of the Blanton Eye Institute, Department of Ophthalmology at Houston Methodist Hospital in Houston, Texas. He is Professor of Ophthalmology, Neurology, and Neurosurgery at Weill Cornell Medicine and an adjunct professor of Ophthalmology at Baylor College of Medicine; Texas A and M College of Medicine; University of Iowa and the University of Buffalo; and Clinical Professor at the University of Texas Medical Branch (UTMB) in Galveston, Texas and the UT MD Anderson Cancer Center.

He is a graduate of the University of Virginia (UVA) undergraduate and UVA School of Medicine. He was an ophthalmology resident and chief resident at Baylor College of Medicine and a clinical neuro-ophthalmology fellow and Fight for Sight postdoctoral research fellow at the Wilmer Eye Institute, the Johns Hopkins Hospital.

Dr. Lee has served in numerous leadership roles at the American Academy of Ophthalmology (AAO) and has received the AAO Achievement Award, Senior Achievement Award, Secretariat Award (three times), and Lifetime Achievement Award. He is a past President, a past Chairman of the Board, and Senior VP for Advocacy of the North American Neuro-ophthalmology Society.

Dr. Lee has received the teaching award 15 times at 7 different academic institutions including the Osler Excellence in Teaching Award, the Baylor College of Medicine Dan B. Jones Teaching Award, University of Iowa Charles Phelps Award, the Texas A and M Mid Career Education award, the HMH Presidential Excellence in Education, and the Houston Methodist Hospital Sherilynn Gordon Memorial Leadership Award. Dr. Lee has been the invited speaker at over 400 national and international medical meetings; has written over 600 peer-reviewed publications and 14 full textbooks; and has given 15 named lectures. His h-index is 68 and his i-10 is 367 with over 18,000 citations. He has been named one of top 30 ophthalmologists in the United States by Newsweek magazine and is the only neuro-ophthalmologist on the list. He lives in Houston, Texas with his wife, Hilary; his two daughters (Rachael and Virginia), and his two cats (Lola and Miss Kitty).



#### **Clare FRASER**

#### Australia

Associate Professor Clare Fraser is a clinician-researcher at the University of Sydney's Save Sight Institute. She is involved in the clinical care of patients, researching the best ways to diagnose and manage neuro-ophthalmic eye conditions as well as being involved in teaching. She is a consultant Visiting Medical Officer at both Sydney Eye Hospital and Liverpool Hospital, and is also in private practice in Sydney.

Dr Fraser has sub-speciality interests in Neuro-Ophthalmology, adult strabismus and clinical electrophysiology.

She completed ophthalmic training at Sydney Eye Hospital in 2006-2009 and went on to further Neuro-Ophthalmic training at Moorfields Eye Hospital and the National Hospital for Neurology, London, England, with Dr Gordon Plant for 18 months. In 2011 she completed a research fellowship at Emory Eye Centre, Atlanta, USA, with Drs Nancy Newman and Valerie Biousse.

Dr Fraser is the Vice President of the The Neuro-Ophthalmology Society of Australia, and is one of their Education Officers. She is also the chair of the North American Neuro-Ophthalmology Society International Relations Committee and is on the committee for the Neuro-Ophthalmology Virtual Education Library. She is on the editorial boards for the Journal of Neuro-Ophthalmology, Neuro-Ophthalmology and Clinical and Experimental Ophthalmology. Dr Fraser is on the board of directors of the Royal Australian and New Zealand College of Ophthalmologists.

In 2017 Dr Fraser was the convenor for the Australian Neuro-Ophthalmology Society meeting in Sydney. She is also a Neuro-Ophthalmology faculty member for APAO and WOC.

Dr Fraser has published over 140 articles in peer-reviewed journals, has written several book chapters including chapters on Optic Neuritis and on Pituitary Tumours. She is a reviewer for Journal of Neuro-Ophthalmology, Clinical and Experimental Ophthalmology as well as the American Journal of Ophthalmology. Her research has been awarded with an Ophthalmic Institute of Australia grant, and has won several international awards including the North American Neuro-Ophthalmology Society prize for the best research presentations in 2005, 2006 and 2011.



## Kong Yong GOH

#### Singapore

Adj Assoc Professor Goh Kong Yong graduated from the National University of Singapore (NUS) in 1984 and obtained his postgraduate degree in Ophthalmology from the Royal College of Surgeons, Edinburgh and a Masters of Medicine in Ophthalmology (NUS) in 1990 and 1991 respectively. He is a Fellow of the Academy of Singapore and has been actively been involved in teaching and training basic and advanced ophthalmology trainees.

He underwent a 12 month fellowship programme at Bascom Palmer Eye Institute to sub-specialise in Neuro-ophthalmology. In addition he under took further training in eye movement disorders at the Royal Prince Albert Hospital (Sydney Australia) and vision rehabilitation at the University of Tuebingen (Germany)

Currently, he is a Visiting Senior Consultant at Tan Tock Seng Hospital; National University Hospital and National Neuroscience Institute. His main practice is at Dr Goh Eye Neuro-ophthalmic and Low Vision Specialist; Mount Elizabeth Novena Hospital.



#### **Rashmin GANDHI**

#### India

Dr. Gandhi practices Neuro-Ophthalmology in Hyderabad, India. He currently serves as an Adjunct Professor at the University of Hyderabad and is a researcher at the Indian Institute of Technology in Chennai. He is the principal investigator of a population-based study focusing on ophthalmic and olfactory biomarkers of Alzheimer's disease, which is supported by the Davos Alzheimer's Collaborative. He is a founding member of the Indian Neuro-Ophthalmology Society and holds the position of director for the fellowship in Neuro-Ophthalmology under the World Headache Society.

7 December 2024 (SATURDAY)



Time	Speakers	Торіс
16:00-16:08	Phoebe LAM	The epidemiology, clinical signs and viral load in quantitative polymerase chain reaction (qPCR)-confirmed acute adenoviral conjunctivitis in Hong Kong
16:08-16:16	Tiffany WU	Effect of public health and social measures on the trend of acute conjunctivitis in Hong Kong
16:16-16:24	Leo Ka Yu CHAN	To scan or not to scan? That is the question. How useful is computed tomography in identifying intracranial space-occupying lesions mimicking NTG?
16:24-16:32	Shui King TSOI	Factors associated with post-selective laser trabeculoplasty (SLT) intraocular pressure (IOP) spike
16:32-16:40	Ho Ming WONG	In Vivo Confocal Microscopy (IVCM) Analysis of Corneal Sub-basal nerve plexus (SNP) and corneal sensitivity after Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC) in glaucoma patients
16:40-16:48	Venice Sze Wai Ll	Neurotrophic keratopathy after transscleral cyclophotocoagulation in neovascular glaucoma patients - a retrospective observational study

Time	Speakers	Торіс
16:48-16:56	Anthony Chuk Him LAI	Efficacy and safety of adjunctive mitomycin C in Ahmed glaucoma valve implantation in a Chinese population
16:56-17:04	Sin Ki YEUNG	Paracentral Acute Middle Maculopathy (PAMM) after Vaccination – A Literature Review
17:04-17:12	Hoi Ching PANG	The association between socio-behavioral variables and visual impairment among the Chinese elderly: A Population-based Cross-Sectional Study
17:12-17:20	Yi Lam WONG	Efficacy of Intense Pulse Light Therapy as the Treatment in Patients with Meibomian Gland Dysfunction : A Retrospective Cohort Study
17:20-17:30	_	Panel Discussion

7 December 2024 (SATURDAY)



Time	Speakers	Торіс
16:00-16:10	Chung Kit CHAN	Advances in Imaging and Ergonomics in VR Surgeries: Experience with the NEW Fully Digital 3D Microscope with C-shaped Suspension Arm
16:10-16:20	Jason PANG	The Role of Vabysmo in treating Retinal Diseases at Grantham Hospital
16:20-16:30	Chung Kit CHAN	Early Fluid Resolution with Faricimab in Patients with nAMD
16:30-16:40	Timothy LAI	Aflibercept in nAMD - 96-week PULSAR Phase 3 Trial fluid Control Post-hoc Analysis
16:40-16:50	Ho Wa Kenny LAI	Unlocking the Potential of 27-Gauge: Practical Insights and Expert Tips
16:50-16:58	Ziyu ZHU	Exploring the Retina-heart Connection: Insights from a Cohort Study using OCTA Imaging
16:58-17:06	Isaac LAU	Quantitative OCTA Metrics as Biomarkers in Cerebral Small Vessel Disease: A Pilot Study
17:06-17:14	Wei WANG	Metabolic Fingerprinting on Photoreceptors Reveals Underpinnings of Eye-body Connection and Predicts Multi-disease Risk
17:14-17:30	_	Discussion



### Chung Kit CHAN

#### Hong Kong, China

Dr Jason CK CHAN is an associate consultant at Hong Kong Eye Hospital (HKEH) and an honorary clinical assistant professor at the Chinese University of Hong Kong (CUHK). He has special interests in Vitreoretinal surgery and Medical Retina. Prior to studying medicine, he obtained his Master of Philosophy in neuroscience from CUHK.



#### Jason PANG

Hong Kong, China

Dr. Jason Pang graduated from The University of Hong Kong in 2018. He is currently a resident trainee in the Department of Ophthalmology at Grantham Hospital and also serves as an honorary clinical tutor for HKU Ophthalmology. His primary area of interest is the retina subspecialty.



### Timothy LAI

#### Hong Kong, China

Professor Timothy Lai is Clinical Professor (Honorary) at the Department of Ophthalmology and Visual Sciences at The Chinese University of Hong Kong, Honorary Clinical Professor at the Department of Ophthalmology at The University of Hong Kong, and Director of the 2010 Retina and Macula Centre, Hong Kong. Professor Lai's clinical and research interests lie in the medical and surgical management of retinal diseases, particularly polypoidal choroidal vasculopathy, central serous chorioretinopathy, myopic maculopathy, diabetic retinopathy and choroidal neovascularization, and has served as a Principal Investigator in over 25 multicenter phase 2, 3 and 4 clinical trials for the treatment of retinal diseases and uveitis.

Professor Lai has published over 290 papers in international peer-reviewed journals and has a Scopus h-index of 63. His academic achievements are well recognized internationally and has received many international awards, including the Nakajima Award from the APAO, the Senior Achievement Award from the AAO, the Constable Lecture Award from the APVRS, and the Senior Achievement Award from the APAO. Professor Lai serves on the editorial boards of over 10 international ophthalmic journals, including Retina, Eye, Clinical and Experimental Ophthalmology, Ophthalmologica, Acta Ophthalmologica, and the Asia-Pacific Journal of Ophthalmology. His other leadership roles include Vice-President of the APVRS, Treasurer of the Asia Pacific Ocular Imaging Society, and Section Head of the International Ocular Inflammation Society.



#### Ho Wa Kenny LAI

Hong Kong, China

Dr. Kenny LAI Ho-wa

MBChB(CUHK), MRCSEd(Ophth), FCOphthHK, FHKAM(Ophthalmology) Honorary Clinical Assistant Professor (Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong)

Specialist in Ophthalmology, C-MER International Eye Care Group

Co-founder and Chief Executive Officer, C-MER RainsOptics Ltd, a research company on smartphone medical devices

Editorial Board Member, Asia-Pacific Journal of Ophthalmology (AI, Big Data and Telemedicine in Ophthalmology)

Executive Committee Member, Project Vision

Dr. Kenny Lai graduated from the Chinese University of Hong Kong, and completed his ophthalmic training in Tuen Mun Hospital. Besides general ophthalmology, his focus areas of interest include retina and refractive surgery. He has a wide variety of research interests, including artificial intelligence development of retinal disease screening model, Implantable Collamer Lens (ICL) surgery, minimally invasive vitreoretinal surgery, and premium intraocular lens.

Driven by his passion in optics and ocular imaging, he developed a novel smartphone fundus camera, aiming to facilitate portable retinal imaging and community screening. He co-founded C-MER RainsOptics Ltd, which developed the FundusLink non-mydriatic pocket smartphone ophthalmoscope. This project received the Red Dot Award for Product Design (Germany 2024), Henry van de Velde Silver Award (Belgium 2024) and Hong Kong Information and Communication Technology (ICT) Awards – Smart Healthcare Award (2024). He is one of the few ophthalmologists with diverse experience across medical services, optical and electronic engineering, software development, and entrepreneurship of tech start-ups.

 8 December 2024 (SUNDAY)

 Session Theme:
 Chair(s):

 When To Order What
 Image: Celia Chen

 Celia Chen
 Toshiaki Goseki

 Dan Milea

 Time: 09:00 - 10:30
 Room: N201A

Time	Speakers	Торіс
09:00-09:12	Susan MOLLAN	Investigations for GCA
09:12-09:24	Celia CHEN	Clinicopathological Correlation : What I have learnt from these cases?
09:24-09:36	Dan MILEA	How to explore Papilloedema
09:36-09:48	Clement TAN	The Cupped Disc Dilemma – Why are we still struggling to tell between NTG and Other Optic Neuropathies?
09:48-10:00	Carmen CHAN	OCT and OCTA in Neuro-Ophthalmology: What's new?
10:00-10:12	Niphon CHIRAPAPAISAN	What to Do in Functional Visual Loss



### Susan MOLLAN

#### United Kingdom

Susan Mollan has an established international reputation in Neuro-ophthalmology. She is a Consultant Neuro-Ophthalmologist at University Hospitals Birmingham and a Honorary Professor at the University of Birmingham, England. She is a board member at the North American Neuro-Ophthalmology Society and an international senior examiner for the Royal College of Ophthalmologists.

She enjoys clinical research, and is situated well within the large team in Birmingham to investigate rare conditions that affect the eye and brain. Her professional research specialties include Idiopathic Intracranial Hypertension (IIH), Giant Cell Arteritis (GCA) and the development of quantification of disease through ocular imaging. She is the director of ophthalmology research and the chief data officer for INSIGHT (a Health Data Research UK hub for eye health https://www.insight. hdrhub.org). INSIGHT is an ever green Health Data Research UK bioresource for eye health (28 million images and linked clinical data).

She actively works to provide pragmatic guidance for clinicians through guidelines and publications (International Headache Society IIH trial guidelines 2023); (IIH consensus guidelines (2018); European League Against Rheumatism GCA guidelines (2019); British Society of Rheumatology GCA guidelines (2020); and the European Headache Federation GCA guidelines (2020). She has been instrumental in key randomized control trials conducted in Idiopathic Intracranial Hypertension and reported the first randomized control trial into weight loss methods in IIH (2021).



### Celia CHEN

#### Australia

Professor Celia Chen is a Clinical Professor with University of South Australia and full academic professor in the College of Medicine and Public Health, Flinders University. She is a consultant neuro-ophthalmologist/clinician-scientist at Flinders University. She completed a prestigious neuro-ophthalmology fellowship at the Wilmer Eye Institute, Johns Hopkins Hospital.

Professor Chen is the current President of the Neuro-Ophthalmic Society of Australia.

She has an excellent research record and is the recipient of both national and international scholarships and awards including the American Australian Education Fellowship, South Australian Science Excellence Award, and the Asia-Pacific Academy of Ophthalmology (APAO) Achievement Award.

Professor Chen is dedicated to providing mentorship and learning opportunities for young ophthalmologists in the Asia-Pacific region. She has been doing field work in Cambodia for over 10 years and providing fellowship opportunity, through APAO Women in Ophthalmology International Fellowship Program, Kim Frumar Scholarship and Eye Surgeon's Foundation Fellowship Program. This has helped young ophthalmologists from a developing country to receive fellowship training in a subspecialty area of ophthalmology, at an international training center of excellence.



### Dan MILEA

#### France

Dan MILEA, MD, PhD is a Neuro-Ophthalmologist and Clinician Scientist, Head of the Neuro-Ophthalmology department and Director of the Rothschild BRAIN Visual and Computational Neuroscience Group at the Rothschild Foundation Hospital, Paris (France). He is also an adjunct Clinician Scientist at the Singapore Eye Research Eye Institute and Professor of Ophthalmology (Angers/France, Copenhagen/Denmark and Duke-NUS Medical School/Singapore).

In 2018 he has created an international Consortium gathering the efforts of more than 40 expert academic centers from over 20 countries (BONSAI: Brain and Optic Nerve Study with Artificial Intelligence), which has published its findings in various journals, such as The New England Journal of Medicine, JAMA Ophthalmol, Neurology, Annals of Neurology, Journal of Neuro-Ophthalmology, etc.

He has mentored numerous clinical and research fellows in Europe and Asia, including France, Denmark, Singapore, India, Malaysia, Thailand, Philippines, while also performing numerous mission trips in Vietnam, Cambodia, Myanmar, India, etc. Author of over 250 peer-reviewed publications and textbooks in Ophthalmology and Neuro-ophthalmology, he has lectured at more than 200 medical and scientific meetings. Dan Milea is currently Co-Editor-in-Chief of the Journal "Neuro-Ophthalmology".



#### **Clement TAN**

#### Singapore

Clement Tan is Associate Professor and consultant ophthalmologist at the National University Hospital, Singapore. He is presently Group Director for Ophthalmology, National University Health Services Cluster, Director of the Division of Graduate Medical Studies, National University of Singapore and Co-Chair of the Joint Committees on Specialist Training in Singapore.

Besides Neuro-ophthalmology, Dr Tan's clinical interests are, cataract surgery and primary care ophthalmology. His other abiding interest is in Medical Education.



### Carmen CHAN

#### Hong Kong, China

Dr. Chan is the Chief of Service and Consultant Ophthalmologist at the Hong Kong Eye Hospital, Clinical Professor (Honorary) at the Department of Ophthalmology and Visual Sciences of the Chinese University of Hong Kong and Honorary Clinical Professor, Department of Ophthalmology, School of Clinical Medicine, The University of Hong Kong.

She was awarded the Prince Philip Scholarship to study medicine at the University of Cambridge and trained initially in general medicine, followed by ophthalmology training in the UK and Hong Kong. She subsequent completed a neuro-ophthalmology fellowship with Dr Neil Miller at the Wilmer Eye Institute, USA. Dr. Chan subspecializes in neuro-ophthalmology and uveitis. Overall, she has published over 80 papers in peer-reviewed journals, and she is an editorial board member of the Journal of Neuro-ophthalmology, Neuro-Ophthalmology, Asia Pacific Journal of Ophthalmology, Eye and the Hong Kong Journal of Ophthalmology. She is the Convenor of the Hong Kong Neuro-Ophthalmology Interest Group, a council member of the Asia Neuro-Ophthalmology Society and a vice-chair of the North American Neuro-Ophthalmology Society International Relations Committee. She is the recipient of the Asia Pacific Academy of Ophthalmology (APAO) Distinguished Service Award in 2013 and Senior Achievement Award in 2024. She is also the secretary of the APAO Women in Ophthalmology standing committee since its inception in 2011. She has been selected as one of the Top 100 ophthalmologists in the Asia Pacific region (AP Eye 100) in 2022.



#### Niphon CHIRAPAPAISAN

#### Thailand

Dr. Niphon Chirapapaisan, MD, is a Professor in Ophthalmology and the Director of Neuro-ophthalmology Service at the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. He also serves as the president of the Thai Neuro-Ophthalmology Society. His primary academic interests include neuroophthalmology and cataract surgery. Dr. Chirapapaisan has been recognized with several awards, including the "Tsutsui-Fujino International Award" from the Japanese Neuro-Ophthalmology Society in 2011, the VDO Cataract Surgery Award from the Thai Cataract and Refractive Surgery Society in 2017 and 2018, and the Distinguished Service Award from APAO in 2024.



Time	Speakers	Торіс
09:00-09:12	Xianqun FAN	Pathogenesis and Targeted Therapy on Retinoblastoma
09:12-09:24	Carol SHIELDS	Ocular Oncology: What's in the Pipeline
09:24-09:36	Wah CHEUK	Pathology Development applicable to Ocular Pathology
09:36-09:48	Dong Mei Ll	Use of AI in Eyelid Cancer Screening
09:48-10:00	Ho-Seok SA	Surgical Management of Complex Orbital Tumor
10:00-10:12	Renbing JIA	Interventional Treatment of Eye Diseases: Retinoblastoma and Beyond
10:12-10:24	David VERITY	Orbital Sarcoma
10:24-10:30	-	Q&A



#### Xiangun FAN

#### China

Professor Fan Xiangun is the chief ophthalmologist at the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. He is the academician of the Chinese academy of Engineering, the distinguished professor of Changjiang Scholar of the Ministry of Education, the chair professor of Shanghai Jiao Tong University, member of the Chinese Academy of Medical Science, the member of the Academia Ophthalmologica Internationalis (AOI), fellow of the Royal College of Ophthalmologists (UK), fellow Ad Hominem of the Royal College of Surgeons in Edinburgh (UK). He is currently the vice president of Shanghai Jiao Tong University, chancellor of Shanghai Jiao Tong University School of Medicine, director of Shanghai key laboratory of Orbital Diseases and Ocular Tumor, the deputy to the 14th National People's Congress. He concurrently serves as the vice chairman of the China Anti-Cancer Association, the president of the Asia-Pacific Society of Ocular Oncology and Pathology (APSOOP), the president of the fifth Asia-Pacific Society of Ophthalmic Plastic and Reconstructive Surgery (APSOPRS). He has won second prizes of the National Science and Technology Progress Award (twice), first prizes of the Shanghai Science and Technology Progress Award (Thrice), the Ho Leung Ho Lee Science and Technology Progress Award, the first innovator award of Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and De Ocampo Lecture, the highest academic achievement award to Asia-Pacific Academy of Ophthalmology (APAO).



#### **Carol SHIELDS**

#### United States

Dr. Carol Shields completed her ophthalmology training at Wills Eye Hospital in Philadelphia and fellowship training in ocular oncology and ophthalmic pathology. She is Director of the Oncology Service, Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, PA USA.

She has authored/coauthored 14 textbooks, 354 chapters in edited textbooks, over 2000 articles in major peer-reviewed journals, and given nearly 1000 lectureships with 76 named lectures. Some prestigious awards that have honored her include:

• The American Academy of Ophthalmology Life Achievement Honor Award (2011) for contributions to the field of ophthalmology.

• Induction into the Academic All-American Hall of Fame (2011) for lifetime success in athletics and career.

• President of the International Society of Ocular Oncology (2013-2015) – the largest international society of ocular oncology.

• Ophthalmology Power List 2014, 2016, 2018, 2020, 2021, 2022, 2023 – Nominated by peers as one of the top 100 leaders in the field. In 2020 and 2023, Dr. Carol Shields was listed at #1 in the Ophthalmology Power List.

• The Donders Award (2003) - given by the Netherlands Ophthalmological Society every 5 years. She was the first woman to receive this award.

America's Best Eye Doctors [July 21, 2021] - Nominated by Newsweek magazine with an overall rank #7 of all ophthalmologists and rank #1 of all female ophthalmologists.
Theodore Roosevelt Award - the highest honor the National Collegiate Athletic Association (NCAA) confers on an individual who earned a varsity letter for sports in college and who became a distinguished citizen of national reputation.

• World Eye-Con 21st Century [2024]. Nominated by the Asia Pacific Society of Ophthalmology and the Asia Pacific Journal of Ophthalmology (APJO) as an original world EYE-CON who helped shaped the world of ophthalmology in the 21st century Each year the Oncology Service manages over 500 patients with uveal melanoma or retinoblastoma, and hundreds of other intraocular, orbital, and conjunctival tumors from the United States and abroad. She and her husband are the proud parents of 7 children, ranging in age from 24 to 36 years.



## Wah CHEUK

#### Hong Kong, China

Dr. Cheuk Wah is a general pathologist with special interest in hematolymphoid tumors, head and neck tumors, gynecology pathology, molecular pathology, eye pathology and particularly IgG4-related disease. Graduating with first class honors in Biomedical Sciences from the University of Hong Kong in 1993. He completed his MBBS in 1996 in the same University.

Dr. Cheuk had initially worked as a resident in Ophthalmology for 6 months at Prince of Wales Hospital before switching to Anatomical Pathology at Queen Elizabeth Hospital. He obtained fellowships from The Royal College of Pathologists of Australasia and The Hong Kong College of Pathologists. He undertook fellowship training under Dr. John KC Chan at Queen Elizabeth Hospital and elective training with Dr. Esther Oliva at Massachusetts General Hospital, Harvard Medical School. Dr. Cheuk has authored over 120 peer-reviewed papers and contributed to key medical texts, including WHO tumor classification blue books and Fletcher's Diagnostic Histopathology of Tumors. Currently, Dr. Cheuk serves as Chief of Service of the Pathology Department at Queen Elizabeth Hospital.



#### Dong Mei Ll

#### China

Dr. Dongmei Li has been working in Beijing Tong Ren hospital for 31 years since she graduated from Chinese Medical University. She obtained her master's degree from Capital medical university. And had been trained in Japan and United States. Her special interests are: Eyelid and Orbital and Socket Reconstructive Surgery.

Vice president of China Medical Association of Ophthalmology, Division of Oculoplastic Surgery and Orbital Disease of Academy of Ophthalmic Surgery
Vice president of China Medical Association of Plastic Reconstruction, Division of Oculoplastic Surgery.

- Membership of American of Oculoplastic Surgery
- Membership of China Medical Association of Women of Ophthalmology
- Editorial Committee Member of Chinese J Ophthalmology

She was awarded the Asia Pacific Academy of Ophthalmology (APAO) Achievement Award (2017) and distinguished service award of APAO 2019.

She has published more than 80 articles, 3 books as editor-in-chief and 4 books as editor-in-chief translator.



## Ho-Seok SA

#### Korea, Republic of

Dr. Ho-Seok Sa is the Professor and Chair of the Department of Ophthalmology at Asan Medical Center, University of Ulsan, Seoul, South Korea. He has led the division of Ophthalmic Plastic and Reconstructive Surgery since 2010. Dr. Sa graduated from the College of Medicine at Seoul National University and completed his ophthalmology residency at Samsung Medical Center. He pursued a fellowship in Ophthalmic Plastic and Reconstructive Surgery (OPRS) under the guidance of Dr. Yoon-Duck Kim at Samsung Medical Center, Seoul. Furthering his expertise, Dr. Sa gained additional research experience in eyelid cancers and orbital tumors as a visiting associate professor at the University of Texas MD Anderson Cancer Center, Houston, TX, USA, under the mentorship of Dr. Bita Esmaeli from 2017 to 2019. He has authored over 60 peer-reviewed academic publications, contributed several chapters to medical books, and holds a patent in 3D printing. Dr. Sa has delivered numerous presentations and lectures at international conferences. His current professional roles include Vice President of the Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery (APSOPRS) (2023-), Executive Director of the Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS) (2023-2024), Secretary of APSOPRS (2022-2023), International Member of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) (2018-), Director of Academic Planning of Korean Society of Aesthetic Surgery (2024-), and Editorial Board Member of the Journal of the Korean Ophthalmological Society (2020-).





David VERITY

United Kingdom

8 December 2024 (SUNDAY)



Time: 09:00 - 10:30

Room: N206-208

Time	Speakers	Торіс
09:00-09:08	Wai Chak CHOY	Global, Regional, and National Trends of Retinopathy of Prematurity Epidemiology in 1990-2021 and the Association with Socio-economic and Healthcare Factors
09:08-09:20	Virender SACHDEVA	Approach to Pediatric Optic Neuritis in 2024
09:20-09:32	Takashi NEGISHI	Diagnosis and Treatment of Juvenile Myasthenia Gravis
09:32-09:40	Jie CHEN	The Peripheral Defocus Designed Spectacle Lenses might Increase Sstigmatism in Myopic Children
09:40-09:48	Jasmine CHUANG	Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness of Paediatric Patients with True and Pseudo-Papilledema
09:48-09:56	Jun Yan ZHANG	The Longitudinal Vision Recovery in 3 months after Primary Pediatric Optic Neuritis onset in Chinese population
09:56-10:04	Vincent YUEN	Effects of Physical Activity and Inactivity on the Microvasculature in Children: The Hong Kong Children Eye Study
10:04-10:12	Kai Ching, Peter LEUNG	Scleral-suture augmented Hummelsheim's Transposition for treatment of Abducens Paralysis: A single centre experience.
10:12-10:30	_	Discussion
### 8 December 2024 (SUNDAY)



Time	Speakers	Торіс
11:00-11:12	Andrew LEE	Decoding NMOSD: Understanding the Diagnosis and Treatment Strategies
11:12-11:20	Chun Ho Joseph CHOI	Local Perspectives in Hong Kong: Unmet Needs and Experiences with Novel Therapies in NMOSD
11:20-11:35	Clare FRASER	MOG Optic Neuritis
11:35-11:50	Laura BONELLI	Ocular Manifestations of MS: other than Optic Neuritis
11:50-12:05	Ambika SELVAKUMAR	Infectious Optic Neuropathy
12:05-12:20	Anthony ARNOLD	Visual loss in Patients with Malignancies



## Andrew LEE

#### United States

Andrew G. Lee, M.D. is the Herb and Jean Lyman Centennial Chair in Ophthalmology and is the Founding Chairman of the Blanton Eye Institute, Department of Ophthalmology at Houston Methodist Hospital in Houston, Texas. He is Professor of Ophthalmology, Neurology, and Neurosurgery at Weill Cornell Medicine and an adjunct professor of Ophthalmology at Baylor College of Medicine; Texas A and M College of Medicine; University of Iowa and the University of Buffalo; and Clinical Professor at the University of Texas Medical Branch (UTMB) in Galveston, Texas and the UT MD Anderson Cancer Center.

He is a graduate of the University of Virginia (UVA) undergraduate and UVA School of Medicine. He was an ophthalmology resident and chief resident at Baylor College of Medicine and a clinical neuro-ophthalmology fellow and Fight for Sight postdoctoral research fellow at the Wilmer Eye Institute, the Johns Hopkins Hospital.

Dr. Lee has served in numerous leadership roles at the American Academy of Ophthalmology (AAO) and has received the AAO Achievement Award, Senior Achievement Award, Secretariat Award (three times), and Lifetime Achievement Award. He is a past President, a past Chairman of the Board, and Senior VP for Advocacy of the North American Neuro-ophthalmology Society.

Dr. Lee has received the teaching award 15 times at 7 different academic institutions including the Osler Excellence in Teaching Award, the Baylor College of Medicine Dan B. Jones Teaching Award, University of Iowa Charles Phelps Award, the Texas A and M Mid Career Education award, the HMH Presidential Excellence in Education, and the Houston Methodist Hospital Sherilynn Gordon Memorial Leadership Award. Dr. Lee has been the invited speaker at over 400 national and international medical meetings; has written over 600 peer-reviewed publications and 14 full textbooks; and has given 15 named lectures. His h-index is 68 and his i-10 is 367 with over 18,000 citations. He has been named one of top 30 ophthalmologists in the United States by Newsweek magazine and is the only neuro-ophthalmologist on the list. He lives in Houston, Texas with his wife, Hilary; his two daughters (Rachael and Virginia), and his two cats (Lola and Miss Kitty).



### Chun Ho Joseph CHOI

Hong Kong, China

Dr. Joseph Choi is currently a neurology specialist at the Division of Neurology of the Prince of Wales Hospital. Dr. Choi graduated from medical school with honors at the Chinese University of Hong Kong in 2016, receiving the Kan Tong Po gold medal of medical studies and the Dr. R. C. Lee gold medal in surgery. He received training in neurology and advanced internal medicine in Hong Kong and obtained his fellowship in Neurology at the Hong Kong College of Physicians in 2023.

Dr. Choi has primary interests in autoimmune neurology and is currently the multiple sclerosis specialist of the Prince of Wales Hospital. He serves as the principal investigator of the N-MOmentum LT study in Hong Kong and as the co-investigator of several BTK-inhibitors clinical trials in people with multiple sclerosis. He also served as a reviewer for the Annals of Internal Medicine and the Journal of Clinical Rheumatology and Immunology.



### **Clare FRASER**

#### Australia

Associate Professor Clare Fraser is a clinician-researcher at the University of Sydney's Save Sight Institute. She is involved in the clinical care of patients, researching the best ways to diagnose and manage neuro-ophthalmic eye conditions as well as being involved in teaching. She is a consultant Visiting Medical Officer at both Sydney Eye Hospital and Liverpool Hospital, and is also in private practice in Sydney.

Dr Fraser has sub-speciality interests in Neuro-Ophthalmology, adult strabismus and clinical electrophysiology.

She completed ophthalmic training at Sydney Eye Hospital in 2006-2009 and went on to further Neuro-Ophthalmic training at Moorfields Eye Hospital and the National Hospital for Neurology, London, England, with Dr Gordon Plant for 18 months. In 2011 she completed a research fellowship at Emory Eye Centre, Atlanta, USA, with Drs Nancy Newman and Valerie Biousse.

Dr Fraser is the Vice President of the The Neuro-Ophthalmology Society of Australia, and is one of their Education Officers. She is also the chair of the North American Neuro-Ophthalmology Society International Relations Committee and is on the committee for the Neuro-Ophthalmology Virtual Education Library. She is on the editorial boards for the Journal of Neuro-Ophthalmology, Neuro-Ophthalmology and Clinical and Experimental Ophthalmology. Dr Fraser is on the board of directors of the Royal Australian and New Zealand College of Ophthalmologists.

In 2017 Dr Fraser was the convenor for the Australian Neuro-Ophthalmology Society meeting in Sydney. She is also a Neuro-Ophthalmology faculty member for APAO and WOC.

Dr Fraser has published over 140 articles in peer-reviewed journals, has written several book chapters including chapters on Optic Neuritis and on Pituitary Tumours. She is a reviewer for Journal of Neuro-Ophthalmology, Clinical and Experimental Ophthalmology as well as the American Journal of Ophthalmology. Her research has been awarded with an Ophthalmic Institute of Australia grant, and has won several international awards including the North American Neuro-Ophthalmology Society prize for the best research presentations in 2005, 2006 and 2011.



### Laura BONELLI

**United States** 

Laura Bonelli, MD Health Sciences Assistant Clinical Professor of Ophthalmology Neuro-Ophthalmology

Dr. Bonelli completed her residency in ophthalmology, as well as fellowships in neuroophthalmology and oculoplastics, at the Hospital de Clínicas, University of Buenos Aires, Argentina. Joining the UCLA Department of Ophthalmology in 2008, Dr. Bonelli specializes in neuro-ophthalmology. She sees patients at the Stein Eye Institute in Westwood and the Stein Eye Center–Santa Monica. A committed educator, she teaches medical student courses at the David Geffen School of Medicine, regularly lectures at educational conferences, and teaches residents and neuro-ophthalmology fellows in the department. She is the director of inpatient consultation services for the Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica, where she oversaw a broad reorganization to improve services and to provide more efficient patient care. In recognition of her work with ophthalmology residents on the consultation services, Dr. Bonelli received the Stein Eye Institute Faculty Teaching Award in 2014 and the Stein Eye Institute Fellowship Faculty Teaching Award in 2024.



## Ambika SELVAKUMAR

#### India

Dr. Ambika Selvakumar is a senior consultant in the Department of Neuro ophthalmology and visual sciences. She currently the Head of the Neuro-ophthalmology services, Sankara Nethralaya a unit of Medical Research Foundation, Chennai. She is the current Vice President – Indian Neuro ophthalmology association. She has many publications in the field of Neuro ophthalmology. She has done observership in Neuro-ophthalmology with legends like Dr.Andrew Lee University of Iowa, Dr JamesGoodwin University of Illinois, Dr Averatna Noronha –University of Chicago and Dr Joel Glaser Bascom palmer eye institution, Miami U.S.A.

She has partcipated as invited speaker in various National and international Neurology and Neurosurgical society conferences, apart from Ophthalmic conferences. She has authored many books like "The Atlas of Neuro-ophthalmology" which was the first Indian Atlas in this specialty 'Atlas of Imaging in Ophthalmology' and has written chapters in many Ophthalmology and Neurology Books. She has received the Athwale award for her work in Neuro ophthalmology. SN - Department of Neuro ophthalmology has bagged four times the Best paper in Neuro ophthalmology in AIOS so far. Her areas of special interest are Optic neuritis, IIH, LHON and Neuro imaging.



### Anthony ARNOLD

### United States

Anthony C. Arnold, MD is Vice Chair for Education, Professor and Chief, Neuro-Ophthalmology Division, Dept. of Ophthalmology, University of California, Los Angeles. He has a research interest in ischemic and inflammatory optic neuropathies, with more than 100 publications. He has served as the President of the AUPO Ophthalmology Program Directors Council 2000-2007, Chair of the ACGME Residency Review Committee for Ophthalmology 2010-2016, Chair of the ACGME Ophthalmology Milestones Development Group 2010-2013, and member of the ACGME Board of Directors 2015-2017, Director of the American Board of Ophthalmology 2008-2016, and President and Chairman of the Board of the North American Neuro-Ophthalmology Society 2008-2012.

### 8 December 2024 (SUNDAY)



Time: 11:00 - 12:30

Room: N202-N203



Time	Speakers	Торіс
11:00-11:15	Xianqun FAN	How to handle Eyelid Sebaceous Cell Carcinoma
11:15-11:25	Dong Mei Ll	Pearls in Managing Malignant Eyelid Tumors
11:25-11:35	Yun FENG	OSSN
11:35-11:45	Renbing JIA	Targeted therapy of ocular malignancy: progress and prospect
11:45-11:55	Jason C YAM	Clinical Service and Research of Retinoblastoma in Hong Kong
11:55-12:05	David JOHNSON	Plaque radiotherapt service for Ocular Oncology in HK
12:05-12:15	Pm FAIROOZ	Updates in lacrimal gland tumors
12:15-12:25	Honglei LIU	Transorbital endoscope-assisted surgery for the refractory orbital tumor.
12:25-12:30	-	Q&A



### Xianqun FAN

### China

Professor Fan Xiangun is the chief ophthalmologist at the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. He is the academician of the Chinese academy of Engineering, the distinguished professor of Changjiang Scholar of the Ministry of Education, the chair professor of Shanghai Jiao Tong University, member of the Chinese Academy of Medical Science, the member of the Academia Ophthalmologica Internationalis (AOI), fellow of the Royal College of Ophthalmologists (UK), fellow Ad Hominem of the Royal College of Surgeons in Edinburgh (UK). He is currently the vice president of Shanghai Jiao Tong University, chancellor of Shanghai Jiao Tong University School of Medicine, director of Shanghai key laboratory of Orbital Diseases and Ocular Tumor, the deputy to the 14th National People's Congress. He concurrently serves as the vice chairman of the China Anti-Cancer Association, the president of the Asia-Pacific Society of Ocular Oncology and Pathology (APSOOP), the president of the fifth Asia-Pacific Society of Ophthalmic Plastic and Reconstructive Surgery (APSOPRS). He has won second prizes of the National Science and Technology Progress Award (twice), first prizes of the Shanghai Science and Technology Progress Award (Thrice), the Ho Leung Ho Lee Science and Technology Progress Award, the first innovator award of Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and De Ocampo Lecture, the highest academic achievement award to Asia-Pacific Academy of Ophthalmology (APAO).



## Dong Mei Ll

#### China

Dr. Dongmei Li has been working in Beijing Tong Ren hospital for 31 years since she graduated from Chinese Medical University. She obtained her master's degree from Capital medical university. And had been trained in Japan and United States. Her special interests are: Eyelid and Orbital and Socket Reconstructive Surgery.

Vice president of China Medical Association of Ophthalmology, Division of Oculoplastic Surgery and Orbital Disease of Academy of Ophthalmic Surgery
Vice president of China Medical Association of Plastic Reconstruction, Division of Oculoplastic Surgery.

- Membership of American of Oculoplastic Surgery
- Membership of China Medical Association of Women of Ophthalmology
- Editorial Committee Member of Chinese J Ophthalmology

She was awarded the Asia Pacific Academy of Ophthalmology (APAO) Achievement Award (2017) and distinguished service award of APAO 2019. She has published more than 80 articles, 3 books as editor-in-chief and 4 books as editor-in-chief translator.



Yun	F	E	N	G
China				



### Jason C YAM

#### Hong Kong, China

Prof Jason Yam is Professor & Undergraduate Division Head at Department of Ophthalmology and Visual Sciences of CUHK, Dean of General Education at Chung Chi College, CUHK, Head of Pediatric Ophthalmology and Strabismus service at Hong Kong Eye Hospital, Head of Ophthalmology Service at Hong Kong Childrens Hospital, Editor-in-chief of the College of Ophthalmologists of Hong Kong, Vice President of Hong Kong Ophthalmology Society. He also serves as the Secretary-General of Asia-Pacific Strabismus and Paediatric Ophthalmology Society (APSPOS); Research Committee, Myopia Committee, and Training & Education Committee Chair of International Paediatric Ophthalmology and Strabismus Council (IPOSC); and Council Member of Asia-Pacific Academy of Ophthalmology (APAO); and Council Member of Asia-Pacific Myopia Society (APMS).

Prof. Jason Yam is PI of Low-concentration Atropine for Myopia Progression (LAMP1), Low-concentration Atropine for Myopia Prevention (LAMP2) study and Hong Kong Children Eye Study (HKCES). He has received funding of more than 100 million USD, and has more than 170 articles in the SCI-indexed journals including JAMA, Lancet Global Health, JAMA Network Open, Ophthalmology etc. LAMP2 study has been selected as one of the Chinas Important Medical Advancements in 2023.

Prof. Jason Yam received the National Science Fund for Distinguished Young Scholars 2024 and the Asia Pacific Academy of Ophthalmology De Ocampo Lecture Award 2024. He was named One of the Ten Outstanding Young Persons in Hong Kong in 2019, and was bestowed Hong Kong Humanity Award 2021, and International Myopia Conference Josh Wallman Memorial Lecture 2022, and American Academy of Ophthalmology Secretariat Award 2023. He was listed among Worlds Top 2% Scientists in the field of Ophthalmology since 2022, and among Top 100 Ophthalmologists in Asia-Pacific Region in 2023.



## David JOHNSON

### Hong Kong, China

Dr David Johnson is an Associate Consultant working in the Department of Clinical Oncology at the Prince of Wales Hospital in Hong Kong. He is actively engaged in research and treatment for head and neck, central nervous system and ocular malignancies.



## India

**Pm FAIROOZ** 

### Honglei LIU

China

Dr. Honglei Liu graduated from the Fourth Military Medical University in 1994, He completed his series training of Ophthalmology and Oculoplastics at Xijing Hospital affiliated to the Fourth Military Medical University. He transferred to Xi'an Fourth Hospital as an invited expert.

He had been trained for orbital diseases in the largest orbital institute at Beijing General Armed Police Hospital under the supervision of Pro. Lihua Xiao. As a visiting scholar, he has been to UCSD Shiley eye institute under the supervision of Pro. Don Kikkawa, Bascom Palmer eye institute and UPMC Skull base center in U.S.A.

He is the vice president of Eye hospital of Shaanxi Province, chairman of Center of Oculoplastic Surgery and Orbital Disease, Guangren Hospital, Northwest University, China. He is serving as the director of the Society of Ophthalmic Plastic and Reconstruction Surgery both in Shaanxi Province and Xi'an City. He also is an international member of American Society of Ophthalmic Plastic and Reconstructive Surgery. He was also the Vice President of APSOPRS of the last term.

### 8 December 2024 (SUNDAY)

Session Theme: HKGS Inaugural Symposium: Dr SP Hui Memorial Lecture + Glaucoma Hot Topic Debates Time: 11:00 - 12:30 Chair(s): Noel Noel Chair(s): Noel Chair(s): Noel Chair(s): Noel Chair(s): 

Time	Speakers	Торіс
11:00-11:04	_	Welcome Remarks
11:04-11:06	Nancy YUEN	Introduction to the Dr. SP Hui Memorial Lecture
11:06-11:08	Noel Ching-Yan CHAN	Citation for Dr. SP Hui Memorial Lecture
11:08-11:28	Calvin PANG	Dr. SP Hui Memorial Lecture
11:28-11:38	Ka Wai WONG	Glaucoma Hot Topic Debates - We should start with surgical intervention, rather than a step-up treatment approach with drugs first, for newly diagnosed early glaucoma - Affirmative
11:38-11:48	Oi Man WONG	Glaucoma Hot Topic Debates - We should start with surgical intervention, rather than a step-up treatment approach with drugs first, for newly diagnosed early glaucoma - Negative
11:48-11:58	Christopher K.S. LEUNG	Glaucoma Hot Topic Debates - Surgery should be performed for progressive normal tension glaucoma (NTG) with low-teen IOP - Affirmative

Time	Speakers	Торіс		
11:58-12:08	Dexter LEUNG	Glaucoma Hot Topic Debates - Surgery should be performed for progressive normal tension glaucoma (NTG) with low-teen IOP - Negative		
12:08-12:18	Nancy YUEN	Glaucoma Hot Topic Debates - Laser peripheral iridotomy should be performed for all cases of primary angle closure suspect (PACS) - Affirmative		
12:18-12:28	Vincent LEE	Glaucoma Hot Topic Debates - Laser peripheral iridotomy should be performed for all cases of primary angle closure suspect (PACS) - Negative		
12:28-12:30	Noel Ching-Yan CHAN , Clement Cy THAM , Nancy YUEN	Closing Remarks		



## Nancy YUEN

### Hong Kong, China

MB,BS (HKU) MPH (HKU), FRCO(UK), FRCS (Edin), FCSHK, FCOphthHK, DipMED (CUHK), FHKAM (Ophthalmology) Specialist in Ophthalmology (Private Practice)

Honorary Clinical Associate Professor, CUHK Honorary Clinical Associate Professor, HKU

Dr. Yuen is a leading figure in the field of Ophthalmology in Hong Kong. She is the past President of The College of Ophthalmologists of Hong Kong (2019-2021). The College serve to maintain the highest standard of Ophthalmologists trough training curriculum design, examinations and continuous medical education program and act as the qualifying body for specialist Ophthalmologists in Hong Kong. Dr. Yuen is fully committed to the development of Ophthalmology, she was the President of the Hong Kong Ophthalmological Society from 2009-2013, uniting the profession to contribute to the high quality eye care in Hong Kong through annual academic symposia, organisations of regional and international conferences, conducting public education for promoting eye health knowledge of the public.

Dr Nancy Yuen is currently working in the private sector, she was the Consultant Ophthalmologist of Prince of Wales Hospital before she joined the private sector. She has sub-specialty interest in Glaucoma and has contributed to many developments which included surgical innovation in management of cyclodialysis and safe surgeries for glaucoma.

Dr Yuen received her undergraduate education in the University of Hong Kong and graduated in1991. She attained her fellowship in Ophthalmology from The Royal College of Surgeons of Edinburgh in 1996 and was awarded the Muthusamy Gold Medal by the Royal College of Surgeons of Edinburgh for achieving the best results worldwide in the year 1996 to 1997.

Dr. Yuen is also very dedicated to training and professional development of ophthalmology both locally and overseas. She is the Honorary Clinical Associate Professor of The University of Hong Kong and the Honorary Clinical Associate Professor of The Chinese University of Hong Kong. She contributes to teaching of medical students, nurses, para-medical professionals and Ophthalmologists. In view of her contribution to the Ophthalmology field, she was awarded the Distinguished Service Award of The Asia Pacific Academy of Ophthalmology in year 2011 and was elected as Fellow of The Royal College of Ophthalmologists of United Kingdom in 2015.

She was further elected the Asia Pacific 100 most influential Ophthalmologists in 2022 in recognition of her contribution in Hong Kong, Asia Pacific Region and beyond.



## Noel Ching-Yan CHAN

#### Hong Kong, China

Dr. Noel Chan graduated from the medical school of The Chinese University of Hong Kong (CUHK) with first class honors and Kan Tong Po Gold Medal for Medical Studies in 2006. She obtained her FRCSEd(Ophth) in 2012 and FHKAM(Ophth) in 2013. She completed her residency and subspecialty training in Hong Kong Eye Hospital and obtained her overseas training in the United States after being awarded the Li-Po-Chun Charitable Trust Overseas Training Scholarships. Dr. Chan sub-specializes in neuro-ophthalmology, glaucoma as well as low vision. She is an international fellow of the North America Neuro-ophthalmology Society (NANOS) and Council member of Asia Neuro-ophthalmology Society (ASNOS) as well as External vice-president of Hong Kong Glaucoma Society. She is currently the Consultant in Prince of Wales Hospital & Alice Ho Miu Ling Nethersole Hospital as well as Honorary consultant of the Department of Health. Academically, she serves as the Honorary Clinical Associate Professor at the Department of Ophthalmology and Visual Sciences as well as Clinical Skills Learning Center in CUHK. She is currently also team heads of glaucoma, neuroophthalmology and electrodiagnostic services in New Territory East Cluster of Hospital Authority.

Dr. Chan's major research area focuses on glaucoma (in particular angle closure glaucoma and normal tension glaucoma), optic neuropathies and ocular imaging. Apart from numerous publications in peer-reviewed journals, book chapters and presentations delivered in local or international conferences, Dr. Chan has served as the secretary for the invited program for Asia Pacific Academy of Ophthalmology (APAO) from 2015 to 2020. She is also the secretary of the standing committee of APAO Ophthalmic Education Committee. In 2016 & 2018, she served as the Asia-Pacific coordinator for the low vision invited program in the World Ophthalmology Congress. Dr. Chan was awarded an outstanding paper in the Kowloon Central Cluster Convention of 2012 & 2014. She has also obtained the best service provider award of Hong Kong Eye Hospital in 2015, APAO Achievement Award in 2017 and Distinguished Young Fellow by Hong Kong Academy of Medicine in 2018. Dr. Chan has served in the College of Ophthalmologist of Hong Kong (COHK) in 2021-2023 and is currently an examiner for COHK.

Dr. Chan has vast experience in delivering health or educational talks to the public and other healthcare professionals physically, on TV programs and via newspaper clips. Dr. Chan is also the Honorary Advisor for two patient groups: Hong Kong Glaucoma Patients' Association and NMO-HK. Apart from volunteering in surgical expeditions in Cambodia, Vietnam and Myanmar, Dr. Chan is also the co-Founder of HK Chapter of Operation International (A global volunteer medical service organization).



## Calvin PANG

#### Hong Kong, China

Prof Calvin C. P. Pang is S.H. Ho Research Professor of Visual Sciences, Chinese University of Hong Kong (CUHK), Director of Shantou University/CUHK Joint Shantou International Eye Center. He is Immediate-Past Chairman of the Department of Ophthalmology and Visual Sciences, CUHK.

His research in genetics of complex and monogenic eye diseases include glaucoma, vitreoretinal diseases, myopia, uveitis, thyroid eye diseases, retinoblastoma and inherited retina diseases. He also studies pharmacokinetics of green tea extract, catechins, and GHRH receptor antagonists in ocular oxidative stress, inflammation, and degeneration, and risk factors of children's eye diseases and childhood myopia. He advocates the concept of "health care through children eye care".

Prof Pang has served as expert reviewer and external examiner of >20 funding organisations and academic institutions worldwide, including the Wellcome Trust, National Eye Institute (USA), Association of Research in Vision and Ophthalmology (ARVO), European Research Council, National Science Foundation China, Changjiang Scholar Program China, University of Melbourne, National University of Singapore and Peking University.

Prof Pang has received the China State Scientific and Technological Progress Award (SSTPA) second-class, Special Achievement Award of Chinese Ophthalmological Society, Asia-Pacific Academy of Ophthalmology (APAO) Senior Achievement Award and APAO Outstanding Service in Prevention of Blindness Award. He was the 2020 ARVO Foundation honoree. He is Honorary Fellow of the College of Ophthalmologists of Hong Kong. He was selected "The Ophthalmologist Power List 2024", top 100 most influential individuals in ophthalmology, by "The Ophthalmologist". He has >600 publications in international peer-reviewed journals, h-index: 86 as of July 2024.



## Ka Wai WONG

### Hong Kong, China

MBChB, MSc in Biomedical Engineering, MRCS (Edinburgh), FCOphthHK, FHKAM (Ophthalmology)

Dr. Jasper Wong is clinician-scientist with broad research interests in both clinical and biomedical engineering fields. He graduated from the Chinese University of Hong Kong (CUHK) and started his ophthalmology residency in the Hospital Authority, with subspecialty training in both anterior segment and glaucoma.

After finishing his master degree in biomedical engineering, he joined the University of Hong Kong (HKU) as clinical assistant professor in 2017. He had also been invited as a visiting lecturer to King's College London in 2019. His biomedical engineering research involved development of novel glaucoma treatment modalities, artificial intelligence in image analysis and teleophthalmology. Clinically, his research focused mainly on various minimally invasive glaucoma surgeries.

Besides his current private clinical practice in Central, Dr. Wong is still serving as honorary clinical assistant professor of Ophthalmology and adjunct assistant professor of mechanical engineering in HKU, as well as adjunct assistant professor of biomedical engineering in the Polytechnic University of Hong Kong.



## Oi Man WONG

#### Hong Kong, China

Dr Wong is currently consultant and glaucoma team coordinator in Hong Kong Eye Hospital (HKEH).

Dr Wong graduated from the medical school of the University of Hong Kong (HKU) in 2008, and was awarded Professor Anthony Hedley Prize in Public Health for her outstanding performance in the Master of Public Health programme at HKU in 2013. She obtained Fellowship of the College of Ophthalmologists of Hong Kong and Royal College of Surgeons of Edinburgh (Ophthalmology) in 2015.

After scholarship-supported observerships in Wills Eye Hospital, Duke Eye Center, Moorfields Eye Hospital and University of Toronto, Dr Wong contributed to introducing minimally invasive glaucoma surgery to needy public patients, and established the HKEH paediatric glaucoma service in collaboration with paediatric ophthalmology team. She has published over 20 articles as first or co-author in prestigious journals e.g. Lancet Digital Health, Nature Biomedical Engineering, and British Journal of Ophthalmology, with special focus on laser treatment for glaucoma, uveitic glaucoma and childhood glaucoma. She is also reviewer for multiple international journals and instructor at various training programs for ophthalmologists locally and in mainland. Dr Wong has received multiple awards for her contributions, including Distinguished Young Fellow of Hong Kong Academy of Medicine in 2022, Young Achiever Award of Hospital Authority and Kowloon Central Cluster in 2024, and was selected as one of

the Ten Outstanding Young Persons 2024 of Junior Chamber International Hong Kong.



### Christopher K.S. LEUNG

#### Hong Kong, China

Christopher Leung is a clinician-scientist in ophthalmology. His areas of specialty encompass glaucoma, the leading cause of irreversible blindness, and the diagnostic imaging of the optic nerve. His research team has been at the forefront of advancing novel concepts and technologies for the early diagnosis of glaucoma and tracking of glaucoma progression. He is also exploring innovative therapeutic strategies, including the development of micro-RNA based gene therapy, aiming at neuroprotection and regeneration of the optic nerve.



## **Dexter LEUNG**

#### Hong Kong, China

BMedSci(Hons), MBChB (CUHK), FRCOphth (Lond), FRCS RCPS (Glasg), MRCS (Edin), FCOphthHK, FHKAM (Ophthalmology)

Dr. Dexter Leung serves as an Honorary Consultant at the Hong Kong Sanatorium & Hospital and is an Honorary Clinical Associate Professor at both the Chinese University of Hong Kong (CUHK) and the University of Hong Kong (HKU).

Dr. Leung graduated with first-class honors in his Bachelor of Medical Sciences at CUHK and later earned his MBChB degree. He began his career as an ophthalmic resident at the Hong Kong Eye Hospital and furthered his training at the prestigious Bascom Palmer Eye Institute in the United States. His surgical expertise includes advanced cataract and glaucoma surgeries, and he is a pioneer in microincisional glaucoma surgery (MIGS).

As an expert in normal-tension glaucoma, Dr. Leung has authored over 75 publications in prestigious peer-reviewed journals and received numerous international awards, including a Best Paper Award from the American Academy of Ophthalmology, and Asia Pacific Academy of Ophthalmology Achievement Award & Distinguished Service Award.

Passionate about preventing blindness, he collaborates with organizations such as the Project Vision Charitable Foundation and ORBIS, providing affordable cataract surgeries and free eye surgeries in mainland China. As past president of the Hong Kong Ophthalmological Society, he promotes public awareness of glaucoma and eye health, having established World Glaucoma Day in Hong Kong.

Committed to education, Dr. Leung has served on the Board of Trustees for Shaw College of CUHK since 2009. His dedication has earned him several accolades, including being named one of the Ten Outstanding Young Persons of the Year in 2010 and receiving the CUHK Faculty of Medicine Distinguished Alumni Award in 2019.



### Vincent LEE

#### Hong Kong, China

LCMHK, M.D. (University of California, San Diego), FC (Ophthalmology) HK, FHKAM (Ophthalmology), Diplomate American Board (Ophthalmology), Fellow ( American Academy of Ophthalmology)

Dr. Lee is a distinguished ophthalmologist and a prominent figure in the field of ophthalmology, currently serving as a Partner at Hong Kong Eye Consultants since 2008. He has held the position of Chairman of the Board at Neurotech, Ltd. since 2010 and has been an active member of the International Council of the International Society of Refractive Surgery since 2021.

Dr. Lee earned his Bachelor of Science with Honors in Chemical Engineering from the California Institute of Technology and later obtained his Doctor of Medicine from the University of California, San Diego. He completed his residency in Ophthalmology at UC San Diego, where he also served as Chief Resident, followed by a Clinical Glaucoma Fellowship at the Jules Stein Eye Institute, UCLA.

Over his illustrious career, Dr. Lee has held multiple prestigious positions. He served as Assistant Clinical Professor at California Pacific Medical Center and as Consultant Physician in the Glaucoma Division at UCLA from 1993 to 1995. Upon returning to Hong Kong, he took on significant roles, including Chief of Service in Ophthalmology at Queen Mary Hospital and Associate Professor in the Department of Ophthalmology & Visual Sciences at The Chinese University of Hong Kong from 1995 to 1999. He then served as Director of the Eye Centre at Hong Kong Adventist Hospital from 1999 to 2008, followed by his role as Chief Executive Officer of the Hong Kong Laser Eye Centre from 2008 to 2017.

8 Dec	cember 2024 (SUNDAY)
Session Theme: Efferent Disorders & Closing Ceremony	Chair(s): Andy Cheng Rashmin Gandhi Satoshi Kashii
Time: 14:00 - 15:30	Room: N201A
Time Speakers	Торіс

14:00-14:12	An-Guor WANG	Third Nerve Palsy Revisited
14:12-14:24	Neil MILLER	Fourth Nerve Palsy: Diagnosis and Management
14:24-14:36	Prem SUBRAMANIAN	TED Patient Journey- from US perspective
14:36-14:48	Jing Liang LOO	Acute Ophthalmoplegia with GQ1b
14:48-15:00	Hui-Chen CHENG	All you need to know about Vertical Gaze Palsy



## An-Guor WANG

### Chinese Taipei

Doctor Wang graduated from Taipei Medical University and completed his ophthalmic residency and fellowship training at Taipei Veterans General Hospital. He graduated from Institute of Clinical Medicine of National Yang-Ming University and became a PhD in the field of neurobiology. He had been visiting and working as a research scientist in 1998~1999 at University of California, Irvine.

Now he is the senior consultant of Neuro-ophthalmology & Strabismus section, Department of Ophthalmology, Taipei Veterans General Hospital. He is currently associate professor at School of Medicine, National Yang-Ming Chiao-Tung University. He serves as the council member of Taiwan Ophthalmological Society. He is currently the secretary general/council member of Asian Neuro-ophthalmology Society (ASNOS) and council member of Asia-Pacific Society of Pediatric Ophthalmology and Strabismus (APSPOS) and Asia-Pacific Academy of Ophthalmology (APAO). He serves as the section editor of "Journal of Neuro-ophthalmology", and as the associate editor of "Neuro-ophthalmology". He also has authored a book "Emergency Neuroophthalmology".



### Neil MILLER

### United States

Dr. Neil Miller is Professor Emeritus of Ophthalmology, Neurology, and Neurosurgery at the Johns Hopkins University School of Medicine. He has authored over 595 articles, 97 chapters, and 16 books, including the 4th edition of "Walsh and Hoyt's Clinical Neuro-Ophthalmology" and has co-edited the 5th and 6th editions of this textbook as well as four editions of an abbreviated version of the textbook: "Walsh and Hoyt's Clinical Neuro-Ophthalmology: The Essentials", the most recent of which was published in 2020. Dr. Miller also has co-authored three editions of "The Neuro-Ophthalmology Survival Guide", a textbook designed for both physicians and students. The third edition was published this year. Dr. Miller has spoken at numerous local, national, and international meetings and has given 67 named lectures around the world. In addition, he has been involved in many clinical trials in the field of neuro-ophthalmology. Many of Dr. Miller's previous Fellows and residents hold faculty positions at major institutions throughout the United States and around the world.



## Prem SUBRAMANIAN

#### United States

Prem S. Subramanian, MD, PhD, is the Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology and is professor of ophthalmology, neurology, and neurosurgery and vice chair for academic affairs at the Sue Anschutz-Rodgers University of Colorado Eye Center/School of Medicine. He is also Adjunct Professor of Surgery at the Uniformed Services University of the Health Sciences. He received his MD with high honors and PhD in molecular and human genetics at Baylor College of Medicine in Houston, Texas. He is a founding member of the medical staff of the Marcus Institute for Brain Health, which serves to improve the functioning of patients with traumatic brain injury through intensive outpatient rehabilitation. He is also an active orbitocranial surgeon with a specific interest in tumors of the skull base and small-incisional approaches. His current research is focused on finding more effective medical treatments for patients at risk for progressive thyroid ophthalmopathy, developing better treatments of vision problems in patients with increased intracranial pressure, and using vestibular and visual therapies to overcome visual and balance dysfunction after traumatic brain injury. He is President of the North American Neuro-Ophthalmology Society, Chair of the Council of the American Academy of Ophthalmology and member of the AAO Board of Trustees and serves on the Board of Directors of the North American Society of Academic Orbital Surgeons; in addition, he has published over 250 research articles, book chapters, and web-based educational materials and is a dedicated educator in several countries around the world.



## Jing Liang LOO

#### Singapore

Dr Loo Jing Liang is Senior Consultant and Head of the Neuro-Ophthalmology at the Singapore National Eye Centre (SNEC). She is also an Adjunct Associate Professor at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) and Duke-NUS Medical School.

She completed her advanced specialist training in Ophthalmology and became a fellow of the Royal College of Surgeons (Edinburgh) and the Academy of Medicine (Singapore) in 2008. Following this, she embarked on a one year Neuro-Ophthalmology fellowship at the Singapore National Eye Centre. She later received the Higher Manpower Development Programme (HMDP) award from the Ministry of Health and underwent further fellowship training under the preceptorship of Professor Neil Miller at the Johns Hopkins Hospital.

As a Clinician Educator, Dr Loo is actively involved in the training of medical students and Ophthalmology residents. She is the Director of Undergraduate Education in SNEC and the Ophthalmology & Visual Sciences Academic Clinical Programme, overseeing the training of students from 3 medical schools in Singapore. She is also a member of the Core Faculty of the SingHealth Residency Programme (Ophthalmology). Being passionate about teaching Neuro-ophthalmology, she has organised and directed numerous Neuro-Ophthalmology Masterclasses and teaching courses since 2011. For her work in medical education, she has won several awards including the "Outstanding Faculty- Singhealth RiSE (Residency in Singhealth Excels ) Awards (2019) " Outstanding Educator - GCEO Excellence Award 2024".

Dr Loo is an Adjunct Research Fellow with the Singapore Eye Research Institute. She has presented at local and international conferences as well as published in international peer reviewed journals.



### Hui-Chen CHENG

### Chinese Taipei

HUI-CHEN CHENG, MD,PhD completed her ophthalmic residency training and fellowship training of neuro-ophthalmology, pediatric ophthalmology and strabismus at the Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. She is currently the attending physician of Neuro-ophthalmology & Strabismus Section of the Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan. She is also the assistant professor of department of ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Dr. Cheng had been the executive secretary of local organizing committee of the 31th Asia-Pacific Academy of Ophthalmology Congress. She is currently the council member of Women in Ophthalmology Standing Committee of the Asia Pacific Academy of Ophthalmology (APAO).

8 December 2024 (SUNDAY)



Time: 14:00 - 15:30

Room: N202-N203

Time	Speakers	Торіс
14:00-14:08	Franz Marie CRUZ	Comparison of Image Review Parameters from Two Different Optical Coherence Tomography Analytical Workflows
14:08-14:18	Marten BRELEN	Four year outcomes of Faricimab in DME - RHONE-X Long Term Extension Tria
14:18-14:28	Nicholas S.K. FUNG	Aflibercept in DME - Outcomes of Phase 2/3 PHOTON Trial by baseline BCVA
14:28-14:38	Hoi Yau Heather TANG	Reducing Traction, Enhancing Safety with 20,000 CPM Cutters
14:38-14:46	Wai Yan LAM	Outcomes of vitrectomy with membrane peeling in Myopic Traction Maculopathy
14:46-14:54	Anne Stephanie Lam BUAN	Long Term Follow-Up of Central Serous Chorioretinopathy (CSCR) after Successful Treatment of Half-Dose Photodynamic Therapy (PDT) or Subthreshold Micropulse Laser (SMLT)
14:54-15:02	Natalie Nga Man TAM	revalence and Risk Factors for Epiretinal Membrane (ERM) in a Hong Kong population aged 50 years and above
15:02-15:10	Jing KONG	Prediction of macular foveal microstructure recovery after idiopathic full-thickness macular hole surgery
15:10-15:30	_	Panel Discussion



### Marten BRELEN

#### Hong Kong, China

Four Year Outcomes of Faricimab in DME - RHONE-X Long Term Extension Trial Biography: Dr Mårten E BRELÉN is an Associate Professor at The Chinese University of Hong Kong (CUHK). He obtained his preclinical medical degree (MA) from Cambridge University where he graduated with 1st Class Honours. His clinical medical degree (BMBCh) was obtained from Oxford University and he has also spent 4 years in research at the University of Louvain in Belgium which led to the degree of PhD in Biomedical Sciences. Clinically Dr Brelén is fellowship trained at the Bristol Eye Hospital, UK in vitreo-retinal surgery and he is a fellow of the Royal College of Ophthalmologists UK (London).

Dr Brelén is the Head of retina service at CUHK Eye Centre and the Team Head for the vitreoretinal service at Prince of Wales Hospital. He is the Lead Coordinator of the clinical fellowship programme for vitreoretinal training and the Director of Pao So Kok Macular Disease Treatment and Research Centre. He is also a Visiting Professor at the Joint Shantou International Eye Centre in Shantou, China.



### Nicholas S.K. FUNG

### Hong Kong, China

Dr. Fung Siu Kay, Nicholas

BA (Wesleyan University, MBChB (CUHK), MRCS (Edinburgh) FCOphthHK, FHKAM (Ophthalmology)

Honorary Clinical Associate Professor, Department of Ophthalmology, The University of Hong Kong

Specialist in Ophthalmology, Hong Kong Sanitorium & Hospital

Dr. Nicholas Fung graduated from Wesleyan University (BA) followed by graduate studies at Harvard University before returning to Hong Kong for his medical studies (MBChB) at the Chinese University of Hong Kong in 2000. He had been working in ophthalmology at Queen Mary Hospital and Grantham Hospital since 2008. Apart from general ophthalmology, his focus in ophthalmology is in vitreoretinal diseases and surgery.

Dr. Fung's research areas in medical retina, include landmark international collaboration studies on age related macular degeneration, diabetic maculopathy, retinal vascular diseases, and polypoidal chorioretinopathy, bringing multiple anti VEGF treatments into Hong Kong. His research in surgical retina includes retinal detachment and macular diseases from macular hole to epiretinal membranes. During the time as Clinical Assistant Professor at HKU, he continued to promote and deliver his research around the world at various International and Regional ophthalmology conferences as well as on local Hong Kong media. His surgical interests have also led to the introduction of the first digital microscope into Hong Kong and SE Asia in 2020.

Dr. Fung is now practicing in Hong Kong Sanitorium & Hospital, and as an Honorary Clinical Associate Professor at Department of Ophthalmology at The University of Hong Kong.



## Hoi Yau Healther TANG

### Hong Kong, China

Dr. Heather Tang is an experienced vitreoretinal surgeon. She received her overseas training under Prof Antonia Joussen from Charite, Germany; Prof Gaurav Shah from Barnes retina institute, US and Prof Yasushi Ikuno from Osaka University, Japan. Her subspecialty interest is complex diabetic retinopathy surgery.

She is currently Honorary Clinical Assistant Professor in the University of Hong Kong and the Chinese University of Hong Kong.

### 8 December 2024 (SUNDAY)



Time: **14:00 - 15:30** 

Room: N206-208

Time	Speakers	Торіс
14:00-14:10	Chun Chieh LAI	Dry Eye Disease in Blepharoptosis Surgery, Cataract Surgery & Thyroid Eye Disease
14:10-14:18	Hei Tung SHEK	Deep Learning Automated Diagnosis and Grading of Cataracts using Colour Fundus Images: The Fundus Cataract-Al Project
14:18-14:26	Kit Wai LIANG	Relationship Between Ocular Surface Signs and Self- Reported Dry Eye Symptoms in Substance Abusers: Implications for Screening and Understanding Neurological Pathways
14:26-14:34	Lok Man Tiffany YEUNG	Summary of femtosecond laser-assisted cataract surgery in Kowloon East Cluster
14:34-14:42	Julia Mercedes VILLALVA	Corneal Endothelial Cell Density and Morphology of Filipino Patients in a Tertiary Level Hospital
14:42-14:50	Lok Man Tiffany YEUNG	Comparison of outcomes of primary and secondary sutureless scleral fixated intraocular lens implantation in adult patients
14:50-15:00	Julia CHAN	Utilising Mono Plus Toric IOL in Clinical Setting: Are Patients & Surgeons Satisfied?
15:00-15:10	Tim ROBERTS	Next generation purely refractive EDOF IOL design
15:10-15:30	-	Panel Discussion



## Chun Chieh LAI

#### Chinese Taipei

Chun-Chieh Lai M.D., PhD Asst. Prof. Ophthalmologist

Department of Ophthalmology, College of Medicine, National Cheng Kung University Dr. Chun-Chieh Lai, M.D., Ph.D., is a distinguished ophthalmologist and a prominent figure in the field of ophthalmology. He currently serves at the Department of Ophthalmology, College of Medicine, National Cheng Kung University in Taiwan. With a career spanning over 15 years, Dr. Lai has specialized in orbit and oculoplasty, cornea, cataract surgery, and pterygium epithelial cell studies. His extensive research and clinical expertise have led to numerous publications in high-impact journals. Notable among his recent works are studies on retrobulbar hematoma, corneal astigmatism, and eyelid papilloma, published in journals such as the Journal of Neuroophthalmology , Ophthalmic Plastic and Reconstructive Surgery and Ophthalmology. Dr. Lai's contributions to ophthalmology extend beyond clinical practice and research. He has been instrumental in advancing surgical techniques and treatments, particularly in the management of nasolacrimal duct obstruction and orbital & thyroid eye disease. His innovative approaches and dedication to patient care have earned him recognition and respect within the medical community.

In addition to his clinical and research endeavors, Dr. Lai is also an active educator, mentoring the next generation of ophthalmologists. His commitment to excellence and his passion for advancing the field of ophthalmology make him a valuable asset in the field.



### **Tim ROBERTS**

#### Australia

Tim Roberts is a Clinical Associate Professor at the University of Sydney and a Consultant Ophthalmic Surgeon at Royal North Shore Hospital. He is an experienced cataract and glaucoma surgeon and is interested in new technologies and treatments in cataract surgery, as well as medical ethics and education. He has published over 60 research papers and book chapters and regularly speaks at events both in Australia and internationally.

Prof. Roberts is a Fellow of RANZCO and previously chaired the NSW QEC, where he oversaw training for ophthalmology trainees. He is also the Academic Lead for Ophthalmology at the SERT Institute at RNSH and coordinates academic programs at the Northern Clinical School, University of Sydney.

He has received national and international awards for his contributions to science and education in ophthalmology, including the Global Achievement Award from the American Academy of Ophthalmology and APACRS. Prof. Roberts has been on the editorial board of the AAO's Cataract textbook and various international journals, and he serves on several committees related to government, industry, universities, and professional organisations.



## Julia CHAN

#### Hong Kong, China

Dr Julia Chan is a specialist in ophthalmology, the Fellow of The College of Ophthalmologists of Hong Kong (FCOphthHK), the Fellow of the Hong Kong Academy of Medicine in the specialty of Ophthalmology (FHKAM(Ophthalmology)) and the Member of the Royal College of Surgeons of Edinburgh (MRCS(Ed)) with subspecialty interest in corneal and external eye (CEE) diseases and refractive surgeries.

She was awarded the Bachelor of Medicine and Bachelor of Surgery (MBBS) of the Faculty of Medicine at the University of Hong Kong in 2015. She has received her ophthalmology training at the Hong Kong Eye Hospital (HKEH) from 2016 and was appointed Clinical Assistant Professor (Honorary) of Department of Ophthalmology and Visual Sciences of the Chinese University of Hong Kong (DOVS, CUHK) before she joined the faculty. She is the Fellow of the CUHK-HKEH-PWH Ophthalmology Subspecialty Fellowship Programme on CEE diseases. She has obtained the Postgraduate Diploma (PDip) in Epidemiology and Biostatistics at the JC School of Public Health and Primary Care at the CUHK in 2023.

Dr Chan has been actively involved in refractive surgeries as well as the diagnosis and treatment of CEE diseases including conjunctival melanoma, ocular Herpes Simplex Virus (HSV) diseases and dry eye disease. She is one of the few supervisors in Hong Kong competent in the training ophthalmology resident trainees on full-thickness as well as lamellar corneal transplantations. Her publications in international peer-reviewed journals include JAMA Ophthalmology. She has been the invited speaker in international conferences including the World Ophthalmology Congress (WOC), Asia Corneal Society (ACS) Biannual Biennial Scientific Meeting, Asia-Pacific Academy of Ophthalmology (APAO) Congress, Congress of Asian Society of Transplantation(CAST) and Asia Pacific Ocular Imaging Society (APOIS) Congress. She is the Scientific Meeting 2026, the secretary of cataract programme in APAO Congress 2024 and 2025, and the Social Committee Chairperson of the 16th Asia-Pacific Vitreo-retina Society (APVRS) Congress. Devoted to public education, she is the author of the bimonthly column on updates of ophthalmic conditions in the Hong Kong Economic Journal.

Dr Chan has special interest in aviation medicine and has been awarded the Australian Certificate of Civil Aviation Medicine (ACCAM) by Monash University. She has been appointed as the Designated Aviation Medical Examiner (DAME) of the Civil Aviation Safety Authority (CASA) of Australia since 2019 and Designated Aviation Ophthalmologist (DAO) since 2023, upholding stringent aviation healthcare standards.

 8 December 2024 (SUNDAY)

 Session Theme:

 Train-the-Trainer and ASMHK

 Image: Chair(s):

 Image: Robert Fung LAM

 Image: N202-N203

Time	Speakers	Торіс
15:45-15:50	Robert Fung LAM	COHK Trainer responsibilities
15:50-16:00	Carmen CHAN	Core Area Trainer Eligibility Application
16:00-16:15	Carmen CHAN	Training curriculum & Elogbook: What Trainers Need to Know
16:15-16:30	Hon Wah YUNG	How to Conduct Active Assessments
16:30-16:45	Connie LAI	How to help trainees prepare for exams, including logbook inspection
16:45-17:00	-	Q&A



## **Robert Fung LAM**

### Hong Kong, China

Dr. LAM Fung Robert, Vice President (Professional Affairs), The College of Ophthalmologists of Hong Kong (COHK)

Dr. Lam earned his medical degree from Australia, where his passion for Ophthalmology ignited. He subsequently completed his specialist training in ophthalmology in Hong Kong, focusing on retinal diseases. Driven by his commitment to academic excellence, he pursued a Master's degree in Public Health at The University of Hong Kong, equipping him with the expertise to teach and perform research.

In his role at COHK, Dr. Lam oversees the development and implementation of all matters related to training and examination, ensuring alignment with international standards while addressing the unique needs of Hong Kong's healthcare system. Dr. Lam is dedicated to improving the training for all trainees amidst high trainer attrition and high workload in all training centres.

Working with his dedicated team, COHK has recently implemented the updated training curriculum with focus on core-area training, simulated training for surgical procedures, active assessments, and competency-based medical education, fostering a culture of lifelong learning among ophthalmologists. Known for his approachable leadership style and unwavering dedication, he continues to inspire his peers and trainees alike with his vision for advancing ophthalmic care through education.

In addition to his professional endeavors, Dr. Lam is an advocate for work-life balance and enjoys travelling in his leisure time. He remains committed to his mission of fostering excellence and innovation in ophthalmology education for the benefit of patients and practitioners alike.



## Carmen CHAN

### Hong Kong, China

Dr. Chan is the Chief of Service and Consultant Ophthalmologist at the Hong Kong Eye Hospital, Clinical Professor (Honorary) at the Department of Ophthalmology and Visual Sciences of the Chinese University of Hong Kong and Honorary Clinical Professor, Department of Ophthalmology, School of Clinical Medicine, The University of Hong Kong.

She was awarded the Prince Philip Scholarship to study medicine at the University of Cambridge and trained initially in general medicine, followed by ophthalmology training in the UK and Hong Kong. She subsequent completed a neuro-ophthalmology fellowship with Dr Neil Miller at the Wilmer Eye Institute, USA. Dr. Chan subspecializes in neuro-ophthalmology and uveitis. Overall, she has published over 80 papers in peer-reviewed journals, and she is an editorial board member of the Journal of Neuro-ophthalmology, Neuro-Ophthalmology, Asia Pacific Journal of Ophthalmology, Eye and the Hong Kong Journal of Ophthalmology. She is the Convenor of the Hong Kong Neuro-Ophthalmology Interest Group, a council member of the Asia Neuro-Ophthalmology Society and a vice-chair of the North American Neuro-Ophthalmology Society International Relations Committee. She is the recipient of the Asia Pacific Academy of Ophthalmology (APAO) Distinguished Service Award in 2013 and Senior Achievement Award in 2024. She is also the secretary of the APAO Women in Ophthalmology standing committee since its inception in 2011. She has been selected as one of the Top 100 ophthalmologists in the Asia Pacific region (AP Eye 100) in 2022.



## Hon Wah YUNG

#### Hong Kong, China

Dr. Yung Hon Wah is currently Consultant Ophthalmologists in Hong Kong East Cluster. He had been council members of the College of Ophthalmologists of Hong Kong (COHK) since 2009. He had been actively involved in the training and examination activities of COHK and was chairman of the training subcommittee of COHK from 2009 to 2019, Vice President (Professional Affair) of COHK from 2019 to 2023 and currently the Vice President (General Affair) of COHK. He had played a leading role in the revision and update of the 2016, 2020 and 2022 training curriculum of COHK.



### Connie LAI

### Hong Kong, China

Dr. Connie Lai is a Consultant working at Hong Kong West Cluster in Hospital Authority and holds an honorary position as Associate Professor at the University of Hong Kong. She is the subspecialty coordinator of the Pediatric Ophthalmology and Strabismus and ROP service.

She is also a member of numerous professional societies and holds reviewerships in international journals.

Her main aim is to make pediatric ophthalmology less of an enigma and helping residents "overcome their fear of the tiny and the adults behind them."

8 December 2024 (SUNDAY)



Time	Speakers	Торіс
15:45-16:00	Alex NG	Premium IOL
16:00-16:15	Christopher SEE	Al in Ophthalmology: A Practical Guide on Medical Legal Issues
16:15-16:30	Kendrick SHIH	Residents' challenge
16:30-17:05	Julia CHAN , Patrick TAM , Oi Man WONG , Irene YEUNG	Work-life balance and life outside the ophthalmologist clinic



Alex NG Hong Kong, China



## Christopher SEE

### Hong Kong, China

Dr. Christopher See is a medical educator, receiving his medical degree from the University of Cambridge (Trinity College), a PGCE from the University of Edinburgh and Ph.D. from HKU in Medical Education. Currently a lecturer in anatomy at the School of Biomedical Sciences, he has received teaching excellence awards from both the University of Manchester and CUHK.

His educational research centres on Artificial Intelligence (AI) in medical education, receiving over 5.6 million HKD of grants and multiple publications in this area. He leads both the AI for Education Community of Practice in CUHK and a Hong Kongwide 1.6 million HKD TDLEG initiative "AI for Education" with 6 partner institutions. He has taught modules on AI in Healthcare, introduction to Machine Learning, Neural Networks and Deep Learning in several medical schools' curricula. He also teaches ethics and law in healthcare AI at CUHK, and has delivered training for the College of Radiologists Hong Kong in this area.



### Kendrick SHIH

### Hong Kong, China

Dr Kendrick Shih is a Clinical Associate Professor and Honorary Consultant at the Department of Ophthalmology. He graduated from HKUMed in 2009 with MBBS and MRes (Medicine) degrees and obtained his specialist qualifications in Ophthalmology in 2016. Kendrick was awarded the 2016 Hong Kong Academy of Medicine Gold Medal for Best Original Research by a Trainee (BORT) and was selected as a 2017 Hong Kong Academy of Medicine Distinguished Young Fellow (DYF). He was the recipient of the 2018 Asia Cornea Society Santen-Asia Educational Grant and underwent training in ocular surface research at the Singapore National Eye Centre under Professor Louis Tong. In the same year, he was also awarded the Asia Pacific Academy of Ophthalmology Achievement Award. Professor Shih currently has over 90 publications in international peer-reviewed journals with an h-index of 27.



## Julia CHAN

#### Hong Kong, China

Dr Julia Chan is a specialist in ophthalmology, the Fellow of The College of Ophthalmologists of Hong Kong (FCOphthHK), the Fellow of the Hong Kong Academy of Medicine in the specialty of Ophthalmology (FHKAM(Ophthalmology)) and the Member of the Royal College of Surgeons of Edinburgh (MRCS(Ed)) with subspecialty interest in corneal and external eye (CEE) diseases and refractive surgeries.

She was awarded the Bachelor of Medicine and Bachelor of Surgery (MBBS) of the Faculty of Medicine at the University of Hong Kong in 2015. She has received her ophthalmology training at the Hong Kong Eye Hospital (HKEH) from 2016 and was appointed Clinical Assistant Professor (Honorary) of Department of Ophthalmology and Visual Sciences of the Chinese University of Hong Kong (DOVS, CUHK) before she joined the faculty. She is the Fellow of the CUHK-HKEH-PWH Ophthalmology Subspecialty Fellowship Programme on CEE diseases. She has obtained the Postgraduate Diploma (PDip) in Epidemiology and Biostatistics at the JC School of Public Health and Primary Care at the CUHK in 2023.

Dr Chan has been actively involved in refractive surgeries as well as the diagnosis and treatment of CEE diseases including conjunctival melanoma, ocular Herpes Simplex Virus (HSV) diseases and dry eye disease. She is one of the few supervisors in Hong Kong competent in the training ophthalmology resident trainees on full-thickness as well as lamellar corneal transplantations. Her publications in international peer-reviewed journals include JAMA Ophthalmology. She has been the invited speaker in international conferences including the World Ophthalmology Congress (WOC), Asia Corneal Society (ACS) Biannual Biennial Scientific Meeting, Asia-Pacific Academy of Ophthalmology (APAO) Congress, Congress of Asian Society of Transplantation(CAST) and Asia Pacific Ocular Imaging Society (APOIS) Congress. She is the Scientific Programme Chairperson of the Asia Corneal Society (ACS) Biannual Biennial Scientific Meeting 2026, the secretary of cataract programme in APAO Congress 2024 and 2025, and the Social Committee Chairperson of the 16th Asia-Pacific Vitreo-retina Society (APVRS) Congress. Devoted to public education, she is the author of the bimonthly column on updates of ophthalmic conditions in the Hong Kong Economic Journal.

Dr Chan has special interest in aviation medicine and has been awarded the Australian Certificate of Civil Aviation Medicine (ACCAM) by Monash University. She has been appointed as the Designated Aviation Medical Examiner (DAME) of the Civil Aviation Safety Authority (CASA) of Australia since 2019 and Designated Aviation Ophthalmologist (DAO) since 2023, upholding stringent aviation healthcare standards.



## Patrick TAM

#### Hong Kong, China

Becoming an ophthalmologist is an attempt to combine a medical career with a hobby. While Patrick was deeply blessed to be given a path his parents paved so he could become a professional, he was consciously aware this job needs to be interesting. His fascination with vintage Rodenstock at the time made the job a perfect match.

While hobbies change and interests rotate, a career is lifelong. During his overseas training in Ocular Inflammation and Uveitis in Moorfields in 2009, he fell into the coffee rabbithole when inadvertently tasted a cup prepared by a gentleman who 3 days later became the World Barista Champion.

It took him 4 years to put Knockbox Coffee on the forefront of specialty coffee in Hong Kong, he's proud to have witnessed the birth of an industry. Traveling the world as judge, a green bean importer, a roaster, and ultimately a dishwasher when he could delegate the Head Barista role to his protege who was crowned HK champion in 2017. He writes and talks extensively on coffee, featuring a weekly Mingpao column for 3 years. He speaks regularly on coffee tasting, its culture, geopolitics and more importantly, the growers. Coffee enables him to travel to the outskirts of Colombian Andes where gorillas hadn't surrendered, or the Great Rift Valley where Ethiopians remain tribal and ancient.

He is now one "final MB" away from the DipWSET in wine. "Clip!", his latest project, is an attempt to explore and popularize food and beverage pairing.



### Oi Man WONG

#### Hong Kong, China

Dr Wong is currently consultant and glaucoma team coordinator in Hong Kong Eye Hospital (HKEH).

Dr Wong graduated from the medical school of the University of Hong Kong (HKU) in 2008, and was awarded Professor Anthony Hedley Prize in Public Health for her outstanding performance in the Master of Public Health programme at HKU in 2013. She obtained Fellowship of the College of Ophthalmologists of Hong Kong and Royal College of Surgeons of Edinburgh (Ophthalmology) in 2015.

After scholarship-supported observerships in Wills Eye Hospital, Duke Eye Center, Moorfields Eye Hospital and University of Toronto, Dr Wong contributed to introducing minimally invasive glaucoma surgery to needy public patients, and established the HKEH paediatric glaucoma service in collaboration with paediatric ophthalmology team. She has published over 20 articles as first or co-author in prestigious journals e.g. Lancet Digital Health, Nature Biomedical Engineering, and British Journal of Ophthalmology, with special focus on laser treatment for glaucoma, uveitic glaucoma and childhood glaucoma. She is also reviewer for multiple international journals and instructor at various training programs for ophthalmologists locally and in mainland.

Dr Wong has received multiple awards for her contributions, including Distinguished Young Fellow of Hong Kong Academy of Medicine in 2022, Young Achiever Award of Hospital Authority and Kowloon Central Cluster in 2024, and was selected as one of the Ten Outstanding Young Persons 2024 of Junior Chamber International Hong Kong.



### Irene YEUNG

Hong Kong, China

Dr. Irene Yeung is a dedicated ophthalmologist, co-founder and currently Head of EC Eye Centre. With a passion to strive for the highest, Dr. Yeung believes in the motto, "life is short, so make the most of it." This philosophy not only drives her professional endeavours but also shapes her approach to personal well-being and work-life balance.

After completion of her undergraduate degree in Computer Engineering and a Master degree in Biomedical Engineering from the University of New South Wales, Dr. Yeung continued to study Medicine in the University of Hong Kong so she could pursue her career to treat humans rather than machines. Dr. Yeung received ophthalmological residency training from the Hong Kong East Cluster team, which provided excellent guidance and tremendous opportunities to ensure every doctor could become a competent and independent surgeon who is patient-centred. Her main interests are in refractive surgery, dry eye disease and utilization of IPL in meibomian gland dysfunction.

Outside of her medical practice, Dr. Yeung is a member of a very active acapella group, Medipella, where they perform regularly to bring positivity to their audience. Dr. Yeung also extends her hobby to K-pop dancing and cake decoration by buttercream flower piping and holds several certification of advanced and master courses and is an instructor of the LKAFCD Association.

As a mother of two young children, Dr. Yeung strives to be a role model for her kids, demonstrating that it is possible to pursue one's passion and have a fulfilling career simultaneously. She regularly does K-pop dancing with her daughter, achieving exercise time as well as family bonding moments..

# Exhibition

Company	Booth No.			
Diamond Sponsors				
Alcon HK Ltd.	S2 & B4			
Roche Hong Kong Limited	S1 & B1			
Platinum Sponsors				
Bayer Healthcare Limited	S3 & B3			
Johnson & Johnson Surgical Vision	S4 & B2			
Gold Sponsor				
Bausch and Lomb (HK) Ltd.	S5			
Bronze Sponsors				
AstraZeneca Hong Kong Limited	\$6			
Gaush Meditech	В6			
Santen	В5			
Exhibitors				
Allergan Hong Kong Limited	C3			
LANSHENG Hong Kong.	В9			
Loyal Tech Group Limited	C4			
Novartis Pharmaceuticals (HK) Ltd	C2			
Reich Pharm Limited	B7-B8			
The College of Ophthalmologists of Hong Kong and The Hong Kong Ophthalmological Society	C1			



## **Diamond Sponsors**





## **Platinum Sponsors**



Johnson&Johnson

## **Gold Sponsor**

### **BAUSCH+LOMB** See better. Live better.

## **Bronze Sponsors**











DAY AND NIGHT FOR DRY EYES

1



1111

1111 1111 Ę

# **Recommended Combination**

Can be used for 6 months after opening

6



6 months shelf life after opening



1111 1111

1111

ii


# Extraordinary Moments made possible with Vivity IOL, the World's #1 EDOF.<sup>1-2</sup>

Implants.

Alcon

\*Based on worldwide sales of AcrySof IQ Vivity® and Clareon® Vivity® IOLs.

References: 1. Market Scope - 2023 Premium Cataract Surgery Market Report; 2023 IOL Market Report. 2. Alcon Data on File, 2022. REF-22137. © 2024 Alcon Inc. HK-CLV-2400001 App. 202403



# **VEGF-A**

# ANG-2

# Start with the Power of 21-3

Shift the paradigm in the treatment of nAMD and DME with DUAL-PATHWAY INHIBITION<sup>4</sup>

**Call for Reporting:** If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong.drug\_safety@roche.com, or (b) Phone: +852 2733 4711.

Further information is upon request.

#### **References:**

- 1. Regula JT, et al. EMBO Mol Med. 2016;8:1265-88.
- 2. Heier JS, et al. Lancet. 2022;399(10326):729-40.
- 3. Wykoff CC, et al. Lancet. 2022;399(10326):741-755.
- 4. VABYSMO Hong Kong Prescribing Information.



#### Roche Hong Kong Limited

22/F, FTLife Tower, 18 Sheung Yuet Road, Kowloon Bay Tel: +852 2723 2832

M-HK-00001503 Valid until 11/1/2026 or until change is required in accordance with the regulatory requirements, whichever comes first.



\*For VABYSMO Prescribing Information, please scan the QR code. Full product information upon request.





vitation

The 36th Annual Scientific Meeting Hong Kong Ophthalmological Symposium

## Bayer Lunch Symposium: A Turning Point in nAMD

- 🗰 🛛 7 Dec 2024 (Sat)
- 12:15 13:15
  - Room N201A, 2/F, New Wings, HKCEC



CHAIRPERSON: Prof. Timothy LAI (HK) Clinical Professor (Honorary), Department of Ophthalmology and Visual Sciences, CUHK, HK



#### SPEAKER:

Dr. Kenneth FAN (USA) Medical and Surgical Retina Specialist, Retina Consultants of Texas, USA

#### Agenda

12:15-12:20	Welcome and Opening Prof. Timothy LAI	
12:20-13:00	A Turning Point in nAMD Dr. Kenneth FAN	
13:00-13:10	Q&A	

L3:00-13:10 Q& All

13:10-13:15 Closing Remarks Prof. Timothy LAI

This meeting is for invited guests only. For enquires, please contact Ms. Grace Mok at +852 8200 2067 or email at grace.mok1@bayer.com

#### Bayer HealthCare Limited 14/F, Oxford House, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong Tel: (852) 8100 2755 Website: www.bayer.com

# ATTAIN PEACE OF MIND with TECNIS PureSee<sup>TM</sup> IOL, the new purely refractive presbyopia-correcting EDOF IOL.<sup>1</sup>

**TECNIS PureSee<sup>™</sup> IOL** with continuous-power technology<sup>1</sup> provides better predictable patient outcomes<sup>2-5</sup>, ensuring high patient satisfaction<sup>6</sup> and **peace of mind for you**.

Find out more with a J&J representative.

TECNIS<sup>®</sup> See More.

## TECNIS PureSee<sup>™</sup>IOL

with TECNIS SIMPLICITY® Delivery System

Vision

#### References:

- 1. TECNIS PureSee™ IOL, Model ZENooV DFU INT, Z311973, current revision
- 2. DOF2023CT4011 Simultions of visual symptoms under defocus for TECNIS PureSee™ IOL. 29 March 2023.
- 3. DOF2023CT4041 Clinical investigation of the TECNIS™ IOL, C1V000 and C2V000 Tolerance to Refractive Error. 17 July 2023.
- 4. Black D. et al. Clinical investigation of tolerance to residual refractive errors following implantation with a refractive extended-depth-of-focus (EDF) IOL. Abstract ESCRS 2023. REF2023CT4129.
- 5. Bala C, et al. Superior intermediate and uncompromised distance quality of vision with a purely refractive extended depth of focus IOL. Abstract ESCRS Vienna 2023. REF2023CT4128.
- 6. DOF2023CT4043 Clinical investigation of the TECNIS™ IOL C1V000 and C2V000. Patient Satisfaction Outcomes 18 July 2023.

Australia: AMO Australia Pty Ltd, 1-5 Khartoum Road, North Ryde, NSW 2113, Australia. New Zealand: AMO Australia Pty. Ltd 507 Mount Wellington Hwy, Mount Wellington, Auckland 1060, New Zealand.

© Johnson & Johnson Surgical Inc. 2024, 2024PP05503.

## Johnson&Johnson MedTech

# THE NEW DIMENSION FULLY DIGITAL VISUALIZATION



0

**BAUSCH+LOMB** 

Please contact your local representative for more information on Bausch & Lomb products. ©2023 Bausch + Lomb Incorporated or its affiliates ©/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.

Bausch & Lomb (HK) Ltd.

Suites 3901 & 3912-14, 39/F, Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. Tel: 2213 3333 HK-SU-2023-10-012 **BAUSCH + LOMB** See better. Live better.

# AMGEN<sup>®</sup> 安進香港

以 病 人 爲 先 帶 領 生 物 科 技 製 藥 爲 治 療 帶 來 希 望

> 想了解安進香港更多 請掃描





For adults living with AQP4 Ab+ NMOSD

who have battled one attack too many



# Strive for

All patients treated with ULTOMIRIS® were relapse-free at a median treatment period of 73.5 weeks\*2 98.6%<sup>#</sup> reduction in the risk of relapse vs placebo<sup>2</sup>

Ultomiris®: Give your patients the chance of zero relapses as soon as possible<sup>3</sup>

HOSPITALISATIONS<sup>+</sup> vs 34% with placebo



HIGH-DOSE ORAL STEROID vs 13% with placebo



PLASMA EXCHANGE<sup>+</sup> vs 21% with placebo



information is available on AstraZeneca Hong Kong Limited Unit 1-3, 11/F, China Taiping Finance Centre, 18 King Wah Road, North Point, Hong Kong Tel: (852) 2420 7388 Fax: (852) 2422 6788



## **TELEON**°

# **PASSION FOR PERFECT VISION**

LENTIS Comfort

The vanguard EDOF-IOL with advanced segmented optics



## LENTIS<sup>®</sup> Comfort

- Excellent visual acuity results for the distance and intermediate ranges
- Natural image and colour perception
- More spectacle independence compared to monofocal standard and mono-EDOF-IOLs results in a better quality of life
- Improved contrast and depth of focus for optimal vision in low light conditions

## ACUNEX<sup>®</sup>

- Hydrophobic Glistening-Free Acrylate
- FDA Certified Bio-material
- Segmental-EDOF
- Excellent Contrast Vision Day and Night

ACUNEX VARIO The standard EDOF-IOL for every patient



# Ikervis<sup>®</sup> breaks the vicious circle of inflammation in dry eye disease,<sup>1</sup> significantly reducing corneal damage.<sup>2,3</sup>



## Innovative formulation for once-daily dosing<sup>15-6</sup>

Ikervis<sup>®</sup> is indicated for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes<sup>5</sup>

Ikervis® is indicated for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents<sup>5</sup>

Please refer to the full package insert for the recommended dose in VKC treatment.



Hore Notes Hoy SM, Dugs 2017;77(17);1909-1916. 2. Leonardi A et al. Eur J Ophthalmol 2016;26(4):287-296. 3. Baudouin C et al. Eur J Ophthalmol 2017;27(6);678-685. Baudouin C et al. Acta Ophthalmol 2018;96:111-119. 5. Ikervis Product Package insert. 6. Lallemand F et al. J Drug Deliv 2012;2012;604204.

**IKERVIS® ABBREVIATED PRESCRIBING INFORMATION:** 

Indication: Treatment of severe keraftils in adult patients with day eye disease, which has not improved despite treatment with tear substitutes. Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents. **Dosage:** [TREATMENT OF SEVERE KERATTIS WITH DRY YEVE DISEASE] The recommended dose is one drop once daily to be applied to the affected eyeb) at bedings. Response to treatment should be reassassed at least evey G monts. [TREATMENT OF SEVERE KKC] Children from 4 years of age and adolescents. The recommended dose is one drop by each adole dose or deroxassed to one drop by each adole dose or deroxassed to any othe exciptions is adopted on the maintained at the treatment conditions. Active or suspected outlar or peri-ocular infection. **Warnings/Precautions:** (KFC) in the treatment conditions. Active or suspected outlar or peri-ocular infection. **Warnings/Precautions:** (KFC) in the treatment conditions. Active or suspected outlar or peri-ocular infection and warning and the each affected eyeb at a balance or to any of the exciptions. Cuttar or peri-ocular infegonacies or peri-ocular infection. **Warnings/Precautions:** (KFC) in the treatment on a balance or peri-ocular infection on the subject on the immune system: Diptributine medicinal products, which affect the immune system: State the end with earlies with autorna. Regular clinical montions should be earlies were non-contart infection and majorances. Catalionium clinica expected outlas on the subject to a support of catality to be applied to a support of advects areaction and may be reinserted at the end were even at the support of classport in the support of classport in the catality of ocular heres is indecide approducts, which affect the immune system: Diptributine medicinal products, which affect the immune system including observation in such patients. With order the event were event at the event event of a classport in the catality in c-administration or clossport in the event were the event in the treatment of c

For healthcare professionals only. For further product information, please refer to the Renvis® package insert. Serice prescribing, please consult the full prescribing information for adverse incident reporting, please email Santem Pharmaceutical (Hong Kong) Ltd., at ht\_product\_satetyd3santen.co



#### Santen Pharmaceutical (Hong Kong) Limited

Unit 1607, 16/F, Concordia Plaza, 1 Science Museum Road, TST East, Kowloon, Hong Kong Phone: +852 2565 6660 Fax: +852 2565 6068

# ONE POWERFUL DROP TODAY<sup>1-4</sup>

could create a life full of possibilities tomorrow.<sup>5–10</sup>

Treat with power.<sup>1-4</sup> Treat with confidence.<sup>11</sup> Step-up to GANFORT<sup>®</sup>

(bimatoprost / timolol eye drops, solution) 0.03% / 0.5%



## Available in bottles and **preservative-free** unit doses.<sup>1</sup>



Scan QR code for Abbreviated Prescribing Information Ganfort\*/ Ganfort\* Pf

Full prescribing information, which is available upon request; bimatoprost 0.3 mg/mL and timolol 5.0 mg/mL

For healthcare professionals only. All adverse event should be reported to AbbVie pharmacovigilance team at drugsafety.pv@abbvie.com References:

Reterences: 1. GANFORT\*. Hong Kong Prescribing Information, August 2022. 2. Pfennigsdorf S et al. Clin Ophthalmol 2013; 7: 1219-1225. 3. Pfennigsdorf S et al. Clin Ophthalmol 2016; 10: 1837-1846. 4. Yilmaz SG et al. Int Ophthalmol 2018; 38(4): 1425-1431. 5. Lichter PR et al. Ophthalmology 2001; 108(11): 1943-1953. 6. Leske MC et al. Ophthalmology 2007; 114(11): 1965-1972. 7. CNTGS. Am J Ophthalmol 1998; 126(4): 487-497. 8. Yue Wang MD et al. Medicine 2017; 96(48): e8019. 9. Peters D et al. Acta Ophthalmologica 2015; 93: 745-752. 10. Sun X et al. Patient Prefer Adherence 2017; 11: 845-852. 11. Allergan. Unpublished Data. [DOF1 -INT-NON-2051227] 2020.



Address: Suite 2404, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong Phone: (852) 2610 2525 Fax: (852) 2219 7397

## CLANSHENG STAARSURGICAL

# **CHANGE VISION CHANGE LIFE**

**Seek Visual Freedom and A Life** Full of New Experiences with EVO+ Visian ICL™



99.4% PATIENTS SURVEYED WOULD DO IT AGAIN

/isian ICL"

ICL HAS BEEN LAUNCHED IN THE MARKET FOR 30 YEARS<sup>3</sup>

vrs

The EVO+ Visian ICL is an evolution in vision correction developed for patients with larger pupils including younger patients. Based on the proven EVO Visian ICL platform (formerly CentraFLOW V4c), EVO+ Visian ICL features an expanded optic (5.0 mm -6.1 mm). EVO+ Visian ICL is designed to achieve a higher level of vision performance.

With its expanded optic zone, it minimizes halos and glare, enhancing visual performance during night driving and other activities requiring clear vision in low-light conditions. Additionally, the EVO+ ICL provides exceptional visual quality with minimal induction of higher order aberrations and improved contrast sensitivity<sup>4,5</sup>. Its central port design restores natural aqueous flow, increasing comfort and efficiency for both surgeons and patients<sup>6</sup>.

# LANSHENG

LANSHENG is an authorized distributor by Staar Surgical. LANSHENG is comprehensively responsible for the distribution, sales, technica support, and after-sales service of EVO+ Visian ICL in Hong Kong. The activities for EVO+Visian ICL conducted in Hong Kong are collaborated and co-created by Staar Surgical and LANSHENG

#### For further cooperation information, please contact: LANSHENG RESOURCES HONGKONG LIMITED

Unit 02.20, F.Peninsula Tower, 538 Castle Peak Road, Kowloon, Hong Kong (**%**)(852)28180266 (**m**)(852)28180189 (**x**)infohk@lanshengmed.com

**References:** 

STAAR Data as of March 2024

Patient Survey, STAAR Surgical ICL Data Registry, 2018

 Participant Subject Net Subject Net Subject 1, 2020
 STAR Data
 Intraindividual Comparison Of Visual Performance After Posterior Chamber Phakic Intraocular Lens With And Without A Central Hole Implantation For Moderate To high Myopia By K.Shimizu, K.Kamiya, A. garashi, K.Shimizu, and T.Shiratani. Am J Ophthalmol 2012. Sep;154(3):486-494.e1.
 Kamiya K, Igarashi A, Shimizu K, Matsumura K, Komatsu M. Visual Performance After Posterior Chamber Phakic Intraocular Lens Implantation and Wavefront-Guided Laser In Situ Keratomileusis for Low to Moderate JO Application 2012;153:1178-1186.
 Moderate Myopia. Am J Ophthalmol. 2012;153:1178-1186.
 Moderate Myopia. King Control L. Belda. Salmerón L. Madrid-Costa D. Montés-Micó R. Clinical outcomes after implantation of a posterior chamber collagen copolymer phakic Intraocular lens with a Situ Keratomileusi. Admiser A, igarashi A, Shimizu A, Shimizu A, Komasu M, Visua Performance Arter Posterior Chamber Phasic Intraocular Lens implantation and waveront-Suided Laser in Stu Relatomileuss for Low to oberate Myopia. Am J Ophthalmol. 2012;153:1178–1186. Alfonso JF, Lisa C, Fernández-Vega Cueto L, Belda-Salmerón L, Madrid-Costa D, Montés-Micó R. Clinical outcomes after implantation of a posterior chamber collagen copolymer phasic intraocular lens with a ntral hole for myopic correction. J Cataract Refract Surg. 2013 Jun;39(6):915-21



Loyal Tech Group Ltd. 忠信科技集團有限公司

— Your Loyal Parter

TEL: 35639548

www.loyaltech.com.hk

## **Our Partners**

		icare
Huvitz	CSSILOR	F.I.S.O.
	<b>OPTIK</b> SN	Tokyo, JAPAN
Reichert	Rexxam Quality in vision care	Crystalvue
CHAROPS	(VOLK)	Keeler



# icare

### iCare EIDON Family

TrueColor high-resolution confocal fundus retinal imaging system with automatic fluorescein Angiography (FFA)



Innovating a higher standard in retinal imaging



#### **REAL-WORLD EVIDENCE**



#### SAFETY PROFILE BASED ON P-SCORE (SUCRA EQUIVALENT)^\*\*\*,4

Bevacizumab

0.11

0.60

Aflibercept

1.00

0.0

1.50







 The treatment regimens available for selection were monthly. PIN and Treat & Extend. In a 2013 poll of FRB investigators, 74% used Treat & Extend, 22% used PIN and 4% used monthly;
 The SARAB study assessed the anatomical and visual outcomes of whiching from allibercept to ranibizumab following persistent or recurrent disease activity in patients with nAMD (poor response to allibercept treatment)<sup>4</sup>
 The SARAB study assessed the anatomical and visual outcomes of whiching from allibercept to cantibizumab following persistent or recurrent disease activity in patients with nAMD (poor response to allibercept treatment)<sup>4</sup>
 The frame of this meta-analytic model. ULCENTS vs. bencizumab and ULCENTS vs. allibercept were compared directly; while allibercept vs. bencizumab following persistent or recurrent disease activity in patients with nAMD (poor response to allibercept treatment)<sup>4</sup>
 Soft profile parameters messured in the study included atophy, refinal test, endophtalmits, occular SAE, atheorthmotic events, systemic SAE. CVD death, depout and death.
 SUCAA-surface under the cumulater analysis curve hoccurs are anilant to SUCAA walkes in the Bayaian network work in the Bayaian network model and the means probability of being the best treatment option.
 A Where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where a core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of 1s theoretically the best treatment option.
 A where as core of BCVA: Best Corrected Visual Acuity; CSRT: Central Sensory Retinal Thickness

BCVA BetConcetted Visual Acoustly CMT: Lemma motiony returner returnes Meter BetConcetted Visual Acoustly CMT: Lemma motiony returner returnes Networks on provide a subale motion on the deviation of the strange function of the strange functio

ET Barrensen ig pregnancy unless the experimentation of the last dose of ranibit

0.50

• Questitish and been studied in patients with active systemic infections or in patients with concurrent oper conditions such a strelial detach the effect of Locensitis patients with Noresening invessels elsevises: visual functions on \$500 and not to used at least 3 months after the last concurrent oper systemic and have been treated with naniburunks. It is recommended to wante an of child-beening potential Based on way interest with Noresening been set to a child-beening potential Based on way interest data, analizama base been treated with naniburunks. It is ecommended to wante and the child-beening potential Based on way interest data, analizama base been treated with naniburunks. It is ecommended to wante to be covered in human newborn/finds is suffixed on the machine streated with naniburunks. The patients with Locens 5 effoly based rest and the streates of the patient shuft on the our concurrent on the patient with Locens. Feldowing treat is detected with their is the forts or includ signment explatibility to the current shuft have the patient shuft on the our concurrent on the patient shuft on the our concurrent on the patient shuft have the patient shuft on the our concurrent on the patient shuft have the patient shuft on the current shuft have the patient shuft have the patient

Systemic

SAE

CVD

death

0.00

LUCENTIS®

Server of mini-the DUR population A meta-majks of pooled safety that form completed, andomized, double masked global studies showed a higher incidence rate of non-servicus, non-sociar wound infection/inflammation in treated with anotherando 5 mg (1357) or a state mark state of the state of sussinument: F1352.netword under twir 2014 met. 101 Heb 2013 4 CL0201068 (1004) + 2021 PSB/GGC4255-4 References: References: 16. Gilles MC, Nguyen V, Daien V, et al. Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2553.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, Pearce J, Eter N, et al. Br J Ophthalmology. 2016;123:254-2554.2. Jin KIV, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623.3. Gale RP, 2021;11:14623.3. Gale



win 's indicated in called for the treatment of heroexcluter well age related modular ageneration (AMU) and will have been been presented by the treatment of heroexcluter is well age related modular ageneration (AMU) and will be treated field presentations construct for presentations for heroen to a visual impairment due called bin 0.2 million (Section 1996) and the section 198 mg of broken treatment of the sections. Herefore there is no constructed by the treatment of a single visit presentations for heroen the section between the total DME). Decome regime and administrations: Single-section will be set to the section of the treatment of a single visit pre-filled syrings for introvirted use ohyl-sections are set and for the treatment of a single visit pre-filled syrings for introvirted use ohyl-sections are set a weeks (month)) for the first 3 days. Thereafter, the physicion may individualise treatment intervals based and pre-section of the first 3 days. Thereafter, the physicion may individualise treatment intervals based and pre-section of the first 3 days. Thereafter, the physicion may individualise treatment intervals based and pre-section of the first 3 days. Thereafter, the physicion may individualise treatment intervals based and pre-section of the first 3 days. Thereafter, the physicion may individualise treatment intervals based and the section of the first 3 days. Thereafter, the physicion may individualise treatment intervals based and present and the first 3 days. Thereafter, the physicion may individualise treatment intervals based and the first 3 days. Thereafter, the physicion may individualise treatment intervals based and the first 3 days. Thereafter, the physicion may individualise treatment intervals based and anotomic days treatment with the section of Immedia (0.05 m) isolation) administered by introvinced injection every excess for the mrss zoosas. Interestret, me prossum more mum-ing consensed by valual cuive point or comparison (p) parameters in plantine without disease activity proteinment every 12 weeks (1) monthly and the second discontinued. Special populations: \*Read impairment to dose adjustment is required. \*Heppetit impairment to dose adjustment is re-supported to color or periodicity friends: \*Active infraccular inflammation. Warnings and precentions: \*Tracebility: In order to its products, the same of the bark number of the dominance points shall be leading resources. \*Tracebility: In order to its points, the same of the bark number of the dominance points bank be leading resources. \*Tracebility: In order to into number of the leading of the same of the dominance of the dominance of the leading the same of the leading the l anti VEGF:

**Retinal Portfolio** 

BEOVU® Imp

**NOVARTIS** 

**U**NOVARTIS

15 secondary andpoint in HAWK and HAREER, confirmatory analysis in HAWK only (1-sided Powhaes for superiority of Beou).<sup>34</sup>
15 secondary andpoint in HAWK and HAREER, the Confirmatory analysis in HAWK only (1-sided Powhaes for superiority of Beou).<sup>34</sup>
REFERENCES: Loss on Prascribing Information HK May 2022. Dupl PLV, KAA A, Quary V, et al. on basel of the HAVK and HAREER Shuty Investigators. HAWK and HAREER: Phy. 3, multicatery, randomized, double-masked triat of brokeJauroma for newaxcador age-related mocolar degeneration. Ophtholmology. 2002;17(1):21-123. Frakada, YL
Howe Bib study of evaluation to the study of the study investigators. HAWK and HAREER: Phys. Rev. Bib study of evaluation to the study of the study investigators. HAWK and HAREER: Phys. Rev. Bib study of evaluation to the study of the study investigators. HAWK and HAREER: Phys. Rev. Bib study of evaluation to the study of the study. Howe Bib study of evaluation to the study of the study of the study of the study. Hawke Bib study of the study of the study of the study of the study. Hawke Bib study of the study. Hawke Bib study of the study of the study of the study of the study. Hawke Bib study of the study. Hawke Bib study of the study. Hawke Bib study of the study. Hawke Bib study of the study o

Novartis Pharmaceuticals (HK) Ltd Suite 2303-08, 23/F, 1111 King's Road, Taikoo Shing, Hong Kong Tel: (852) 2882 5222 Fax: (852) 2577 0274 ©2024Novartis FA-11309606 Dec 2024



POSIFORLID®

The concept for healthy eyelids.



# The Right Treatment For Blepharitis





# VABYSMO<sup>®</sup> (faricimab injection): The first and only VEGF <u>and</u> Ang-2 pathway inhibitor for the treatment of neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular oedema (DMO).<sup>1\*</sup>

Demonstrated non-inferior

from baseline (average of

+ 5.8 letters (95% CI: 4.6, 7.1) + 5.1 letters

mean change in BVCA

Weeks 40, 44 & 48)

VABYSMO is indicated for the treatment of:

- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular oedema (DMO)

TENAYA

VABYSMO (n=334)

Aflibercept (n=337)

12

Weeks

8

#### nAMD

Comparator-controlled trials of VABYSMO vs. aflibercept in **nAMD** demonstrated non-inferior mean change in BCVA<sup>†</sup> from baseline at Year 1.<sup>1‡</sup>

Mean change in BCVA (measured by the Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) from baseline to Year 1 (based on an average at Weeks 40, 44 and 48)<sup>5</sup> with VABYSMO 6.0 mg up to Q16W and aflibercept 2.0 mg Q8W (primary endpoint)<sup>1</sup>

The recommended dose for nAMD is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 4 doses, followed by anatomic and visual acuity evaluations at Weeks 20 and 24 to inform dosing intervals of 8, 12 or 16 weeks through Week 60.

In TENAYA and LUCERNE, VABYSMO treatment intervals were extended up to 16 weeks at Week 48 in patients without disease activity."

The proportion of patients on each of the different treatment intervals at Week 48<sup>1,2#</sup>

Patients should be assessed regularly. Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion.<sup>1</sup>

16 20 24 28 32 36 **40 44 48** 



12 16 20 24 28 32 36 40 44 48

Weeks

Demonstrated non-inferio

mean change in BVCA from baseline (average o Weeks 40, 44 & 48)

+ 6.6 letters

+ 6.6 letters

LUCERNE

VABYSMO (n=331)

Aflibercept (n=327)

10

8

6

7 dean

0

0

4 8

etters)

change in BCVA (ETDRS |



BCVA=best corrected visual acuity; CI=confidence interval; ETDRS=early treatment diabetic retinopathy study; Q8W=every 8 weeks; Q12W=every 12 weeks; Q16W=every 16 weeks

\* Comparative clinical significance has not been established.

† Measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

‡ Randomized, 1:1, multi-centre, double-masked, active comparator-controlled studies in wet AMD. Treatment regimens were: aflibercept 2 mg Q8W after three initial monthly doses, or VABYSMO, after the first 6 mg four monthly doses (Weeks 0, 4, 8, and 12). Patients received 6 mg Q16W, Q12W or Q8W dosing based on assessments of pre-specified visual and anatomic criteria at Weeks 20 and 24 as well as treating physician clinical assessment. Patients remained on these fixed dosing intervals until Week 60 without supplemental therapy.

§ Average of Weeks 40, 44 and 48.

1 Protocol-defined disease activity assessment, measured at active dosing visits, was based on relative changes to BCVA and CST, together with investigator assessment at Weeks 20 and 24.

- # Percentages are based on number of patients randomly assigned to the VABYSMO group who had not discontinued the study at week 48.
- Comparative significance with aflibercept is unknown. Trials were not designed for head-to-head comparison of VABYSMO's durability vs. aflibercept because extended fixed 12-week or fixed 16-week dosing regimens have not been studied in double-masked phase 3 registrational trials for aflibercept.

#### References:

1. VABYSMO Hong Kong Prescribing Information.

2.Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. *Lancet*. 2022;399(10326):729-740.

#### Call for Reporting:

If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong,drug\_safety@roche.com, or (b) Phone: +852 2733 4711.

Roche

Roche Hong Kong Limited 22/F, CTF Life Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong Tei: (852) 2723 2832 \*For VABYSMO product information, please scan the QR code. Full product information will be provided upon request.



M-HK-00001819 approved in October 2024 is valid for 2 years or until change is required in accordance with regulatory requirements, whichever comes first.

## ARGOS<sup>®</sup> with Image Guidance by ALCON<sup>®</sup>

ARGOS

# FASTER.<sup>1-4,Δ</sup> EASIER.<sup>5,6,\*</sup> BETTER.<sup>1,2,7,8,^</sup>

The ARGOS<sup>®</sup> Biometer with Image Guidance by Alcon<sup>®</sup> is the smart planning solution that keeps efficiency<sup>1-3</sup> and accuracy<sup>7,8</sup> flowing through your clinic

<sup>≜</sup>Compared to IOL Master 700 (1,4), IOL Master 500 (2,3), Lenstar LS900 (2). \*Compared to VERION™ Reference Unit. ^ ARGOS biometer has shown better acquisition rates in dense cataract compared to IOL Master 700 (1), IOL Master 500 and Lenstar LS900 (2). ARGOS biometer has shown better acquisition rates in dense cataract compared to IOL Master 700 (1), IOL Master 500 (2).

#### **References:**

1. Tamaoki A, Kojima T, Hasegawa A, et al. Clinical evaluation of a new swept-source optical coherence biometer that uses individual refractive indices to measure axial length in cataract patients. Ophthalmic Res. 2019;19:1-13.

- 2. Shammas HJ, Ortiz S, Shammas MC, Kim SH, Chong C. Biometry measurements using a new large-coherence-length swept-source optical coherence tomographer.] Cataract Refract Surg. 2016;42:50-6
- 3. Hussaindeen JR, Mariam EG, Arunachalam S, et al. Comparison of axial length using a new swept-source optical coherence tomography-based biometer.PLOSONE.December2018.
- 4. ZEISS† IOLMaster† 700 510k Submission 2015.
- VERIONTM Reference Unit User Manual 2019
- 6. ARGOS® Biometer User Manual 2019.

7. Whang W, Yoo Y, Kang M, Joo C. Predictive accuracy of partial coherence interferometry and swept-source optical coherence tomography for intraocular lens power calculation. Sci Rep. 2018;8(1):13732

8. Shammas HJ. Accuracy of IOL power formulas with true axial length versus simulated axial length measurement in 318 eyes using an OCT biometer. 2019 ASCRS ASOA Annual Meeting. May 2019.

Medical Devices manufactured by Alcon comply with all applicable laws and regulations. For indications, contraindications and warnings please refer to the relevant product's instructions for use.

This content is intended for Healthcare Professionals only, not for general public



# ATTAIN PEACE OF MIND with TECNIS PureSee<sup>TM</sup> IOL, the new purely refractive

presbyopia-correcting EDOF IOL.<sup>1</sup>

**TECNIS PureSee<sup>™</sup> IOL** with continuous-power technology<sup>1</sup> provides better predictable patient outcomes<sup>2-5</sup>, ensuring high patient satisfaction<sup>6</sup> and **peace of mind for you**.

Find out more with a J&J representative.

TECNIS<sup>®</sup> See More.

## TECNIS PureSee<sup>™</sup>IOL

with TECNIS SIMPLICITY® Delivery System

Vision

- References:
- 1. TECNIS PureSee™ IOL, Model ZENOOV DFU INT, Z311973, current revision
- 2. DOF2023CT4011 Simultions of visual symptoms under defocus for TECNIS PureSee™ IOL. 29 March 2023.
- 3. DOF2023CT4041 Clinical investigation of the TECNIS™ IOL, C1V000 and C2V000 Tolerance to Refractive Error. 17 July 2023.
- Black D. et al. Clinical investigation of tolerance to residual refractive errors following implantation with a refractive extended-depth-of-focus (EDF) IOL. Abstract ESCRS 2023. REF2023CT4129.
- 5. Bala C, et al. Superior intermediate and uncompromised distance quality of vision with a purely refractive extended depth of focus IOL. Abstract ESCRS Vienna 2023. REF2023CT4128.
- 6. DOF2023CT4043 Clinical investigation of the TECNIS™ IOL C1V000 and C2V000. Patient Satisfaction Outcomes 18 July 2023.

Australia: AMO Australia Pty Ltd. 1-5 Khartourn Road, North Ryde, NSW 2113. Australia. New Zealand: AMO Australia Pty. Ltd 507 Mount Wellington Hwy, Mount Wellington, Auckland 1060, New Zealand.

© Johnson & Johnson Surgical Inc. 2024, 2024PP05503.

## Johnson&Johnson MedTech





# A CLASSIC UPGRADE

NOW AVAILABLE



- O BCVA gains from baseline with EYLEA® 8mg were non-inferior vs. EYLEA® 2mg with as few as ~8 injections in 2 years (after 3 loading doses) in nAMD and DME.2-5#\*
- o ~8 out of 10 (nAMD) and ~9 out of 10 (DME) patients randomised to EYLEA® 8mg q16 maintained 16week treatment intervals from baseline through Week 96.2-5#\*

In PULSAR, a 96-week, multicentre, randomised, double-masked, head-to-head trial, access EYLEA® Bmg vs. EYLEA® 2mg in treatment-naive nAMD patients. The randomization of patients is in a ratio of 1 [2q8] : 1 [8q12]; 1 [8q16]. In the 2q8 arm (n=336], 8q12 arm (n=335] and Bqlb arm (n=339] arm (n=339] maskline in BCV(non-inferiority) at week 48<sup>10</sup>

In PHOTON, a 96-week, multicenter, randomized, eceived 5 initial monthly injections, while the 8q12 lenoting disease activity. The primary endpoint wa tion of patients is in a ratio of 1 (298): 2 (8912): 1 (8916). In the 298 arm (n=167) sly treated DME patients. The random tervals for the EVLEA® 8mg groups wi nge from ba riority) at week 48.45

bbreviations: BCVA = Best corrected visual acuity; DME = Diabetic macular oedema; nAMD = N

References: 1. EVLEA (Aflibercept) 8mg Hong Kong Prescribing Information. Aug 2024. 2. Korobelnik JF. AAO 2023. 3–6 November 2023. San Fran ophthalmology-conference-list/ARVO-2023 Accessed Sep 2024. 4. Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8 mg in diabetic macular or 4031155-63. 5. Do DV. Anglogenesis. 3 February 2024. Virtual Intravitoreal publicationsberger.com/ophthalmology-conference-list/Anglogenesis-2024.

References: 1. EVLEA (Allibercept): Bring Hears Korg Prescribing International and Prescribing International allibercept B mg in calcing terms. Ophthalmology conference-list/Anglogenesis. 3 February 2024. Vitual: https://congrespublications.bayer.com/ophthalmology-conference-list/Anglogenesis-2024. Accessed Sep 2024. EVLEA' Solution for Intravirteal Injection 16.3 mg/mL. Abbreviated Prescribing Information (Pieser refer to the full prescribing information before prescribing) Indication for User: EVLEA' (Milbercept) is indicated for the treatment of neovascular west age-related macular age-related

#### r HealthCare Limited

14/F, Oxford House, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong Tel: (852) 8100 2755 Website: www.bayer.com

Copyright © 2024 Bayer HealthCare Limited

# ATTAIN PEACE OF MIND with TECNIS PureSee<sup>TM</sup> IOL, the new purely refractive

presbyopia-correcting EDOF IOL.<sup>1</sup>

**TECNIS PureSee<sup>™</sup> IOL** with continuous-power technology<sup>1</sup> provides better predictable patient outcomes<sup>2-5</sup>, ensuring high patient satisfaction<sup>6</sup> and **peace of mind for you**.

Find out more with a J&J representative.

TECNIS<sup>®</sup> See More.

## TECNIS PureSee<sup>™</sup>IOL

with TECNIS SIMPLICITY® Delivery System

Vision

- References:
- 1. TECNIS PureSee™ IOL, Model ZENOOV DFU INT, Z311973, current revision
- 2. DOF2023CT4011 Simultions of visual symptoms under defocus for TECNIS PureSee™ IOL. 29 March 2023.
- 3. DOF2023CT4041 Clinical investigation of the TECNIS™ IOL, C1V000 and C2V000 Tolerance to Refractive Error. 17 July 2023.
- Black D. et al. Clinical investigation of tolerance to residual refractive errors following implantation with a refractive extended-depth-of-focus (EDF) IOL. Abstract ESCRS 2023. REF2023CT4129.
- 5. Bala C, et al. Superior intermediate and uncompromised distance quality of vision with a purely refractive extended depth of focus IOL. Abstract ESCRS Vienna 2023. REF2023CT4128.
- 6. DOF2023CT4043 Clinical investigation of the TECNIS™ IOL C1V000 and C2V000. Patient Satisfaction Outcomes 18 July 2023.

Australia: AMO Australia Pty Ltd. 1-5 Khartourn Road, North Ryde, NSW 2113. Australia. New Zealand: AMO Australia Pty. Ltd 507 Mount Wellington Hwy. Mount Wellington, Auckland 1060, New Zealand.

© Johnson & Johnson Surgical Inc. 2024, 2024PP05503.

## Johnson&Johnson MedTech



# 'EARS **OF BREAKTHROUGH IN GLAUCOMA TREATMENT**

#### **V** Indication

VYZULTA<sup>™</sup> (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.



#### One molecule, two pathways

Lowers IOP by increasing outflow through both the trabecular meshwork and uveoscleral pathway<sup>1</sup>



#### **Remarkable efficacy**

Reduced the mean IOP up to 9.0 mmHg from baseline<sup>2\*</sup>



#### **Demonstrated safety**

<1% discontinuation rate due to ocular adverse effects<sup>1</sup>

VYZULTA Action of the second se

OR TOPICAL OPHTHALMIC USE c only 2.5 mL

VYZULTA" llatanoprostene

bunod ophthalmic solution) 0.024% w/v

Sterile

\*VOYAGER study design: a randomized, parallel-group, phase 2 study, which compared the efficacy and safety of 4 doses of VYZULTA<sup>TM</sup> and latanoprost 0.005% in 413 patients with open-angle glaucoma or ocular hypertension. Primary endpoint was the change of mean diurnal IOP at day 28 from baseline. The mean IOP at baseline was 26.0 mmHg in the VYZULTA<sup>TM</sup> 0.024% group and 26.2 mmHg in the latanoprost 0.005% group? IOP=intraocular pressure

References: 1. VYZULTA Hong Kong prescribing information. 2. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99(6): 738-45.

INDICATION VYZULTA<sup>TM</sup> (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. DOSAGE INDICATION VYZULTA<sup>TM</sup> (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. **DOSAGE AND AMINISTRATION** The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer VYZULTA<sup>TM</sup> (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of prostaglandin analogs may lessen the intraocular pressure (IDP) in patients with open-angle glaucoma or ocular hypertension. **DOSAGE AND AMINISTRATION** The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer VYZULTA<sup>TM</sup> (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of prostaglandin analogs may lessen the intraocular pressure (LIP VYZULTA<sup>TM</sup> is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five (5) minutes apart. **IMPORTANT SAFETY INFORMATION** • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent. • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation. • Use with caution in patients with a bistory of intraocular inflammation (iritis/uveitis). VYZULTA<sup>TM</sup> should generally note used in patients with a torive intraocular inflammation. • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients. •

VYZULTA™ and the V design are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2024 Bausch & Lomb Incorporated. <sup>®</sup>/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. All rights reserved. HK-PH-2024-09-035

For healthcare professional only. Please refer to full Prescribing Information and additional Important Safety Information for VYZULTA™.

**BAUSCH+LOMB** See better. Live better.

Bausch & Lomb (H.K.) Ltd. Suites 3901 & 3912-14, 39/F Tower 6, The Gateway, 9 Canton Road Tsim Sha Tsui, Kowloon, Hong Kong Tel: (+852) 2213 3333

# Leading The Preservative-free GLAUCOMA Treatment



**POWER UP** WITH DUAL EFFICACY IOP CONTROL'

Preservative-Free

28-40%

IOP

REDUCTION

from baseline

#### TAPCOM'- S: POWER UP YOUR IOP CONTROL WHEN MONOTHERAPY IS NOT ENOUGH EFFECTIVE IOP REDUCTION AT VARIOUS BASELINE PRESSURE <sup>2</sup>



**TAPCOM®-S 15yg/mL tafluprost + 5mg/mL timelol maleate eye drops, solution in single-dose container.** Active ingredients: 15micrograms/mL + 5 mg/mL eye drops, solution in single-dose container. Indications: Reduction of intraocular pressure (OP) in adult patients with open angle dates or rouge in rouge in a combination with pen angle dates as planet. The does as planet, the does as planet. The does as planet, the does as planet, the does as planet, the does as planet. The does as planet, the does as p

Please consult the full prescribing information prior to administration. For adverse events reporting, please email Santen Pharmaceutical (Hong Kong) Ltd. at hk\_product\_safety@santen.com



#### Santen Pharmaceutical (Hong Kong) Limited

Unit 1607, 16/F, Concordia Plaza, 1 Science Museum Road, TST East, Kowloon, Hong Kong Phone: +852 2565 6660 Fax: +852 2565 6068



# S SE

of Dual-Pathway inhibition

For the treatment of adult patients with **nAMD** and visual impairment due to **DME**<sup>1</sup>

## **Delivers extended durability**

with ~80% of patients on Q12W or Q16W treatment intervals at Year 2<sup>2</sup>

## **Demonstrated comparable safety** profile to aflibercept over 2 years<sup>2,3</sup>



References: 1. VABYSMO Hong Kong Prescribing Information 2. Khanani AM et al. TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 2024, in press. 3. Wong et al. Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 2023, in press. 4. Roche data on file.

Call for Reporting: If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong.drug\_safety@roche.com, or (b) Phone: +852 2733 4711.



Roche Hong Kong Limited Roche 22/F, CTF Life Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong Tel: (852) 2723 2832

M-HK-00001818 approved in October 2024 is valid for 2 years or until change is required in accordance with regulatory requirements, whichever comes first.

\*For VABYSMO product information, please scan the QR code. Full product information will be provided upon request.





# THIS IS STABILITY

# This is HYPER VIT DUAL BLADE VITRECTOMY PROBE

# Reduce pulsatile traction with

200000

CUTS PER MINUTE at similar single-blade flow rates using 25+<sup>®1</sup> and 27+<sup>®2</sup> gauge probes<sup>1</sup>

Please refer to product direction for use (or operator manual) for list of indications, contraindications and warnings. References:1. Alcon data on file. Alcon Laboratories, Inc; June 2018. 2. Alcon data on file. Alcon Laboratories, Inc; June 2018.



# **THIS IS STABILITY**



## **Engineered for Control**

When combined with valved cannulas and CONSTELLATION® Vision System's IOP compensation, the HYPERVIT® Dual Blade Vitrectomy Probe enables stable, closed-system intraocular surgery.

**Continuously Open Port Reduces Fluidic Turbulence\*** 



ULTRAVIT® Vitrectomy Probe at 7500 CPM



Advanced ULTRAVIT® Beveled High Speed Probe at 10 000 CPM



HYPERVIT® Dual Blade Vitrectomy Probe at 20 000 CPM

\*For illustrative purposes only



Continuously open port improves vitreous flow<sup>2</sup>

Peak Traction Force<sup>†, §, 1</sup>

20 000 cuts per minute observed to reduce pulsatile traction at similar single-blade flow rates  $^{\rm 1}$ 

<sup>+</sup>HYPERVIT<sup>®</sup> Dual Blade Vitrectomy Probe 25+<sup>®</sup> Ga compared at 20 000 CPM (maximum cut rate in core mode) to Advanced ULTRAVIT<sup>®</sup> Probe 25+<sup>®</sup> Ga at 10 000 CPM (maximum cut rate in core mode) and ULTRAVIT<sup>®</sup> Vitrectomy Probe 25+<sup>®</sup> Ga at 7500 CPM (maximum cut rate in core mode) <sup>\*</sup>95% confidence interval, n = 8 probes <sup>\*</sup>95% confidence interval, n = 30 probes

Vitreous Flow Rate<sup>^, ‡, 2</sup>

#### Continuously open port improves vitreous flow<sup>2</sup>

Peak Traction Force<sup>^, §, 1</sup>

20 000 cuts per minute observed to reduce pulsatile traction at similar single-blade flow rates<sup>1</sup>

<sup>^</sup>HYPERVIT<sup>®</sup> Dual Blade Vitrectomy Probe 27+<sup>®</sup> Ga compared at 20 000 CPM (maximum cut rate in core mode) to Advanced ULTRAVIT<sup>®</sup> Probe 27+<sup>®</sup> Ga at 10 000 CPM (maximum cut rate in core mode) and ULTRAVIT<sup>®</sup> Vitrectomy Probe 27+<sup>®</sup> Ga at 7500 CPM (maximum cut rate in core mode) <sup>1</sup>95% confidence interval, n = 6 to 12 probes

95% confidence interval, n = 30 probes

Watch Out: Per AP3 (CORP-001959), promotional materials that make daims about the positive or beneficial attributes of a Product should generally be accompanied by a basic succinct statement of the most relevant contraindications, warnings, precautions and side effects associated with the Product.

> Affiliates must include the Important Product Information (IPI) consistent with the local approved labeling.

> The IPI would typically include: Indications and Usage; Contraindications, Warnings, Precautions and Adverse Reactions.

THIS IS A GLOBAL TEMPLATE. IN ACCORDANCE WITH AP3, ALCON GLOBAL STANDARDS, AND THE GMRC MSP, THIS DOCUMENT MUST BE REVIEWED AND APPROVED IN ACCORDANCE WITH LOCAL LAWS AND CODES VIA A LOCAL REVIEW PROCESS BEFORE IT MAY BE UTILIZED.

References: 1. Alcon data on file. Alcon Laboratories, Inc; June 2018. 2. Alcon data on file. Alcon Laboratories, Inc; June 2018.







# A CLASSIC UPGRADE





**Upgrade from EYLEA® 2mg** to new EYLEA® 8mg and achieve sustained disease control for your nAMD and **DME** patients<sup>1</sup>

- O BCVA gains from baseline with EYLEA® 8mg were non-inferior vs. EYLEA® 2mg with as few as ~8 injections in 2 years (after 3 loading doses) in nAMD and DME.2-5##
- o ~8 out of 10 (nAMD) and ~9 out of 10 (DME) patients randomised to EYLEA® 8mg g16 maintained 16-week treatment intervals from baseline through Week 96.2-5#\*

\*In PULSAR, a 96-week, multicentre, randomised, double-masked, head-to-head trial, access EYLEA\* 8mg vs. EYLEA\* 2mg in treatment-naive nAMD patients. The randomization of patients is in a ratio of 1 (2q8) : 1 (8q12) : 1

In PHOTON, a 96-week, multicenter, randomized, double-masked, head-to-head trial, assess EYLEA<sup>®</sup> 8mg vs. EYLEA<sup>®</sup> received 5 initial monthly injections, while the Bql2 arm (n-328) and Bql6 arm (n-163) both received 3 initial monthly i enoting disease activity. The primary endpoint was change from baseline in BCVA (non-inferiority) at week 48.<sup>45</sup> nalve or previously treated DME patients. The randomization of patients is in a ratio of 1 (2q8): 2 (8q12): 1 (8q16). In the 2q8 arm (n=167) eek 16, dosing intervals for the EYLEA® 8mg groups were shortened if patients met pre-specified dose regimen modification criteria

tions: BCVA = Best corrected visual acuity; DME = Diabetic macular oedema; nAMD = Neovascular age-rela

 San Francisco, US. 3. Spitzer M. ARVO 2023. 23-27 April 2023. New Orleans, USA. https://congresspublications.bayer.com/ macular oedema. [PHOTON]: 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024, nesis-2024. Accessed Sep 2024. References: 1. EVLEA (Afflibercept) Bmg Hong Kong Prescribing Information. Aug 2024. 2. Korobelnik JF. AAO 2023. 3–6 November 2021 ophthalmology-conference-list/ARVO-2023 Accessed Sep 2024. 4. Brown DM, Boyer DS, Do DV, et al. Intravirusal affibercept B mg in diabetic 4/3/IIS-63. B. DV. Anglogenesis. 3 February 2024. Virusi Integritorgrespublications beyr com/ophthalmology-conference-list/Anglogen-Elst/Anglogenesis. 3 February 2024. Virusi Integritorgrespublications beyr com/ophthalmology-conference-list/Anglogene-tistant and the second sec mber 2023, San Fr

403/153-63. 5 Do DV. Anglogenesis. 3 February 2024. Virtual. https://compressup/lications.bayer.com/ophthalmiology-conference-licat/Anglogenesis. 2 February 2024. Virtual. https://compressup/lications.bayer.com/ophthalmiology-conference-licat/Anglogenesis.2 February 2024. Virtual.https://compressup/lications.bayer.com/ophthalmiology-conference-licat/Anglogenesis.2 February 2024. Virtual.https://compressup/lications.bayer.com/ophthalmiology-conference-licat/Anglogenesis.2 February 2024. Virtual.https://compressup/lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.bayer.com/ophthalmiology-conference-lications.

#### **Bayer HealthCare Limited**

Ja/F, Cxford House, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong Tel: (852) 8100 2755 Website: www.bayer.com

Copyright © 2024 Bayer HealthCare Limited

# ClitC. SMOOTH AS SILK

elita

## A GENERATIONAL LEAP IN CORNEAL REFRACTIVE SURGERY

- Ultra-low pulse energy<sup>1</sup>
- Continuous surface scanning<sup>1</sup>
- Sub-micron precision<sup>1</sup>



# **VEGF-A**

# ANG-2

# Start with the Power of 21-3

Shift the paradigm in the treatment of nAMD and DME with DUAL-PATHWAY INHIBITION<sup>4</sup>

**Call for Reporting:** If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong.drug\_safety@roche.com, or (b) Phone: +852 2733 4711.

Further information is upon request.

#### **References:**

- 1. Regula JT, et al. EMBO Mol Med. 2016;8:1265-88.
- 2. Heier JS, et al. Lancet. 2022;399(10326):729-40.
- 3. Wykoff CC, et al. Lancet. 2022;399(10326):741-755.
- 4. VABYSMO Hong Kong Prescribing Information.



#### Roche Hong Kong Limited

22/F, FTLife Tower, 18 Sheung Yuet Road, Kowloon Bay Tel: +852 2723 2832

M-HK-00001503 Valid until 11/1/2026 or until change is required in accordance with the regulatory requirements, whichever comes first.



\*For VABYSMO Prescribing Information, please scan the QR code. Full product information upon request.



### Alcon Vision Suite



# Revealthe unexpected Discover LuxOR<sup>®</sup> REVALIA<sup>™</sup>

Alcon's microscope for anterior and posterior procedures, delivering excellent visualization through proprietary ILLUMIN-i technology<sup>1-4</sup>.



\* Compared to conventional focused illumination microscopes. Assuming 200 mm working distance, LuxOR Revalia adds 65 mm to the focal length, resulting in 33% increase vs a conventional 200mm microscope <sup>†</sup> Compared to Z. Lumexx T, Lumexx 700, and Leixx M-820 microscopes

#### References

1. LuxOR Revalia User Manual 2. Cionni RJ, Pei R, Dimalanta R, et al. Evaluating red reflex and surgeon preference between nearly-collimated and focused beam microscope illumination systems. Transl Vis Sci Technol. 2015;4(4):7. 3. Alcon data on file, 2014. 4. Schwiegerling J & Dimalanta R. Depht of focus measurements of ophthalmic surgical microscopes. Poster presented at: The Association for Research in Vision and Ophthalmology; May 1-5, 2016; Seattle, WA. 5. Alcon drawing number 955-7210-004, 2014, Scientific Support Document, Communication for Alcon LuxOR Red Reflex and Depth of Focus Calculations. 6. Centurion Vision system User Manual. 7. Verion Digital Marker M User Manual

TECNIS Eyhance<sup>™</sup> IOL

reddot winner 2023



# Set your sights higher

Enhanced intermediate vision compared to a traditional monofocal<sup>3</sup> Better image contrast day and night than competitor IOLs.<sup>4</sup>

# The Modern IOL designed to elevate expectations for everyone.

**1.0** line improvement for enhanced **intermediate visual acuity**<sup>3</sup> 45% better image contrast verses Clareon® at night4 8 out of 10 patients achieve spectacle independence for intermediate vision<sup>3</sup>

TECNIS Eyhance™ Toric II IOL Toric II

### Superior rotational stability<sup>5.6</sup>

< 1 degree absolute mean rotation seen at 3 months<sup>6</sup> 100% of surgeries had <5 degrees of rotation at 3 months<sup>6</sup>

### Johnson&Johnson MedTech



1. Z311524E\_A TECNIS Eyhance™ IOL with TECNIS Simplicity® Delivery System US DFU. 2. Z311525E\_A TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity® Delivery System DFU. 3. R Mencucci, et al. J Cataract Refract Surg 2020; 46: 378-387. 4. Auffarth, et al. Cataract Refract Surg 2021; 47(2): 184-191. 5. Takaku R, Nakano S, lida M, et al. Influence of frosted haptics on rotational stability of toric intraocular lenses. Sci Rep 2021; 11: 15099. https://doi.org/10.1038/s41598-021-94293-3.6. DOF2021CT4019 - Clinical investigation of rotational stability of the TECNIS™ Toric II IOL- Steele Study NXGT-202-QROS. 20 Aug. 2021.

AMO Australia Pty Ltd, 1–5 Khartoum Road, North Ryde, NSW 2113, Australia, | AMO Australia Pty. Ltd 507 Mount Wellington Hwy, Mount Wellington, Auckland 1060, New Zealand. © Johnson & Johnson Surgical Vision Inc. 2023 PP2023CT5674

# The **Gr8** future has **NOW ARRIVED!**

A MARTIN ST

## **Enabling beyond** q16 up to q20 intervals for **nAMD** and **DME**

Loading doses

Months Injection Interval

3 + 5 = Gr8!

The

ONLY

anti-VEGF

agent

for nAMD and **DME** patients

EYLEA® 8mg (aflibercept 114.3mg/ml, solution for injection)

References: 1. EYLEA (Aflibercept) 8mg Hong Kong Prescribing Information. Aug 2024.

EYLEA<sup>®</sup> Solution for Intravitreal Injection 114.3 mg/mL

EYLEA\* Solution for intravitreal injection 114.3 mg/mL Abbreviated Prescribing Information (Please refer to the full prescribing information before prescribing) Indication for Use: EYLEA\* (Affibercept) is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and NME indications. The recommended dose (Adult) for EYLEA\* Brng, equivalent to 0.07 ml of solution. Please do refer to section 4.2 in the Julp rescribing information for details. Eylea is for intravitreal injection only, please do refer to section 4.2 in the Julp rescribing information for details. Eylea for the duble be clearly recorded; Intravitreal injection on substance or to any of the excipents listed in section 6.1 of the full PI; Occular or periocular inflammation. Warnings and Precautions: Traceability: To improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded; Intravitreal injection exclosed and managed appropriately. Traceability: To improve the traceability of biological medicinal products, the name and the batch number of the administered PI). Proper aseptic injection techniques must always be used when administering Eylea. Patients should be instructed to report any symptoms suggestive of endophthalmitis or any of the above-metioned events without delay and should be propripately. Intravoluar pressure increases in Intravicual pressure have been seen within 60 minutes of an intravitical injection, including those with Eylea (see section 4.8 of the full PI). Both the intraocular pressure and perfusion of the optic nerve head must therefore be monitored and managed appropriately. Special precaution is needed in patients with poory controlled glaucoma (do not injection a signs or symptoms of intraocular inflammation, egg-pain, photophobia, or redness, which may be a clinical sign attributable to typersensitivity to the administered (JII PI). For the data sign attributable to typersensitive to the dattributed dat

P-EYL\_8mg-HK-0003-1

#### **Baver HealthCare Limited**

14/F, Oxford House, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong Tel: (852) 8100 2755 Website: www.bayer.com

Copyright © 2024 Bayer HealthCare Limited



# S SE

of Dual-Pathway inhibition

For the treatment of adult patients with **nAMD** and visual impairment due to **DME**<sup>1</sup>

## **Delivers extended durability**

with ~80% of patients on Q12W or Q16W treatment intervals at Year 2<sup>2</sup>

## **Demonstrated comparable safety** profile to aflibercept over 2 years<sup>2,3</sup>



References: 1. VABYSMO Hong Kong Prescribing Information 2. Khanani AM et al. TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology 2024, in press. 3. Wong et al. Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 2023, in press. 4. Roche data on file.

Call for Reporting: If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong.drug\_safety@roche.com, or (b) Phone: +852 2733 4711.



Roche Hong Kong Limited Roche 22/F, CTF Life Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong Tel: (852) 2723 2832

M-HK-00001818 approved in October 2024 is valid for 2 years or until change is required in accordance with regulatory requirements, whichever comes first.

\*For VABYSMO product information, please scan the QR code. Full product information will be provided upon request.







# VABYSMO<sup>®</sup> (faricimab injection): The first and only VEGF <u>and</u> Ang-2 pathway inhibitor for the treatment of neovascular (wet) age-related macular degeneration (nAMD) or diabetic macular oedema (DMO).<sup>1\*</sup>

Demonstrated non-inferior

from baseline (average of

+ 5.8 letters (95% CI: 4.6, 7.1) + 5.1 letters

mean change in BVCA

Weeks 40, 44 & 48)

VABYSMO is indicated for the treatment of:

- Neovascular (wet) age-related macular degeneration (nAMD)
- Diabetic macular oedema (DMO)

TENAYA

VABYSMO (n=334)

Aflibercept (n=337)

12

Weeks

8

#### nAMD

Comparator-controlled trials of VABYSMO vs. aflibercept in **nAMD** demonstrated non-inferior mean change in BCVA<sup>†</sup> from baseline at Year 1.<sup>1‡</sup>

Mean change in BCVA (measured by the Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) from baseline to Year 1 (based on an average at Weeks 40, 44 and 48)<sup>5</sup> with VABYSMO 6.0 mg up to Q16W and aflibercept 2.0 mg Q8W (primary endpoint)<sup>1</sup>

The recommended dose for nAMD is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 4 doses, followed by anatomic and visual acuity evaluations at Weeks 20 and 24 to inform dosing intervals of 8, 12 or 16 weeks through Week 60.

In TENAYA and LUCERNE, VABYSMO treatment intervals were extended up to 16 weeks at Week 48 in patients without disease activity."

The proportion of patients on each of the different treatment intervals at Week 48<sup>1,2#</sup>

Patients should be assessed regularly. Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion.<sup>1</sup>

16 20 24 28 32 36 **40 44 48** 



12 16 20 24 28 32 36 40 44 48

Weeks

Demonstrated non-inferio

mean change in BVCA from baseline (average o Weeks 40, 44 & 48)

+ 6.6 letters

+ 6.6 letters

LUCERNE

VABYSMO (n=331)

Aflibercept (n=327)

10

8

6

7 dean

0

0

4 8

etters)

change in BCVA (ETDRS |



BCVA=best corrected visual acuity; CI=confidence interval; ETDRS=early treatment diabetic retinopathy study; Q8W=every 8 weeks; Q12W=every 12 weeks; Q16W=every 16 weeks

\* Comparative clinical significance has not been established.

† Measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

‡ Randomized, 1:1, multi-centre, double-masked, active comparator-controlled studies in wet AMD. Treatment regimens were: aflibercept 2 mg Q8W after three initial monthly doses, or VABYSMO, after the first 6 mg four monthly doses (Weeks 0, 4, 8, and 12). Patients received 6 mg Q16W, Q12W or Q8W dosing based on assessments of pre-specified visual and anatomic criteria at Weeks 20 and 24 as well as treating physician clinical assessment. Patients remained on these fixed dosing intervals until Week 60 without supplemental therapy.

§ Average of Weeks 40, 44 and 48.

1 Protocol-defined disease activity assessment, measured at active dosing visits, was based on relative changes to BCVA and CST, together with investigator assessment at Weeks 20 and 24.

- # Percentages are based on number of patients randomly assigned to the VABYSMO group who had not discontinued the study at week 48.
- Comparative significance with aflibercept is unknown. Trials were not designed for head-to-head comparison of VABYSMO's durability vs. aflibercept because extended fixed 12-week or fixed 16-week dosing regimens have not been studied in double-masked phase 3 registrational trials for aflibercept.

#### References:

1. VABYSMO Hong Kong Prescribing Information.

2.Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. *Lancet*. 2022;399(10326):729-740.

#### Call for Reporting:

If you have a suspected side effect or problem to report regarding one of our products, please contact or send the information to the Roche Patient Safety team via: (a) Email: hong\_kong,drug\_safety@roche.com, or (b) Phone: +852 2733 4711.

Roche

Roche Hong Kong Limited 22/F, CTF Life Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong Tei: (852) 2723 2832 \*For VABYSMO product information, please scan the QR code. Full product information will be provided upon request.



M-HK-00001819 approved in October 2024 is valid for 2 years or until change is required in accordance with regulatory requirements, whichever comes first.

